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Therapeutic antibodies have achieved exceptional clinical success in the treatment 
of cancer and other human diseases. Now, new approaches are required to enhance the 
potency of antibodies to further increase the number of patients responding to therapy. By 
engineering the antibody Fc domain through mutation of the amino acid sequence, 
binding affinity to activating or inhibitory Fc receptors on effector cells can be increased 
to modulate the cellular immune response. However, attaining selectivity for closely 
related Fc receptors has proved challenging and the technique has not been applied to 
access the function of antibody isotypes other than IgG. Here we present new methods 
for enhancing antibody potency using both hybrid IgA/G and aglycosylated Fc domains. 
In the first instance, a chimeric antibody Fc domain has been created by combining 
residues from IgA with those from IgG. The new variant, MutD, introduces binding to 
FcαRI while retaining affinity for certain members of the FcγR family. ADCC assays 
show MutD, when part of a full length trastuzumab antibody against Her2 antigen, can 
kill Her2-overexpressing tumor cell lines as effectively as IgA antibodies. Moreover, 
MutD shows improved assembly compared to IgA and thus provides access to potent 
FcαRI function while overcoming the expression and purification barriers that have 
limited the use of IgA as a therapeutic. Alternatively, aglycosylated antibodies may be 
 vii 
engineered for exceptional effector function. Glycans anchored to residue N297 of the 
antibody IgG Fc domain are typically critical in mediating binding toward the FcγRs. 
Yet, using a full length bacterial IgG display system, we have isolated aglycosylated 
Fc1004 with mutations that confer a 160-fold increase in the affinity toward the low 
affinity FcγRIIa-R131 allele as well as high selectivity against binding to the remarkably 
homologous inhibitory receptor, FcγRIIb. Incorporation of this engineered Fc into 
trastuzumab resulted in a 75% increase in tumor cell phagocytosis by macrophages 
compared to that of the parental glycosylated trastuzumab with medium Her2-expressing 
cancer cells. In vivo testing of Fc1004 using NOD/SCID mouse model, reconstituted by 
adoptive transfer of leukocytes from FcγRIIa-R131 homozygous donors, showed a 
promising reduction in tumor burden in SkBr-3 Her2+ xenografts.  
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Chapter 1: Introduction 
ANTIBODIES AS THERAPEUTICS 
Antibodies are an essential part of the adaptive immune response that serves to 
protect a host against an immense diversity of disease causing agents. As a key aspect of 
antibody function, immune cells may be linked to pathogenic targets with exceptional 
specificity to enact a vast array of inflammatory and anti-inflammatory actions that 
modulate the immune response during the resolution of an infection. Harnessing these 
molecules as protein therapeutics has revolutionized the treatment of human disease over 
the last century by curing or extending survival times of patients with notoriously 
difficult to treat conditions such as cancer, bacterial infection and autoimmunity. The 
advent of recombinant DNA technology has rapidly improved the discovery of new 
antibodies with specificity against nearly any target desired. As of February 2013, 34 
monoclonal antibodies have been approved for treatment in the US, generating over $ 64 
billion in sales in 2012 [1, 2]. This figure constituted more than 50 % of the total sales for 
all biologics in the same year. The success of antibodies in the clinic is the culmination of 
more than one hundred years of intensive investigation encompassing the fields of 
immunology, medicine and protein engineering. Antibodies were first used 
therapeutically, albeit unknowingly, in 1890 when Emil von Behring and Kitasato 
Shibasaburo first demonstrated the concept of ‘passive immunization’ [3]. This technique 
involved the transfer of serum from animals immunized with diphtheria, to animals with 
a current infection, in order to clear the disease. Later, the approach was adapted in the 
1940’s for use in humans to treat patients with measles [4]. However, despite widespread 
use of this technology in the early 20th century little was known about the biochemical 
and molecular nature of the antibodies conferring protection. Breakthroughs in the late 
1950’s and early 1960’s led to the discovery of antibody structure thus paving the way 
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for facile manipulation of the amino acid sequence and subsequent function that make 
these molecules so successful as drugs today [5, 6]. The following sections outline 
several new and novel approaches being developed to create next generation antibody 
therapeutics with enhanced potency. 
 
ANTIBODY STRUCTURE AND CLASSES 
Largely due to the work of the Nobel laureates Edelman and Porter, antibodies 
were found to be tetramers comprised of two identical heavy and two identical light 
polypeptide chains (Figure 1.1). In addition to several intramolecular disulfide bonds 
within the antibody domains, the structure is further stabilized by intermolecular disulfide 
bonds between the heavy chains in the flexible hinge region as well as disulfide bonds 
that serve to link the light and heavy chains. This pairing of the heavy chain variable 
(VH) and light chain variable (VL) domains creates an antigen binding pocket that 
determines antibody specificity. Within the variable domains, contacts with cognate 
antigens are primarily mediated by regions of especially high sequence diversity termed 
the complementary determining regions (CDRs). 
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Figure 1.1:   Typical Antibody Structure. 
Antibodies are comprised of two heavy and two light chains assembled in a 
tetramer. Binding sites for Fc receptors are indicated in purple for each 
isotype. Interchain disulfide bonds are indicated yellow. 
 
While antibody VH/VL specificity is essential in focusing the immune response towards 
a particular pathogen, the constant region of the antibody ultimately determines how the 
pathogen is cleared. Humans express five main antibody classes (IgG, IgA, IgM, IgD and 
IgE) each characterized by a unique constant region that can promote inflammatory or 
inhibitory responses by interaction with various components of the immune system. 
Critically important to this function is the Fc domain where the majority of receptor 
binding occurs, as shown in Figure 1.1. In addition to mediating the clearance of 
pathogens, the Fc domain is also responsible for controlling the pharmacokinetics of each 
antibody class through interaction with specialized receptors that recycle the antibodies 
from serum (Table 1.1).  
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Table 1.1:  The Average Immunoglobulin Isotype Concentrations and Half-life in 
Human Sera. 
Isotype Allotype Antibody Concentration 
(mg/mL) 
Serum Half Life 
(days) 
IgG 
IgG1 7.2 – 7.8 [7] 21 [8] 
IgG2 2.4 – 3 [7] 21[8] 
IgG3 0.6 – 1.2 [7] 7.1[8] 
IgG4 0.36 – 0.72 [7] 21[8] 
IgA IgA1 1.12 – 2.90 [9] 5.9 [9] IgA2 0.12 – 0.47[9] 4.5 [9] 
IgE IgE 0.0003 [10] 2 [11] 
IgM IgM 1.47 ± 0.84 a [12] 10 [11] 
IgD IgD 0 – 0.061 [13] 2.8 [14] 
a indicates ± 1 SD 
  
In healthy human serum, IgG is represented at the highest concentrations and 
meditates potent immune function by binding to Fc gamma receptors (FcγRs), 
complement proteins or by direct neutralization of targets such as viruses. Within this 
isotype, 4 subclasses are found (IgG1, IgG2, IgG3 and IgG4) each with distinct binding 
profiles to the FcγRs and factors from the complement cascade. IgG1 and IgG3, which 
most strongly activate complement and bind the FcγRs, are typically produced in 
response to protein antigens whereas IgG2 and IgG4 more often respond to carbohydrate 
moieties [15]. IgG1 has been widely adopted for therapeutic purposes both for its potent 
Fc function and also because this antibody subclass is characterized by an extraordinarily 
long half-life of ~21 days as a result of the recycling action of FcRn receptors that are 
constitutively expressed on epithelial cells.  
In some applications however, the use of other antibody isotypes might confer 
certain physiological advantages. For example, although no therapies have been approved 
to date, IgA antibodies have evolved to be well suited for immune defense at mucosal 
surfaces. In fact, due to the immense surface area of the mucosa, the average human 
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synthesizes 66 mg/kg/day of all forms of IgA, more than all the other immunoglobulin 
classes combined [16]. Several adaptations have emerged to allow for transport of such 
large quantities of antibody across the mucosal epithelial and to protect IgA from 
proteolytic challenge in the harsh mucosal environment. IgA first dimerizes by 
association with the J chain protein, thus creating a molecule with enhanced antigen 
affinity by avidity, before binding to the polymeric Ig receptor (pIgR). A transcytosis 
event follows and the pIgR is cleaved to release secretory IgA into the mucosa. The 
cleaved fragment of the pIgR (secretory component) remains bound to stabilize the IgA 
dimer as well as promote adherence to the surrounding mucous [17]. Furthermore, the 
predominant subclass secreted to the mucosa, IgA2, contains heavily glycosylated and 
very short hinge regions which offer further protection from proteases.  
IgA is also curiously represented in monomeric form at higher serum 
concentrations in humans than in the sera of other animal species. As shown in Table 1.1, 
the allotypes of IgA can comprise up to 25% of the total serum immunoglobulins. The 
reasons for this uniquely high concentration are yet to be determined, but a leading 
hypothesis suggests humans can use serum IgA to reduce inflammation in the periphery 
by engagement to Fc receptors [18].  Mechanisms such as this could be important in 
reducing any undesirable inflammatory activity mediated by a therapeutic antibody. 
In contrast to IgA and IgG much less is known about the therapeutic potential of 
the remaining human antibody isotypes. Holding nearly equal serum representation as 
IgA is IgM which is uniquely expressed as a pentamer by forming disulfide linkages 
between the CH4 domains of adjacent antibodies [19]. In pentameric form, the J chain 
can also associate with IgM to allow for secretion via the pIgR at mucosal surfaces. IgM 
antibodies typically have low somatic hypermutation and as a result are lower in affinity 
than their IgG or IgA counterparts. Avidity generated by the pentameric structure 
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provides a boost to raise the apparent affinity of the complex. The final two isotypes, IgE 
and IgD, have the lowest serum representation of all the antibodies and the shortest serum 
half-lives.  IgE is most often implicated in allergy and in response to parasite infection 
[20]. IgD on the other hand is normally expressed in membrane bound form on B cells 
and the function it might fulfill in serum is not clear.  
 
Antibody Glycosylation 
 Post translational modification by the addition of glycans plays an essential role 
in fine-tuning antibody structure and interaction with the immune system. IgG function 
and immune cell recruitment is particularly dependent on N-linked glycosylation at 
residue N297 for promoting interaction with various Fc receptors. The loss of 
glycosylation either through enzymatic digestion or expression in systems lacking 
glycosyltransferase machinery results in the near complete loss of antibody mediated cell 
cytotoxicity (ADCC) [21]. Other antibody isotypes, such as IgA, contain additional O-
linked and N-linked glycosylation sites and in humans close to 30% of Fab domains have 
N-linked glycosylation [22]. The biotechnology sector has spent considerable effort 
ensuring the glycan composition on therapeutic antibodies is consistent and well defined 
from batch to batch by engineering sophisticated expression systems and cell lines [23-
25]. Inconsistency of the glycan composition can have a huge impact on the therapeutic 
effect of an antibody. The most notable example is the lack of fucosylation at the free 
terminus of the antibody glycan which improves the affinity of IgG for FcγRIIIa by 50 
fold [26]. Conversely, the presence of high levels of terminal sialylation induces anti-
inflammatory effects though stronger antagonism of the DC-SIGN receptor  [27].   
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ANTIBODY BIOLOGY AND FUNCTION 
The mechanism of antibody generation is an ancient and highly conserved 
evolutionary adaptation. Understanding this process is essential in the design and 
discovery of new antibody therapeutics. In vivo, enormous antibody diversity is achieved 
through the mechanism of VDJ recombination in pre B cells in which genomic loci (V, D 
and J genes) are rearranged to form VH domains and spliced together with the IgM 
constant domain locus [28]. While combinatorial selection of V, D and J elements from a 
large genomic pool generates substantial antibody sequence variety, most of the diversity 
is concentrated in the CDR3 regions due to non-templated end joining of the D and J 
segments. The antibody VL domain undergoes a similar process but lacks the D segments 
of the VH. Some estimates put the potential number of unique antibodies that can be 
generated by this process (VH and VL domain diversity) in excess of 1 x 1013 [29]. 
Following rearrangement of the germline DNA, pre B cells egress from the bone marrow 
to germinal centers in the peripheral lymph tissue where IgD generated from alternative 
splicing of the IgM locus is up-regulated on B cell surfaces to form immature B cells 
[30]. The germinal center provides an ordered environment rich with the co-stimulatory 
signals required to mature B cells in with strict specificity for a single antigen. To ensure 
responses are mounted against potential pathogenic threats, circulating antigen presenting 
cells (APCs) return from surveying the periphery to display foreign antigens in peptide 
form on major histocompatibility complexes (MHCs) (Figure 1.2). 
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Figure 1.2:  The Role of Antibodies in Mediating Inflammatory Responses by Bridging 
the Innate and Adaptive Arms of Immunity. 
Antigen presenting cells sample circulating antigen to activate helper T cells 
which in turn activate antigen specific B cell responses. Coating of target 
pathogens by these antibodies elicits a wide range of killing responses 
including antibody dependent cell phagocytosis (ADCP), antibody 
dependent cell cytotoxicity (ADCC), the release of cytokines and 
chemokines to influence the local immune environment and the activation of 
the complement pathway. 
 
MHCs on the surfaces of APCs are recognized by T cell receptors to activate the adaptive 
arm of immunity either through the generation of antigen specific CD4 T helper cells or 
by activation of potent cytotoxic CD8 T cells with direct cell killing ability. CD4 helper T 
cells provide strong activation and maturation signals for B cells expressing membrane 
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bound IgM (B cell receptor) of the correct specificity. In certain circumstances, such as 
multivalent polysaccharide antigens, B cells may also be activated in a T cell-
independent manner when multivalent antigens binding directly to the B cell receptor 
[31]. This is especially important as it allows for antibodies to be generated to 
conformational epitopes rather than just linear peptides. In either case, once a B cell 
matures class switch recombination may be initiated, in which the constant domain 
sequences of IgM or IgD are replaced with those of IgG, IgA or IgE. The isotype of the 
antibody is determined by many complex factors including the nature of the T cell help if 
present, the nature of the antigen and the cytokine environment in the germinal center. 
After class switching, soluble antibody is secreted but further affinity and specificity 
refinement may be made by successive rounds of activation-induced (cytidine) deaminase 
(AID) mediated somatic hypermutation [32].  Once suitable VH and VL sequences have 
been generated, mature B cells can either terminally differentiate plasma cells that 
produce massive quantities of antibodies or become memory cells, ready to respond 
rapidly to new onsets of the same infection. The criteria by which the immune system 
controls antibody selection for memory is yet to be fully defined but it appears high 
affinity is not the sole governing factor. 
 
FcγR Mediated Function 
Both native antibodies generated during an immune response and recombinant 
therapeutic antibodies have an impressive array of mechanisms by which to destroy 
targets. Importantly, antibodies can facilitate activation of the innate or ‘non-specific’ 
immune system as well as the adaptive or ‘acquired’ immune system (Figure 1.2). Innate 
immunity provides a rapid frontline response to target commonly encountered pathogen 
motifs whereas the slower adaptive immune response described above provides longer 
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lasting specific protection. However, in some cases direct neutralization by antibodies is 
sufficient to confer protection such as the case with the clearance of some viruses [33]. In 
either case, understanding the vital role antibodies play in clearing infection allows for 
new strategies to be developed for creating better therapeutics.     
In some cases, multivalent antigens allow many antibodies to bind simultaneously 
and form immune complexes (ICs) in a process known as opsonization. The close 
aggregation of a large number of Fc domains allows for the recruitment of immune cell 
subsets through interaction with surface bound Fc receptors [34].  
 
Table 1.2:  The Distribution and Affinity of the Human FcγRs for IgG. 
 
 
A subtle balance of FcR affinity, quantity of membrane bound FcR molecules and the 
nature of the transduced signal ultimately determine the outcome of the cellular immune 
response. The most widely studied receptors are those that bind IgG or FcγRs. In humans, 
three main classes of IgG activating receptors are expressed (FcγRI, FcγRIIa, FcγRIIIa) 
while only a sole inhibitory receptor exists (FcγRIIb) (Table 1.2) [35]. The activating 
receptors trigger inflammatory signals via an immune-tyrosine activating motif (ITAM) 
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either as an intracellular tail of the receptor protein or through non-covalent association 
with a common gamma chain. A signaling cascade follows, beginning with SYK kinase 
and resulting in ERK, p38 and JNK signaling up-regulation to promote ADCC, ADCP, 
cytokine release and oxidative burst depending on the cell type activated [36] (Figure 
1.2). Inhibitory signals are induced in a similar manner by FcγRIIb which contains an 
intercellular immunotyrosine inhibitory motif (ITIM). Phosphorylation of the ITIM by 
LYN results in the recruitment of SHIP phosphatase and the blocking of signaling 
pathways that would otherwise activate the cell. 
Of the activating receptors FcγRI is best defined by an unusually high affinity due 
to the presence of a third extracellular domain. The exact role of this receptor in immune 
responses is not clear but several reports have demonstrated a strong ability to cross-
present antigenic peptides in MHC complexes on professional APCs such as dendritic 
cells [37]. Cross presentation leads to the induction of strong cytotoxic T cell responses 
and is very important in the clearance of pathogens. FcγRI expression is also reported on 
several other cell types at varying levels; however the inflammatory state of the 
surrounding environment can have profound impact on receptor levels on cell surfaces. 
For example, the expression of FcγRI on neutrophils is increased significantly upon 
treatment with G-CSF [38].   
FcγRIIa is the most widespread activating receptor with expression on most 
myeloid cells excepting lymphocytes and natural killer (NK) cells. Both high and low 
responding allelic variants are found in the population (H131 and R131 respectively) and 
the high affinity polymorphism is thought to have improved response to therapeutic 
antibodies and an improved clearance rate of immune complexes [39-41].  Unlike FcγRI 
and FcγRIIIa this receptor has the ITAM domain as a part of its intracellular tail rather 
than requiring the common gamma chain.  
 12 
FcγRIIIa is perhaps the best understood Fc receptor and is expressed on 
professional APCs (macrophages, dendritic cells) as well as mast cells, NK cells and 
monocytes (Table 1.2).  Importantly, FcγRIIIa strongly activates NK cell mediated 
ADCC, a mechanism that is shown to contribute strongly to the therapeutic effect of 
several clinical antibodies [42, 43]. Much of the evidence supporting this finding is due to 
the poorer therapeutic response for some cancers in donors homozygous for the lower 
affinity F158 polymorphism rather than the high affinity V158 polymorphism [44]. 
FcγRIIIa also has an unusual receptor homologue, FcγRIIIb, with a nearly identical 
extracellular domain but lacking any intracellular signaling domain. Strangely, this 
receptor does not recruit the common gamma chain for signaling and thus little is known 
about its function, except that it possibly associates with FcγRIIa in some cases [44].  
The extracellular domain of the sole IgG inhibitory receptor FcγRIIb shares 93% 
sequence identity with FcγRIIa and down-regulates or often overrides the inflammatory 
response generated by activating FcγRs. Notably, FcγRIIb plays a critical role in 
preventing the development of autoimmunity by regulating B-cell responses at multiple 
stages of development [45, 46]. The loss of this essential receptor function in FcγRIIb 
knockout mice leads to development of autoantibodies [47]. In the context of therapeutic 
antibodies, FcγRIIb is important in defining the activating-to-inhibitory ratio (A/I) as 
determined by the affinity of the Fc domain for certain activating FcγRs (FcγRI, FcγRIIa, 
FcγRIIIa) divided by the Fc affinity for FcγRIIb. The A/I ratio has been used to evaluate 
the likelihood of clinical success of various antibody isotypes and engineered Fc variants; 
higher ratios typically correlate with activation of a more potent ADCC response [48, 
49]. This was convincingly demonstrated in a seminal paper by Clynes and Ravetch in 
which FcγRIIb knockout xenograph mice (A/I > ∞) showed greatly reduced tumor 
burden when treated with clinical grade Herceptin [50]. However, more recent studies 
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have revealed counter intuitive functions of FcγRIIb suggesting the interplay between 
activation and inhibition is much more complex. For example, FcγRIIb appears to be 
required for immunostimulatory activity in the function of agonistic anti-CD40 antibodies 
[51].  
The exceptional half-life of IgG is mediated by FcRn a heterodimeric receptor 
that binds to the Fc domain at the CH2/CH3 interface. The FcRn name is derived from 
the essential function it performs in neonates whereupon maternal IgG is transcytosed 
across the placenta to provide protection against pathogens until the adaptive immune 
system can be trained in the first few weeks of life. At physiological pH in serum, IgG 
binds to FcRn with very poor affinity. However, random pinocytosis of humoral fluids by 
epithelial cells serves to sequester antibodies in acidified endosomes. The shift to a lower 
pH markedly improves IgG affinity for FcRn thus allowing transport across the cell layer. 
In adult life this pH dependency means IgG is bound to FcRn at the endosomal 
membrane and sorted for return to the cell surface rather than being targeted for 
degradation [52]. Surprisingly, this receptor has been found to play a key role in the cross 
presentation of antigen by certain dendritic cell subsets which is important for the 
induction of cytotoxic T cell responses [53].    
 
FcαRI Receptor Mediated Function 
  While the FcγRs have been intensively studied in order to elucidate the 
mechanism of action of therapeutic IgG antibodies, the receptors of other antibody 
isotypes can have surprisingly potent action. The Fc domain of IgA associates with 
several receptor classes including FcαR1, pIgR (transcytosis of IgA), and Fcα/μR 
(receptor internalization and endocytosis) [54].  The best characterized of these receptors 
is FcαR1 or CD89, a close homologue of the leukocyte Ig-like receptors [55]. FcαR1 is 
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constitutively expressed on many cells of the myeloid lineage such as neutrophils, 
macrophages, Kuppfer cells and eosinophils but not on lymphocytes, mast cells and 
basophils [56]. In contrast to IgG binding to FcγR receptors, glycosylation of the Fc 
domain is not essential for binding to the FcαR1 and aglycosylated Fc domains bind with 
similar affinity [57]. This receptor can both activate and inhibit potent inflammatory 
responses depending on the level of receptor aggregation triggered by IgA crosslinking 
via the bivalent binding of antigens [58]. In effect, non-specific inflammatory responses 
would be reduced in the periphery while targeted inflammatory responses strongly 
activated at required sites. When activation does occur, recruitment of the common 
gamma chain bearing an ITAM motif to FcαRI triggers phagocytosis, respiratory burst 
and cytokine release [59]. On neutrophils, the interaction of IgA with FcαR1 is far more 
effective at tumor cell killing than any other class of Fc receptor and was the motivation 
for the work presented in Chapter 1 [60].  
 
Fc Mediated Activation of the Classical Complement System 
 As well as leveraging powerful killing effects by cellular recruitment, IgG isotype 
antibodies can also recruit proteins from the classical complement pathway to directly 
lyse target cells or mark them for clearance (Figure 1.2). Initially, the C1 complex binds 
to the antibody Fc domain thus triggering conformational changes that result in 
proteolytic cleavage of C3 to deposit C3b fragments on the target surface. Once again the 
glycan appended to N297 in the Fc domain is critical in facilitating the C1q subunit 
interaction. C3b can mark the pathogen for complement receptor mediated phagocytosis 
or go on to recruit other complement proteins to form a membrane attack complex that 
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lyses the cell. Complement action is suspected to be particularly important in the 
clearance of some lymphoma cancers [61].   
 
MONOCLONAL ANTIBODIES IN THE CLINIC 
A combination of superb specificity and the exceptional ability of antibodies to 
activate both the adaptive and innate arms of the immune system have largely contributed 
to their clinical and commercial success. The exploitation of monoclonal antibodies as 
therapeutics was facilitated greatly by Milstein and Kohler in 1975 who developed 
hybridoma technology for which they received a share of a Nobel prize in 1984 [62]. 
Hybridomas are generated by the fusion of a murine myeloma cell line and a B cell 
producing a single antibody clone to create an immortalized cell line. Problems with the 
severe immunogenicity of murine antibodies, whereupon adaptive immune responses are 
induced against non ‘self’ proteins, have limited their introduction to the clinic and the 
first approved monoclonal Muromomab showed limited efficacy after the first few doses. 
It was not until 1984 when Morrison et al described chimerization [63]. In this approach, 
VH domains from murine antibodies are grafted onto human constant domains to reduce 
the number of epitopes recognized as foreign. The process was further refined by 
humanizing antibodies where instead of the entire VH only the complementary 
determining regions (CDRs) are grafted into a human antibody framework [64] (Figure 
1.3).  
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Figure 1.3:  The Path to Developing Fully Human Antibodies.
Antibody technology has progressed since the discovery that murine 
antibodies could be generated from hybridomas to the point where fully 
human antibodies are entering the clinic. 
 
Only a few years later phage display was discovered enabling the production of 
fully human synthetic libraries of antibodies to be screened. Despite the immense 
promise of this technology only one antibody generated by this method for the treatment 
of arthritis has been approved by the FDA, a testament to the power of the adaptive 
immune system in generating high affinity antibodies [65].  In the last few years the 
advent of revolutionary new genomic editing technology has enabled the proliferation of 
a large number of humanized mice where the VH genes from humans are introduced to 
the germline in place of murine versions. Several competing humanized transgenic mice 
including the Xenomouse, VelocImmune mouse and HuMab mouse are being used by the 
pharmaceutical industry. With the wide availability of technology to generate fully 
human antibodies, new methods to improve antibody efficacy are critically required for 
the clinic. Even with blockbuster antibody drugs only moderate improvements in life 
expectancy are often seen. For example, in clinical trials with the anti-CD20 antibody 
Rituxumab, only 48 % of the patients treated showed either complete or partial responses 
after a 12 month period [66]. Even more striking, a phase III clinical trial with Herceptin 
(anti-Her2/neu for metastatic breast cancer) provided only a 5 month average survival 
extension over standard chemotherapy treatment [67]. When coupled with the high cost 
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of antibody therapy due to the requirement for strictly controlled mammalian expression 
under sterile conditions, improved survival times are essential for future antibody 
treatments. 
 
NEXT GENERATION THERAPEUTICS BY ANTIBODY ENGINEERING 
Several strategies have been developed to enhance antibody potency in vivo 
including; higher variable domain affinity for a target, targeting towards specific epitopes 
to have greater therapeutic effect, improved effector function by Fc modification and 
enhancement of pharmacokinetic and pharmacodynamics properties of antibodies [68, 
69]. However, there is a limit to the effectiveness of variable domain affinity maturation. 
At a certain point the off rate of the antibody becomes so slow that only minute gains in 
performance are achieved. On the other hand, modification of the Fc domain to modulate 
the balance of binding affinities for the FcγRs, or even to use as a scaffold on which a 
payload may be attached, have shown considerable promise (Figure 1.4). Of note is the 
recent FDA approval of the antibody drug conjugate Trastuzumab-DM1 [70]. However, 
many other sequence or glycan engineered variants are now reaching late stage clinical 
trials as discussed in the following section.  
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Figure 1.4:  Strategies for Improving Antibodies by Engineering the Fc Domain. 
A) Antibody drug conjugates use the Fc domain as a carrier to attach a 
payload of cytotoxic drugs B) engineering the glycan moieties can influence 
binding to the FcγRs to either increase of reduce inflammatory function C) 
making antibodies aglycosylated renders the Fc immune silent but it is 
possible to fix certain confirmations by D) amino acid mutation to improve 
or reduce contacts with cognate Fc receptors. 
 
Amino Acid Modification in Glycosylated Antibodies 
Modification of the Fc domain was first achieved in glycosylated antibodies by 
mutation of the polypeptide structure. In a landmark paper by Shields et al., high 
resolution alanine scanning of the Fc domain identified a large number of residues that 
either enhanced and reduced binding to FcγRI, FcγRIIa, FcγRIIb, FcγRIIIa and FcRn 
[71]. As part of this work several mutations were reported to enhance binding to 
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activating receptors over FcγRIIb thus providing the framework for a proliferation of 
engineered variants. Initial engineering efforts focused heavily on improving binding to 
FcγRIIIa. Unlike macrophages or neutrophils, NK cells express predominantly the 
activating FcγRIIIa receptor and not the inhibitory receptor FcγRIIb. Evidence suggested 
that these cells were largely responsible for the killing action of some clinical antibodies, 
such as trastuzumab [43]. However, the absence of a homeostatic mechanism for the 
down regulation of NK cells that have been activated by immune complexes has led to 
some controversy as to the significance of NK cells in antibody mediated tumor clearance 
[36].   
Xencor used saturation mutagenesis and screening to guide the design of several 
variants to find, among others, the triple mutation S239D/I332E/A330L that exhibits over 
100 fold improvement in affinity for FcγRIIIa while maintaining an enhanced A/I ratio 
[72]. The improved affinity translated in vitro to significant improvements in NK 
mediated cell killing of Her2+ tumor cell lines and several clinical trials are in progress to 
test S239D/I332E variants of this engineered Fc domain (XmAb5574) [73, 74]. Xencor 
has also reported variants with enhanced binding to FcγRIIa in order to improve 
macrophage mediated phagocytosis. In total more than 900 variants were constructed and 
screened against the whole FcγR panel  Surprisingly, the single mutation G238A was 
able to confer an impressive 70 fold increase in affinity for FcγRIIa while simultaneously 
improving the A/I ratio by 15 fold [75].  
To improve the throughput of engineered and glycosylated Fc discovery several 
groups have used yeast screening technologies to express large libraries of variants. In the 
yeast system, proteins may be expressed as a fusion to Aga2 protein which forms a 
disulfide linked complex with Aga1 on the cell surface [76, 77]. Using this technology, 
Macrogenics screened more than 1 x 107 mutations for variants with enhanced A/I ratios. 
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A group of 5 mutations was found to improve specific cell lysis of HT29 tumor cells the 
most (F243L, R292P, Y300L, V305I, P396L) and this translated to enhanced survival of 
mice when injected with ovarian cancer or B cell malignancies [78]. 
 More recently, several variants with extremely low A/I ratios (High FcγRIIb 
binding and low FcγRIIa or FcγRIIIa binding) have been published. In some cases high 
binding to FcγRIIb is desirable, particularly for autoimmune diseases and allergic 
responses where attenuation of misdirected immune responses is essential for treatment. 
Xencor found the mutations S267E and L328F could confer an impressive 430 fold 
increased affinity for FcγRIIb but also retained considerable affinity for FcyRIIaR131 [79]. 
When these mutations were added to an anti-CD19 antibody, significant suppression of 
humoral immunity was observed in mice grafted with B cells taken from sufferers of 
systemic lupus erythematosus and challenged with tetanus toxoid antigen. The 
recruitment of inhibitory FcγRIIb to the BCR signaling complex greatly increases the 
threshold required for activation of B cells. This engineered variant is now in phase I 
clinical trials to determine safety profiles and dosage regimes. The same engineered Fc 
domain has also been fused to an IgE Fc domain to create a tandem Fc structure. 
Crosslinking the inhibitory FcγRIIb receptor with the high affinity receptor for IgE, 
prevents mast cell degranulation, a key contributing mechanism to allergy and 
inflammation [80].  
 An Fc domain with even greater selectivity for FcγRIIb than the S267E/L328F 
variant was made with the goal of reducing residual affinity for FcyRIIaR131. Using high 
resolution mutagenesis, guided by a crystal structure of the mutant Fc in complex with 
FcγRIIb, residues in the Fc structure were identified with selective binding to FcγRIIb 
[81]. Six residues E233D, G237D, H268D, P271G, Y296D and A330R when combined 
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provide 217 fold improved binding to FcγRIIb while maintaining binding to the 
activating receptors at close to or below wild type levels. 
 
Glycan Modification for Enhanced Therapeutic Effect 
Other than mutation of the Fc amino acid sequence, significant effort has been 
directed at tailoring the composition of the N297 glycan in antibodies by developing 
highly sophisticated mammalian or non-mammalian expression systems [82-84]. 
Changes to glycan composition can have a large influence on the affinity of FcγR binding 
and on the heterogeneity of glycosylation introduced by cell expression systems has been 
a long standing problem. One key example of such efforts is glyco-engineered Pichia 
pastoris, which expresses antibodies with human N-glycan structures, a technology 
developed by GlycoFi and acquired by Merck for $400 million in 2006 [85]. Over 95% 
of antibodies produced in Chinese hamster ovary (CHO) cells, and 70% of those 
produced in mouse myeloma cells, are fucosylated [86].  However, the non-fucosylated 
fraction of serum IgG shows markedly enhanced FcγRIIIa binding [26], which results in 
the induction of potent ADCC responses by NK cells in vitro.  Hence, the expression of 
non-fucosylated antibodies has attracted significant commercial interest.  Production can 
be accomplished using FUT8 (α-1,6 fucosyltransferase; intrinsic fucosylating enzyme) 
knockout cell lines [87].   
Anti-inflammatory responses might also be mediated by antibodies if the glycan 
terminus is sialylated to promote interaction with the DC-SIGN receptor. The DC-SIGN 
receptor is a C-type lectin receptor expressed on macrophages and dendritic cells which 
typically recognizes mannose carbohydrates [88]. Nevertheless, some studies have shown 
DC-SIGN interaction with α2,6-sialylated structures, such as those in the Fc domain, and 
could provide a mechanism behind the success of intravenous Ig (IVIG) treatment for 
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autoimmune diseases [89, 90]. Measurement of circular dichroism spectra of  sialylated 
Fc domains revealed that a closed conformation (distance between CH2 domains small) 
is adopted relative to the wild type form [91]. This evidence has led to the hypothesis that 
closed conformations trigger anti-inflammatory properties whereas open structures are 
more activating through binding to the FcγRs. However, this hypothesis remains 
contentious in literature especially since the recent publication of a sialylated Fc crystal 
structure failed to demonstrate a ‘closed’ CH2 domain conformation relative to wild type 
Fc domains [92, 93].   
 The impact of these new glycan engineered mutants in the clinic is yet to be seen 
and more data is required especially in comparison with wild type antibodies to truly 
measure their effect [94]. In the meantime, new strategies should be investigated as we 
hypothesize that high affinity for an activating receptor is possibly not as important as 
extreme receptor specificity. 
 
Aglycosylated Antibodies as Novel Therapeutics 
The use of aglycosylated full length antibodies for therapy offers two important 
advantages:  First, recent studies have shown that aglycosylated antibodies can be 
engineered to bind to FcγRs and thus elicit potent ADCC responses [95, 96]. Of 
particular significance is the high degree of Fc polypeptide flexibility conferred by the 
lack of glycosylation that can be exploited to elicit unique FcγR selectivity, in turn 
opening the way for new mechanisms of immunotherapy [97].  Second, bypassing 
glycosylation greatly simplifies bioprocessing both because control of glycan isoforms 
ceases to be a problem and because aglycosylated antibodies can be produced in 
prokaryotic or lower eukaryotic hosts, leading to much faster development timelines.  To 
date, aglycosylated antibodies in clinical trials have been expressed in E. coli, yeast and 
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CHO cells.  In addition, the production of full length, aglycosylated antibodies in algae 
has been described although no clinical trials with antibodies produced in this system 
have been reported [98].   
The idea of using aglycosylated antibodies in the clinic was initially met with 
skepticism because of concerns with immunogenicity of the aglycosylated form, the 
possibility for altered pharmacokinetics in vivo and antibody stability during formulation 
and storage [99].  These concerns have since been largely dismissed opening the way for 
the clinical development of a number of aglycosylated IgG antibodies (Table 1.3). 
 
Table 1.3:  Aglycosylated Antibodies in Current or Past Clinical Trials. 
Antibody Target antigen Origin Company Clinical trial phase 
TRX518 GITRa  
Humanized 
(Mouse) 
GITR, MA, USA /  
Tolerx, MA, USA I (Ongoing) 
MTRX1011A CD4  
Humanized 
(Rat) 
Genentech, CA,USA  
/ Tolerx, MA, USA 
I (Failed to meet 
pharmacodynamic 
targets) 
TRX4 
(Otelixizumab) 
CD3 
 
Humanized 
(Rat) Tolerx, MA, USA 
III  
(Failed to meet 
endpoint) 
OA-5D5 
(MetMAb) 
HGFb 
 
Humanized 
(Mouse) Genentech, CA,USA III (Ongoing) 
ALD518 (BMS-
945429) IL-6 Humanized 
Alder 
Biopharmaceuticals, 
WA, USA 
II (Completed) 
 
The first aglycosylated antibody to enter clinical trials was ChAglyCD3 
(otelixizumab, Tolerx), a humanized version of a rat derived IgG1 directed against the 
CD3 T cell marker [10].  The aglycosylated form of the antibody was shown to be well 
tolerated in patients despite concerns of an initial cytokine burst release.  However, 
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despite promising results in early phase clinical trials, otelixizumab did not meet its phase 
III endpoint and development was halted [100-102] [97].  Despite the closure of Tolerx, 
two additional aglycosylated antibodies continued to clinical trials with sponsorship from 
other corporations. The first, TRX518, is a fully humanized IgG1 that binds to the 
glucocorticoid-induced tumor necrosis factor receptor (GITR) on CD3+ T cells, which 
stimulates the activation of tumor-antigen-specific T effector cells and simultaneously 
abrogates the suppression by T regulatory cells [103]. Second, MTRX1011A was a 
humanized rat IgG1 anti-CD4 mAb which was designed to suppress CD4 T cells that 
contribute to the pathogenesis of rheumatoid arthritus but failed Phase I as the 
pharmacodynamic activity did not meet the requirement for disease reduction [104]. 
Alder Biopharmaceuticals (WA, USA) completed a successful phase II clinical 
trial for an aglycosylated, humanized anti-interleukin-6 antibody (ALD518) [74].  The 
yeast-expressed ALD518 contains a mutation at N297 that abolishes glycosylation.  
Pharmacokinetic studies revealed that ALD518 has a serum half-life of 25 days, which is 
comparable to the typical half-life of glycosylated antibodies in humans [105]. Genentech 
(CA, USA) developed a novel “one-arm” (monovalent) anti-cMet antibody (MetMAb, 
OA-5D5) that acts exclusively as an antagonist to compete with the natural cMet ligand, 
hepatocyte growth factor (HGF), in the treatment of glioblastoma [106, 107].  Notably, 
the “one-arm” antibody is produced in E. coli by expressing a bi-specific Fc that 
capitalizes on the “knobs-in holes” approach for IgH (IgG heavy chain) 
heterodimerization with only one of the two IgH chains containing a Fab domain.  The 
use of the monovalent OA-5D5 was necessitated by the finding that a conventional IgG 
with the same antigen specificity activates cMet by receptor crosslinking.  The 
aglycosylated version of MetMAb was selected for clinical development in order to 
reduce agonistic activity through receptor engagement by the Fc domain.  Initial 
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preclinical data suggested the clearance rate of the antibody would be faster than its 
bivalent counterpart but phase I clinical data subsequently revealed a promising 
pharmacokinetic profile [108]. Phase II trials successfully demonstrated improved 
survival time in some patients and phase III studies are now underway to determine 
which subset of patients would benefit most from MetMAb treatment [109]. 
Importantly, MetMAb is the first therapeutic full-length antibody that is 
manufactured in E. coli.  This is significant on three accounts: First, it indicates that 
earlier concerns regarding the efficiency IgH : IgL (IgG light chain) pairing and possible 
product heterogeneity due to aberrant disulfide bond formation in bacteria can be 
successfully addressed at an industrial scale.  Second, it demonstrates the use of bacteria 
for preparative IgG expression now opens the way for capitalizing on the numerous tools 
available for achieving very high yields of secreted proteins in bacteria [110].  Third, 
since E. coli does not have any protein glycosylation machinery it enables the production 
of fully aglycosylated antibodies without any N- or O- linked glycans while leaving 
residue N297 unmodified.    
The engineering of aglycosylated antibodies, while not at the clinical trial level 
has also proved successful in creating promising new variants. Sazinsky et al. created 
small saturation libraries (amino acid residues at 296-299, 297-299, and 297-300) 
targeting the C’E loop of CH2 region that has been known to be critical for FcγR 
interaction [111].  By using yeast surface display and flow cytometric screening, they 
isolated Fc variants exhibiting high binding affinity to FcγRIIa.  Despite the use of 
eukaryotic yeast for surface display of IgG molecules, variants containing mutations at 
the canonical N-linked glycosylation sequence (Asn-X-Ser/Thr) generated aglycosylated 
IgG instead of mannosylated IgGs.  A S298G/T299A double mutant was shown to be 
aglycosylated when expressed in HEK293 cells but displayed FcγRIIa and FcγRIIb 
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affinities comparable to those of glycosylated, wild-type IgG.  In a human FcγRIIa 
transgenic mouse model, an anti-platelet antibody containing the S298G/T299A 
mutations was shown to mediate platelet reduction suggesting that the engagement of 
FcγRIIa by the engineered antibody results in a physiologically relevant effect.  
Jung et al. developed a robust system for the display of combinatorial libraries of 
aglycosylated Fc domains in E. coli and the isolation of variants that bind to desired 
fluorescently labeled FcγRs using flow cytometry [95].  Screening of very large libraries 
(~109 transformants) led to the isolation of a mutant containing two amino acid 
substitutions, E382V/M428I within the CH3 region that conferred binding to FcγRI with 
an affinity nearly identical to that of glycosylated IgG1 antibodies.  Quite remarkably, 
this Fc mutant showed no binding to any other FcγRs (FcγRIIa, FcγRIIIa or, most 
importantly FcγRIIb).  The E382V/M428I amino acid substitutions were introduced into 
the anti-Her2 antibody trastuzumab (trastuzumab-Fc5), which was preparatively 
expressed in E. coli by high cell density fermentation.  Trastuzumab-Fc5 elicited 
dendritic cell-mediated ADCC in sharp contrast to the clinical grade glycosylated 
trastuzumab which lacked the ability to activate dendritic cells.  Interestingly, when 
trastuzumab-Fc5 was expressed in glycosylated form in HEK293 cells it lost its 
selectivity for FcγRI and displayed binding to FcγRIIb (as well as FcγRIIa and FcγRIIIa) 
which in turn suppressed its ability to potentiate target tumor cell clearance with dendritic 
cells as effectors.  The finding that glycosylation suppresses the FcγRI selectivity of 
trastuzumab-Fc5 and the location of the E382V/M428I mutations in the CH3 far away 
from the FcγR binding interface supported the hypothesis that these mutations may act by 
stabilizing a particular aglycosylated Fc conformer.  
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Figure 1.5:  The Aglycosylated Fc5 Mutant.
An Aglycosylated Fc domain crystal structure (PDB: 3S7G) overlaid with the 
E382V and M428I mutations from Fc5 which confer highly selective binding to 
FcγRI. 
 
Small angle X-ray (SAXS) scattering experiments revealed that radius of gyration for the 
Fc5 variant is greater than a glycosylated IgG Fc but less than a wild type aglycosylated IgG Fc 
[112]. Because SAXS involves measurement of proteins in solution, many crystal packing 
artifacts can be avoided that may occur in crystallization methods. The result suggests a 
structural change is induced by the additional mutation in Fc5 which appears to limit the 
‘openness’ of the structure in a manner that promotes binding to FcγRI.  
Long term, aglycosylated antibodies engineered for FcγR binding specificity and 
activation may bypass the necessity for mammalian cell expression/glycoengineering and, 
importantly, establish novel mechanisms of antibody function. Chapters 3 and 4 of this work 
focus on the discovery and characterization of a new aglycosylated Fc domain engineered for 
enhanced binding specifically to FcγRIIa over FcγRIIb that displays greatly enhanced 
macrophage recruitment over wild type IgG. 
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Looking Beyond the IgG1 Isotype 
In order to further expand the function of Fc domains, the therapeutic action of antibody 
isotypes other than IgG should be considered to further enhance antibody effector function or, in 
the case of anti-inflammatory antibodies, make the Fc domain more immune silent. Typically, 
the IgG1 antibody subclass has been used to form the backbone of FDA approved therapeutics 
because of strong activation of ADCC and CDC. However, some of the more recent approvals 
have been of the IgG2 (panitumumab) or IgG4 (natalizumab, gemtuzumab ozogamicin) 
subclasses, which both exhibit greatly reduced Fc function [113]. These classes have also been 
hybridized in the Fc domain of eculizumab to further reduce inflammatory effector function 
[114].  
Conversely, Fc domains with strong ADCC and CDC activation have been created by 
shuffling the constant domains of IgG1 and IgG3. When grafted to anti-CD20 variable domains 
this new Fc was able to significantly reduce B cell levels in the blood of cynomologus monkeys 
as compared to a wild type IgG1 control suggesting the utility of domain shuffling as a method 
for enhancing antibody function [115]. Despite the promise of this method shuffling between 
completely separate antibody isotypes such as IgG and IgA to potentially combine the best 
features of both has not been attempted. As such, this area remains open for exploration as 
described in Chapter 1 of this work. 
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Chapter 2:  Engineering of an IgG/IgA Chimeric Fc Domain with FcαRI and 
FcγR Receptor Binding  
INTRODUCTION 
A key part of antibody function is the recruitment of immune cells that can mediate 
potent antibody dependent cell cytotoxicity (ADCC) responses against target antigens (or cells) 
[44]. Initiation of the ADCC response depends on the interaction of the Fc region of antibodies 
with cell surface receptors (FcRs) located on immune effector cells [36, 48]. To provide 
modulation of the inflammatory response, several antibody isotypes have evolved (IgG, IgA, 
IgE, IgM or IgD) with unique binding profiles for both activating and inhibitory FcRs [116-118]. 
Currently, all FDA approved antibody therapeutics are of the IgG subclass that interact with 
FcγRs on effector cell subsets [2]. In particular, NK cells expressing high levels of FcγRIIIa have 
been implicated as the primary effector cells in the anti-tumor activity of some clinical antibodies 
[43, 119]. Yet evidence is emerging that other cell subsets, such as neutrophils, might also 
significantly contribute to tumor clearance in the clinic [120]. In line with this finding, recent 
murine xenograft studies have shown that neutrophils are directly linked to the reduction in 
tumor burden by alemtuzumab and trastuzumab IgG antibodies [121, 122]. However, in addition 
to the FcγRs engaged by IgG, neutrophils also express high levels of FcαRI receptors which can 
induce potent inflammatory action when cross-linked by IgA immune complexes [44, 123]. Both 
ADCC (oxidative burst, degranulation) and ADCP responses have been observed upon FcαRI 
activation [124-128]. In fact, IgA can bind FcαRI to activate neutrophils more potently than IgG 
antibodies can via the FcγRs [129, 130]. Hence, the efficacy of ADCC might be improved by 
enabling the engagement of neutrophil and other effector cell populations that are not normally 
activated as potently or not at all by IgG class antibodies.   
The ability to strongly recruit neutrophils for cancer therapy is an attractive avenue of 
exploration since the neutrophil population comprises the greatest fraction of innate effector cells 
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found in circulation. It is also possible to rapidly expand neutrophils in vivo for therapy by 
injection of GM-CSF cytokine [123]. As mentioned above, immune complexes formed by IgA 
isotype antibodies can activate neutrophils to display potent cytotoxic effects towards target 
cells.  However,  despite the potential promise for using the IgA isotype to exploit the potent 
inflammatory effects of FcαRI function for neutrophil mediated therapy, its therapeutic use has 
been disfavored due to its low expression yields [131]. Part of the problem  with IgA expression 
is the heavily glycosylated hinge region of the antibody that includes up to six O-linked 
glycosylation sites [132]. Glycosylation not only impacts protein expression level but also 
introduces the potential for heterogeneity during production which can affect the 
immunogenicity and stability of protein therapeutics [133, 134].  
We hypothesized that engineering FcαRI binding into an IgG molecule could alleviate 
these concerns. Furthermore, IgA antibodies cannot bind FcγRs and hence cannot elicit the same 
kind of ADCC, ADCP and CDC reactions that IgG molecules are capable off.  To do so would 
require combination therapy with IgA and IgG therapeutic antibodies which would be both 
clinically complicated and costly. Instead, engineering a chimeric IgG Fc domain that engages 
both Fcα and Fcγ receptor classes synergistically could address these issues [135]. In this work 
we report the generation of a new class of engineered Fc domains that are able to bind both Fcα 
and Fcγ receptors. Specifically, an IgGl antibody Fc domain was engineered to introduce de novo 
binding to the IgA FcαRI receptor while retaining near to wild type affinity for several FcγRs. 
This new chimeric Fc domain and its derivatives, when incorporated into full length antibodies, 
offer a broader range of effector function relative to either IgG or IgA alone.  We show that such 
chimeric antibodies elicit potent ADCC with neutrophils as effector cells mediating the killing of 
Her2+ breast cancer cells in vitro.   
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MATERIALS AND METHODS 
Alanine Mutagenesis 
Alanine scanning mutagenesis on IgA was performed to help identify residues important 
for binding to FcαRI. Based on crystal structure and Rosetta modeling, 11 sites in the IgA Fc 
domain were selected for alanine scanning mutagenesis (Figure 2.1). The following IgA mutants 
containing L257A (constructed using primers TKA4, TKA5), L258A (constructed using primers 
TKA6, TKA7), E313A (constructed using primers TKA8, TKA9), N316A (constructed using 
primers TKB1, TKB2), H317A (constructed using primers TKB3, TKB4), R382A (constructed 
using primers TKB7, TKB8), E389A (constructed using primers TKC1, TKC2), M433A 
(constructed using primers TKC5, TKC6), E437A (constructed using primers TKD1, TKD2), 
L441A (constructed using primers TKD5, TKD6), and F443A (constructed using primers TKE1, 
TKE2) were generated using Quikchange PCR with pTrc-DsbA IgA CH2 CH3 as the DNA 
template. Cloning into the mammalian expression vector pMaz-IgH was achieved by Gibson 
assembly [136] after amplification of the individual Fc domains (Primers WK346 and WK347) 
and amplification of the pMaz-IgH-FcγRI-His backbone (Primers WK212 and WK314). 
Following transformation into E. coli JUDE-1 cells, the mutant genes were sequenced and DNA 
was prepared for transient transfection in HEK293F cells (Invitrogen). The IgA mutants were 
purified by Ni-NTA chromatography. PBS (25x) was added to a final concentration of 1x in 
addition to 10 mM imidazole, and the solution was passed through Ni-NTA affinity columns for 
IMAC chromatographic isolation of the Fc proteins. Bound protein was washed with PBS 
containing 20 mM imidazole and eluted in PBS with 250 mM imidazole directly into Amicon 10 
kDa spin columns for buffer exchange and concentration. ELISA analysis was used to evaluate 
binding to FcαRI. Briefly, each IgA variant was coated at 4 µg/mL onto Ni-NTA ELISA plates 
(Qiagen), then FcαRI-GST at 10 µg/mL was added to the first well and serially diluted before 
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detection with goat anti-GST HRP (GE Healthcare). TMB substrate was added and the reaction 
quenched with 1 M H2SO4 before the absorbance was measured at 450 nm. 
 
Construction and Expression of Fc Domain IgA/G Chimeras 
All plasmids and primers are described in Tables A.1 and A.2. DNA sequences for 
mutants B-D were assembled by PCR using oligonucleotide primers synthesized in house shown 
in Table A.3 (Mutant B - WK188, 190, 194, 196, 198, 200, 202, 204, 206, 207; Mutant C - 
WK188, 191, 194, 196, 198, 200, 202, 204, 206, 207; Mutant D - WK188, 192, 194, 196, 198, 
200, 202, 204, 206, 207). Each of the IgG mutants were then cloned into pMaz-FcγRI-His by 
Overlap Extension PCR [137]. Double stranded megaprimers for mutant B (pMaz-IgH MutB) 
were generated with primers WK366 and WK209 and for both mutants C (pMaz-IgH MutC) and 
D (pMaz-IgH MutD) using primers WK370 and WK209. Exchange of the CH2 loop of MutD 
with that from IgA was performed similarly by OLE PCR. A megaprimer was generated using 
pMaz-IgH-MutD as a template with the primers WK385 and WK386 for cloning back into 
pMaz-IgH-MutD. Following DpnI digestion of all PCR reactions and transformation into JUDE-
1 cells, plasmid DNA was prepared (Qiagen, HiSpeed Plasmid Midi Kit) for transfection. 
293Fectin Transfection Reagent (Invitrogen) was used to transfect HEK293F (Invitrogen) cells 
cultured in GIBCO FreeStyle™ 293 Expression Medium (Invitrogen) in accordance with the 
manufacturer’s instructions. Five to six days after transfection, the cell suspension was 
centrifuged at 2,000 rpm for 10 min to recover the supernatant fraction. Ni-NTA was used to 
purify the IgA/G chimeras as described in the previous method section.  
 
Mammalian Expression of Fc receptors 
FcαRI-GST, FcγRI-GST, FcγRIIa-R131-GST, FcγRIIb-GST, and FcγRIIIa-F158-GST 
were produced by transient transfection of HEK293F cells (Invitrogen) using the pMaz-IgH 
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(U.S. Patent No. 8,043,621) derived expression vectors described in Table A.1. Glutathione 
Sepharose (GE Healthcare) affinity chromatography was used according to the manufacturer’s 
instructions to purify each variant to >95 % purity as assessed by SDS-PAGE. PBS at 25x 
concentration was added to the filtered supernatants six days after transfection to make a final 
PBS concentration of 1x, and the mixture was passed twice over the column. The column was 
washed with 100 mL of 1x PBS to remove nonspecifically bound protein. 4 mL of 1x PBS 
containing 10 mM reduced glutathione was used for elution into 10 kDa filter columns. 
 
Fc Receptor Binding ELISAs 
ELISA plates (Qiagen) were coated with 4 µg/mL of each of the mutant Fc domains in 1x 
PBS (pH 7.4) overnight at 4 °C. The next day the plates were blocked for 2 h at room 
temperature with 2 % milk in 1x PBS containing 0.05 % Tween (PBST) and washed 3 times in 
PBST at pH 7.4. To the first well, 66 µL of 20 µg/mL of either FcαRI-GST, FcγRI-GST, 
FcγRIIa-R131-GST, FcγRIIb-GST, or FcγRIIIa-F158-GST dissolved in PBS with 2 % milk 
(PBSM) was added followed by 1:4 serial dilution. After 1 hour of incubation at room 
temperature, the plates were washed and 50 µL PBSM was added containing 1:5000 goat anti-
GST HRP (GE Healthcare) for 1 hour. To develop the plates, the wells were washed 3x with 
PBST, 50 µL TMB substrate was added per well (Thermo Scientific), 50 µL of 1 M H2SO4 was 
added to neutralize, and the absorbance at 450 nm was recorded.  
 
Construction and Expression of Full Length IgA/G Chimeras and Control Antibodies 
All plasmids and primers are described in Tables A.1 and A.2. Plasmids for expression of 
wild type trastuzumab IgG heavy chain (pMaz-IgH-trastuzumab), trastuzumab kappa light chain 
(pMaz-IgL-trastuzumab) and trastuzumab IgG N297D heavy chain (pMaz-IgH-N297D-
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trastuzumab) were constructed as described previously [96]. Inserts for trastuzumab IgA heavy 
chain (Primers WK353 and WK354) and trastuzumab MutD heavy chain (Primers WK364 and 
WK 356) were amplified for cloning into the pMaz-IgH (U.S. Patent No. 8,043,621) expression 
plasmid by OLE PCR. In each case plasmid pMaz-IgH-trastuzumab was used as the DNA 
template. After transformation into E. coli JUDE-1 cells, colonies were isolated for sequencing 
and DNA was prepared for each heavy chain and combined with an equal mass of light chain 
plasmid for transient transfection in HEK293F cells (Invitrogen). Five to six days after 
transfection, the cell suspension was centrifuged at 2000 rpm for 10 min to recover the 
supernatant fraction. Trastuzumab IgG and trastuzumab IgG N297D were purified over protein 
A affinity columns whereas trastuzumab IgA and trastuzumab MutD were purified over protein 
L affinity columns. Briefly, the supernatants were passed through 0.22 μm filters before addition 
to polypropylene columns packed with either Protein A high capacity agarose resin (Thermo 
Scientific) or Protein L agarose resin (Invivogen). The resulting flow-through was collected and 
passed twice more through the column before any unbound protein was washed away with >10 
CV (Column Volume) of 1x PBS. All antibodies were eluted with 3 mL of 100 mM citrate buffer 
(pH 3.0) and immediately neutralized with 1 mL of 1 M Tris (pH 8.0). Samples were buffer‐
exchanged into 1x PBS using Amicon Ultra‐4 (Millipore) spin columns with a 10 kDa cutoff and 
the purity of purified samples was assessed by 4‐20 % gradient SDS‐PAGE gel (NuSep). 
  
Mammalian Expression of Monomeric FcγRIIa, FcγRIIb and FcαRI Receptors 
The genes encoding monomeric low affinity Fc receptors (FcγRIIa and FcγRIIb) and 
FcαRI were generated by Gibson assembly as follows:  The backbone of the pcDNA3.4 vector 
(Invitrogen) was amplified in two segments; a 2.5 kb fragment (using primers WK426 and 
WK463) and a 3.5 kb fragment (using primers WK425 and WK464). The insert for FcyRIIa-
R131 was created using primers WK448 and WK461 with plasmid pMaz-IgH-FcγRIIaR131-His 
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as a template. Similarly the insert for FcγRIIb was generated using primers WK450 and WK462 
with pMaz-IgH-FcγRIIb-GST as a template. To clone monomeric FcαRI into pcDNA3.4, the 
receptor insert was amplified from pMaz-IgH-FcαRI-GST using the primers WK459 and 
WK460. Each insert was combined with the two backbone segments for 60 min at 50 °C in a 
Gibson master mix [136], to create the plasmids pcDNA3.4-FcγRIIb-His and pcDNA3.4-
FcγRIIaR131-His, before transformation into E. coli. The respective plasmids for FcγRIIa-R131, 
FcγRIIb and FcαRI expression were transfected for five to six days using Expi293F cells 
(Invitrogen). Purification was performed by Ni-NTA affinity chromatography as described 
previously and expression confirmed by 4-20 % SDS page gel. 
 
SPR Affinity Measurements 
A Biacore 3000 instrument (GE Healthcare) was used to determine equilibrium KD 
values for MutD binding to FcγRIIa-R131, FcγRIIb and FcαRI. In all cases amine coupled BSA 
reference channels were used to subtract nonspecific binding signal. For evaluation of FcαRI 
binding to trastuzumab MutD and trastuzumab IgA, CM5 chips were immobilized with each of 
the antibodies (1820 RU and 1500 RU respectively) by amine coupling at pH 5.0 in 50 mM 
Sodium Acetate buffer. Concentrations ranging from 6 μM to 0 nM of soluble monomeric FcαRI 
were flowed in duplicate across the chip at 30 μL/min for 240 μL. A single step regeneration was 
used after each binding event; 5 min of 150 mM formic acid pH 5.0. A 1:1 Langmuir isotherm 
model ( A B AB+  ) was fit to the equilibrium data to obtain apparent KD values for each of 
the interactions.  
For affinity determination of FcγRIIb and FcyRIIa-R131 binding to trastuzumab MutD 
and trastuzumab IgG, antibodies were immobilized by amine coupling to CM5 chips (4310 RU 
and 4030 RU respectively) at pH 5.0 in 50 mM Sodium Acetate buffer. Concentrations ranging 
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from 10 μM to 0 μM of monomeric FcγRIIb and FcγRIIa-R131 were flowed in duplicate across 
the chip at 20 μL/min until an equilibrium state was achieved. Dissociation was performed using 
an 8 min step in the HBS-EP running buffer (GE Healthcare). A 1:1 Langmuir isotherm model 
was fit to the equilibrium data to obtain KD values for each of the interactions.  
To determine antibody affinity for FcγRI, CM5 chips (GE Healthcare) were covalently 
immobilized with trastuzumab MutD (1140 RU) or trastuzumab IgG (820RU) by amine coupling 
in 50 mM pH 5.0 Sodium Acetate buffer. Duplicate concentrations ranging from 37.5 nM to 0 
nM of soluble FcγRI (R&D systems) were flowed in random order across the chip at 30 μL/min. 
The chip was regenerated after each binding event by contact with 100 mM Sodium Citrate pH 
4.5 for 30 s. The resulting binding profiles were fit to a 1:1 Langmuir isotherm model using 
Biaevaluation 3.0 software.  
 
ADCC Assays 
Human neutrophils were isolated from Heparin-treated fresh human blood gathered from 
anonymous donors (IRB protocol 2012-08-0031) on the day prior to the ADCC assay. 10 mL of 
blood was diluted 1:1 with PBS (Mediatech) and layered over 13 mL of room temperature 
Histopaque 1077 (Invitrogen) in 50 mL conical tubes. The mixture was centrifuged at 2500 rpm 
for 30 min at 25 °C with no brake during the deceleration phase. Serum, Histopaque and 
mononuclear cells were discarded. The pellet was resuspended in 4 °C cold shock buffer (155 
mM Ammonium Chloride, 10 mM Potassium Bicarbonate and 0.1 mM EDTA) and incubated on 
ice for 10 min to lyse the red blood cells. The neutrophil fraction was isolated by centrifuging at 
1300 rpm for 7 min and washing twice with 50 mL PBS. After the final wash, the neutrophils 
were resuspended in RPMI media containing 10 % FBS as well as 50 ng/mL IFN-γ (Peprotech). 
The cells were cultured overnight at a concentration of 5 x 106 cells/mL in a 24 well plate under 
a humidified atmosphere of 5 % CO2. The following day expression of FcγRI and FcαRI was 
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determined by florescence activated cell sorting (FACS) to confirm activation. Meanwhile, 
SkBR-3 tumor cells (ATCC) were cultured in McCoy’s 5a media containing 10 % FBS 
(Invitrogen) and Penicillin-Streptomycin (Invitrogen). On the day of the assay the tumor cells 
were recovered by trypsinization and labeled for 90 min with Cr51 (Perkin Elmer) in a 1mL 
volume at a density of 1 x 106 cells/mL. The tumor cells were washed 3 times in RPMI 
containing 10 % FBS and seeded in 96 well V bottom plates at 5000 cells/well. Antibody 
variants at various concentrations were added to opsonize the tumor cells for 30 min at 37 °C. 
Neutrophils were then added at a 80 : 1 effector : tumor (E:T) cell ratio and the plates incubated 
at 37 oC with 5 % CO2 for 4 h. Supernatants were recovered and 50 µl was added to Uncoated 
Scintiplate-96 plates (PerkinElmer). After overnight drying the plates were read in a MicroBeta 
scintillation counter (PerkinElmer).  
 
Mammalian Expression of FcRn Peptide Fusion to MutD 
In order to reintroduce FcRn Binding to the MutD framework a C-terminal fusions with 
either a linear (QRFVTGHFGGLYPANG) or a cyclic binding peptide 
(QRFCTGHFGGLHPCNG) were generated by Gibson assembly [138].  The linear peptide 
insert was created using primers JL-GS-L-Rn 1 and JL-GS-L-Rn 2 and the cyclic peptide insert 
was generated with JL-GS-C-Rn 1 and JL-GS-L-Rn 2 primers. The vector backbone was created 
by amplifying a 6.5 kb fragment from pcDNA3.4-IgH-Trastuzumab-MutD using primers JL-
Gibson R and JL-Gibson F. Following transformation into E. coli and sequencing to verify 
cloning success the linear and cyclic variants were transfected into Expi293 cells as above. After 
5 days of culture the proteins were isolated by Protein L chromatography as described above and 
eluted in 100 mM pH 2.7 glycine HCl. 
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FcRn Binding ELISA Assay 
ELISA plates were coated with 4 μg/mL FcRn in PBS overnight. The following day 
wells were blocked with PBST containing a 2 % milk solution for 2 h at room temperature and 
washed 3x with PBST at pH 7.4. To the first well antibody variant was added at 140 μg/mL in 
either pH 7.4 PBS or pH 5.8 PBS with 40 mM MES and serially diluted by a factor of 4. After 1 
hour at room temperature the plates were washed 3x with either pH 7.4 PBS or pH 5.8 PBS with 
40 mM MES respectively depending on the pH at which the antibody was bound. The presence 
of antibody was detected by 1 hour incubation with a 1:5000 dilution of goat anti-human Cκ 
HRP in PBST with 2 % milk, washing with pH 7.4 PBS or pH 5.8 PBS with 40 mM MES buffer 
and development with 50 μL TMB substrate. The reaction as quenched with 50 μL 1M H2SO4 
was added to neutralize, and the absorbance at 450 nm was recorded.  
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RESULTS 
Characterization of IgA interaction with the FcαRI receptor 
Before the publication of a co-crystal structure that established the IgA CH2/CH3 domain 
interface as the binding site for FcαRI, mutagenesis studies had identified several key residues in 
the IgA structure that are critical for this interaction [139]. The substitutions L257R, P440A, 
A442R and F443R into the Fc domain of IgA showed ablation of FcαRI binding and the 
mutation P440R resulted in a significant reduction in binding to FcαRI. Notably, the mutation of 
residues distal to the CH2/CH3 hinge region of the IgA Fc (G259R) showed no impact on this 
interaction. Moreover, it was observed that despite a large disparity in sequence identity between 
bovine IgA and human IgA, the high conservation of residues in the CH2/CH3 binding pocket 
allows bovine IgA to bind human FcαRI [139]. This evidence suggested that chimeras between 
IgA and IgG antibodies may be functional in receptor binding assuming certain core residues are 
left unchanged. Guided by the crystal structure of IgA in complex with FcαRI [140], we first 
sought to identify the influence of additional residues to those previously published, particularly 
in the α2 loop of the IgA CH2 (Figure 2.1A and B). A panel of human IgA Fc domain mutants 
was constructed by Quikchange mutation to introduce alanine residues in place of the wild type 
residues at 11 sites (Figure 2.1A and B). IgA residues were selected for mutation based on their 
proximity to FcαRI in the co-crystal structure and residues 257 and 433 were included for 
comparison with previously published results [139].  
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Figure 2.1:  Residues Selected for Alanine Scanning in the Human IgA Fc Domain. 
The Fc domain was expressed with the hinge region and the tailpiece was truncated 
to remove the C-terminal cysteine responsible for dimerization.  
 
To improve the affinity of FcαRI for the IgA alanine mutants, the receptor was cloned 
with a C-terminal GST fusion, a dimeric protein, to promote dimerization of the FcαRI 
exodomain in solution. Dimerization of the receptor greatly improves the chances of FcαRI 
binding to IgA though avidity effects and reduces the apparent rate of dissociation. ELISA 
analysis revealed that mutation of position L257 in the α1 loop had little effect on binding 
affinity to FcαRI, consistent with previous reports [139] (Figure 2.2). However, a significant 
ablation in affinity for FcαRI was observed when residue L258 was altered. Previously, mutation 
of this residue to arginine had showed a similar reduction in binding [141], yet further 
investigation by non-reducing SDS-PAGE gel analysis showed poor assembly of this particular 
construct (Figure A.1). Disruption of the secondary structure of the protein can cause misfolding 
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or changes to the tertiary structure to prevent proper formation of the interchain disulfide bonds 
in the hinge region.  
 
 
Figure 2.2: ELISA Analysis of Binding between IgA Variants with Alanine Point Mutations.  
 
Interestingly, mutations to the IgA CH2 α2 loop all had a large impact on binding to 
FcαRI with the exception of the Histidine at position 317. This region was poorly resolved in the 
crystal structure but our result indicates the possibility of hydrogen bond interaction between 
E313, or N316, with Y86 in the FcαRI structure. In the IgA CH3 domain, charged residues in the 
C beta sheet (R382 and E389) were moderately important for binding. Towards the C-terminus 
of the IgA Fc, M433 was critical for binding as a key part of the hydrophobic binding pocket. 
Likewise, while mutation of the charged reside E437 did not influence binding, alanine 
substitution of the proximal hydrophobic residues L441 and F443 had a moderate contribution to 
the binding affinity.  
IgA has two N-linked glycan sites in the Fc domain at positions 263 and 459 and heavy 
O-linked glycosylation in the hinge at positions 225, 236, 228, 230 and 232 [57]. Studies 
removing glycans by enzymatic digestion [142], or by mutation of the single glycan site N263 
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[57] showed little glycan influence on FcαRI affinity, yet in each case the removal of glycans is 
incomplete or the structure has been mutated from wild type. To mitigate these concerns we 
expressed an aglycosylated wild type IgA1 truncated to remove the tailpiece in bacteria that lack 
all glycosylation transferase machinery. Binding to dimeric FcαRI was determined by ELISA 
and showed only a slight reduction as compared to full length human IgA, possibly due to poor 
assembly of the bacterial construct (Figure A.2A and B).    
 
Construction and Receptor Binding Properties of Hybrid IgA/IgG Mutants 
Antibodies of all isotypes are comprised of domains belonging to the immunoglobulin 
superfamily and share an exceptional level of structural homology even if there is low amino 
acid sequence identity [143]. Swapping of entire Ig domains, such as the VH, is regularly 
performed to create chimeric antibodies [63]. Likewise, in the case of the VH domain, CDR3 
loops within the Ig domain may be vastly altered to change the specificity of binding [64]. 
Therefore, we reasoned the tolerability of the VH domain to large scale sequence swaps might be 
extended to the Fc region (CH2 and CH3 domains) of immunoglobulins. Based on the 
information obtained from the alanine scanning, several Fc domain-swap variants were made in 
order to recapitulate binding affinity for FcαRI in an IgG1 scaffold (Figure A.3).  Residues in the 
IgG1 CH2 and CH3 domains were replaced with corresponding IgA1 sequences. Mutant B 
replaces IgG1 residues 336-443 (KGQPR….LSPGK, Kabat numbering [144]) with IgA1 
residues 335-444 (SGNTF…KTIDR). This mutant was generated as a negative control for 
ELISA assays and was previously been shown not to have affinity for the FcαRI receptor [139]. 
Mutant C replaces IgG1 residues 336-443 (KGQPR….LSPGK) and 242-254 
(PKPKDTLMISRTPE) with IgA1 residues 336-443 (SGNTF…KTIDR) and 245-257 
(PALEDLLLGSEAN), respectively. In the IgA:FcαRI crystal structure the α1 IgA CH2 domain 
loop (PALEDLLLGSEAN) makes extensive contacts with the FcαRI receptor [140]. Therefore 
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the entire α1 loop (PALEDLLLGSEAN) from IgA was substituted into IgG in order to preserve 
native contacts. Mutant D replaces IgG1 residues 336-443 (KGQPR…LSPGK) and 242-254 
(PKPKDTLMISRTPE) with IgA1 residues 336-443 (SGNTF…KTIDR) and 245-257 
(PALEDLLLGSEAN), respectively, but also contains an additional glycine following IgA1 
residue 257. The glycine residue was added to ensure that the length of the modified IgG CH2 
polypeptide is consistent with that of wild type IgG, thus preserving secondary structure 
contacts. Furthermore, the addition of glycine to the C-terminal end, rather than the N-terminal 
end of the α1 loop, was found to be critical for assembly of the hybrid Fc domain (data not 
shown). ELISA analysis of variant binding to dimeric FcαRI showed complete loss of binding 
for MutB whereas both MutC and MutD displayed comparable binding (Figure A.4A). However, 
SDS-PAGE analysis showed that the MutD Fc assembled into the dimeric form much more 
efficiently than either MutB or MutC highlighting the importance of the introduced glycine 
residue to the structure (Figure A.4B).   
Surprisingly, exchange of the α2 loop in the CH2 domain of MutD (residues 307-315 
TVLHQDWLN) with IgA residues 307-315 (PGCAEPWNH), identified via alanine scanning, 
did not confer improved binding to FcαRI as compared to the unmodified MutD construct. In an 
attempt to minimize the potential diversity of residues exchanged, Rosetta protein modeling 
software was used to computationally design several additional variants with substitutions to the 
IgG α2 loop. Again, while similar binding affinity to MutD was observed, no significant 
improvements in binding to FcαRI were seen by ELISA analysis (data not shown). Hence, MutD 
was selected for further characterization.    
 
Evaluation of Full Length IgA/G Hybrid Binding to Fc Receptors and Complement Factors 
 In order to fully recapitulate possible steric and conformation effects generated by the 
presence of the Fab when Fc receptors are engaged, MutD was expressed in HEK293 cells as a 
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full length antibody. Control isotype IgG and IgA antibodies were also expressed in the same 
system to minimize glycan heterogeneity introduced by different expression hosts. When 
compared by SDS-PAGE to full length IgA, MutD showed a higher percentage of fully 
assembled protein indicating a greater propensity for correct hinge region disulfide bond 
formation (Figure 2.3). Circumventing troublesome IgA expression is key to harnessing its 
therapeutic power and we have consistently noted higher MutD expression levels in HEK293F 
cell culture than IgA.  
   
 
Figure 2.3:  4-20 % SDS-PAGE Analysis of Full Length Expression of Trastuzumab 
Antibodies.  
 The dissociation constants (KD) of MutD, IgA and IgG for FcαRI and the various Fcγ 
receptors were determined by surface plasmon resonance (SPR) (Table 2.1). For evaluation of 
KD values to the low affinity receptors FcγRIIa, FcγRIIb and FcαRI interactions, equilibrium 
binding studies were performed by immobilization of the antibody to the chip surface and the 
injection of soluble monomeric receptors [145, 146]. Kinetic analysis was used to determine 
binding affinity, including on and off rates, for immobilized antibody interaction with soluble 
high affinity FcγRI receptors.  
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Table 2.1: SPR Data for MutD Binding to Fc Receptors. 
Full length IgG, IgA or MutD antibodies were amine coupled to a CM5 chip surface 
in 10 mM pH 5.0 Sodium Acetate buffer. Equilibrium binding was established for 
the low/moderate affinity FcγRIIa, FcγRIIb and FcαRI by flowing monomeric 
receptor analyte at 30 μL/min. Receptors were left to dissociate in running buffer 
with the exception of FcαRI which was regenerated with 5 min of contact with 150 
mM pH 5.0 formic acid. Kinetic assays were performed on the high affinity FcγRI 
receptor interactions and the chip was regenerated in 100 mM pH 4.5 citrate buffer. 
N.D indicates binding not detected. 
 
 
 
The FcαRI:IgA complex naturally forms with 2:1 stoichiometry but apparent affinities 
can be determined using a simplified 1:1 Langmuir binding model at equilibrium. The mutations 
made to form MutD introduce de novo binding to FcαRI with an apparent affinity of 502 nM, 
only slightly reduced from the KD value of 233 nM determined for wild type IgA. Surprisingly 
we found that MutD also retains binding for select FcγRs despite the introduction of large 
structural changes to the CH3 and CH2 domains. FcγRI was shown to bind with a KD of 0.83 nM 
essentially identical to the KD of 0.36 nM displayed by wild type IgG. For each of the FcγRIIa 
and FcγRIIb receptors which have a high degree of sequence identity, the binding affinity for 
MutD (2.02 μM and 4.33 μM respectively) was reduced by 50% as compared to that of wild type 
IgG (1.14 μM and 2.55 μM respectively). However, binding affinity for FcγRIIIa was completely 
lost. Because the mutations to MutD structure lie outside the putative FcγRIIIa binding site it is 
likely conformational shifts within the CH2 domain altered the Fc structure in a manner 
detrimental to binding to FcγRIIIa. To investigate the loss of FcγRIIIa binding further, an IgG 
variant was generated with only resides 245-257 from the α1 swapped with those from IgA 
(PKPKDTLMISRTPE > PALEDLLLGSEAN). This new variant displayed limited binding to 
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FcγRIIIa by ELISA, suggesting the both the CH2 and CH3 domains of IgG play an essential role 
in binding to this receptor (Figure 2.4).  
 
 
Figure 2.4:  ELISA Analysis of Variant Binding to FcγRIIIa. 
Hydrophobic ELISA plates were coated with 4 μg/mL of each antibody variant 
and FcγRIIIa-GST was serially diluted. Bound receptor was detected by goat 
anti-GST HRP. 
 
 FcαRI binds to IgA antibodies at the CH2/CH3 interface in the Fc domain 
whereas the FcγRs bind near the hinge region and the upper CH2 domain. The 
overlapping nature of the binding sites for FcγRI, FcγRIIa/b and FcγRIIIa requires 
engagement of these receptors to be mutually exclusive. By introducing FcαRI binding to 
MutD while retaining binding to FcγRs we inferred that simultaneous binding of multiple 
receptors might now be possible. As a positive control, a tandem Fc antibody was 
constructed containing an IgA Fc domain as a C-terminal fusion to a full length antibody. 
Simultaneous binding of FcαRI and His-tagged FcγRI receptor was detected by sandwich 
ELISA using an anti-His HRP secondary antibody as described in Figure 2.5A.  The data 
in Figure 2.5B revealed that FcαRI and FcγRI bind concurrently to MutD. Since FcαRI 
and also FcγRI share the common gamma chain to transduce activation signals, this 
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finding might imply this variant could trigger strong cellular responses by bringing 
surface bound activating receptors into closer proximity than a typical Fc domain.  
 
 
Figure 2.5:  ELISA Analysis Shows MutD can Simultaneously Bind to both FcαRI and 
FcγRI. 
A) Sandwich ELISA design. The ELISA plate was coated with 4 μg/mL of 
dimeric FcαRI followed by 4 μg/mL of each antibody variant. Monomeric 
His tagged FcγRI was serially diluted and detected with anti-His HRP. B) 
Concurrent MutD binding to FcγRI and FcαRI. A full length IgA variant 
was constructed with a C-terminal IgG Fc fusion for use as a positive 
control (IgA Fc – IgG Fc).   
 
As the FcγRs share a common binding site with C1q, the first molecule in the 
classical complement pathway, we suspected C1q affinity might be retained in the MutD 
variant. IgG binding to the complement protein C1q triggers a cascade that is essential in 
the clearance of bacteria and has been implicated in the clinical mechanism of Rituximab 
(anti-CD20) for the treatment of lymphoma [61]. ELISA analysis revealed MutD has 
approximately 10 fold lower affinity for C1q compared to wild type IgG whereas IgA did 
not bind over the range of concentrations tested as expected (Figure 2.6). IgA is reported 
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to activate complement by an alternative C1q-independent pathway and was therefore 
included as a negative control [147]. 
 
 
Figure 2.6:  MutD Binds C1q from the Classical Complement Pathway.
Variants were coated at 4ug/mL on hydrophobic plates and C1q was serially 
diluted. Detection of bound C1q was performed using a sheep anti-C1q HRP 
polyclonal secondary. 
 
In vitro Recruitment of Effector Cells by IgA/G Hybrid Antibodies for Tumor Cell 
Killing 
In vitro cell based ADCC assays provide an important method by which to 
evaluate immune activation by antibody variants. Importantly, these assays are designed 
to mimic the in vivo formation of immune complexes upon antigen-antibody interaction, 
which generates high Fc domain avidity for the FcRs. In addition, as the FcRs are bound 
to cell surfaces, steric effects are accounted for that are not included when evaluating the 
binding interaction of soluble FcRs with antibodies by SPR or ELISA. The gold standard 
for evaluating antibody performance in the killing of tumor cells by ADCC is the Cr51 
release assay. Tumor cells are loaded with radioactive Cr51 which is released to solution 
for detection by a scintillation counter upon cell lysis. A higher radioactive count per 
minute (cpm) indicates better tumor cell lysis efficiency and the percentage of lysis is 
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calculated as 100 x (cpm sample – cpm background) / (cpm max lysis – cpm 
background).  Maximum lysis is determined by incubating tumor cells in a complete lysis 
buffer to release all intracellular Cr51. 
In order to test our MutD variant, neutrophils were chosen as effector cells as they 
express high levels of both FcαRI and FcγRs and have been shown to mediate potent 
cytotoxic responses when activated [125] (Figure A.7). Neutrophils were isolated from 
fresh anti-coagulated human blood obtained from healthy donors in accordance with IRB 
protocol #2012-08-0031. Following red blood cell lysis, the cells were cultured overnight 
with IFN-γ to mimic the inflammatory environment associated with infection or the 
presence of a tumor. IFN-γ has been reported to upregulate the expression of FcγRI on 
neutrophils [148] and this was confirmed by FACS using anti-FcγRI fluorescent 
antibodies for each donor (Figure 2.7). After overnight culture, the neutrophil fraction 
was mixed with Cr51 loaded Her2+ SkBr-3 tumor cells opsonized with anti-Her2 
trastuzumab antibody variants. As a negative control an aglycosylated trastuzumab IgG 
was included that contains the glycan eliminating N297D mutation. Removal of the 
antibody Fc glycan greatly reduces antibody affinity for the FcγRs. All of the antibodies 
used in the ADCC assay were analyzed for lipopolysaccharide (LPS) levels prior to use 
to ensure <1 EU/mg was present. LPS can cause antibody independent activation of 
neutrophil samples that might introduce bias to the ADCC results [149].  
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Figure 2.7:  MutD Mediated Killing of Her2+ SkBR-3 Cells by ADCC. 
Neutrophils were purified from fresh blood and cultured overnight in the 
presence of 50 ng/mL IFN-γ. The levels of FcγRI on the neutrophils were 
measured before combination with MutD, aglycosylated N297D, IgA or IgG 
trastuzumab variants at concentrations between 10 and 0.1 μg/mL. Tumor 
cell lysis was determined by release of Cr51 isotope for a 80:1 E:T ratio. 
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Overnight culture of neutrophils from each donor with IFN-γ induced only a 
moderate two fold increase in FcγRI expression (Figure 2.7). However, culture with the 
cytokine did help to maintain neutrophil viability in excess of 95 % for all donors as 
determined by trypan blue staining. We observed trastuzumab MutD induced high levels 
of neutrophil mediated ADCC at antibody concentrations as low as 0.1 μg/mL. Despite 
the reduced affinity of MutD for FcαRI as compared to IgA, the percentage lysis was 
comparable to trastuzumab IgA. This observation suggests some FcγR activity might be 
contributing to MutD mediated neutrophil activation. The contribution of FcγR activation 
to tumor cell lysis is likely small as exemplified by the low percentage killing by wild 
type IgG (3-4 fold less tumor lysis than than IgA). Surprisingly, aglycosylated antibodies 
containing the N297D mutation also showed some small level of tumor cell killing in 
excess of the no antibody negative control levels. Recent work has shown that while 
binding to the FcγRs is greatly reduced in aglycosylated antibodies, residual affinity for 
high affinity FcγRI be amplified by avidity effects when in immune complex form to 
activate immune cells [150].  
 
Approaches for Half-life Extension of MutD Hybrid IgA/G antibodies 
 The serum half-life of IgG antibodies is greatly enhanced by binding to FcRn 
[52]. Under acidic conditions (pH < 6.5) FcRn binds tightly to IgG sequestered within 
early stage endosomes formed following the pinocytosis of fluid from circulation. Upon 
return to the cell surface, the slight alkalinity of the serum (pH 7.4) triggers release back 
into circulation. Unfortunately, the amino acid substitutions made at the CH2/CH3 hinge 
region to generate MutD have abolished affinity for FcRn and binding to this receptor 
was not detected (Table 2.1). The loss of FcRn binding is likely to reduce the serum half-
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life of MutD, although FcαRI binding has been shown to have a moderate contribution in 
the recycling of IgA antibodies [151]. However, both linear (QRFVTGHFGGLYPANG) 
and cyclic peptides (QRFCTGHFGGLHPCNG) have been recently discovered which 
bind to FcRn in a pH dependent manner; low binding is observed at pH 7.4 and high 
binding at acidic pH 5.8 [138]. We thought to evaluate FcRn binding to C-terminal 
fusions of each of the peptides with full length trastuzumab MutD.  
 
 
Figure 2.8:  Characterization of MutD with C-terminal Peptide Fusion Binding to FcRn 
at pH 5.8 and 7.4.
FcRn was bound to the plate surface and antibodies at 1 μM were added 
before detection with anti-Human heavy and light chain HRP secondary 
antibody at a 1:5000 dilution. 
 
When analyzed by ELISA, fusion of the cyclic FcRn binding peptide to MutD had 
the highest binding to FcRn at both pH 5.8 and substantial but reduced binding at pH 7.4 
(Figure 2.8). By contrast, fusion of linear peptide fusion did not show significant 
difference in binding between pH 5.8 and 7.4. The inefficient release of antibody at 
physiological pH can have the unintended consequence of reducing the serum half-life of 
therapeutic antibodies [152]. The binding of clinical grade IgG Herceptin without any 
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peptide fusion to FcRn was barely detectable by ELISA suggesting the peptide fusions 
have affinity for FcRn far in excess of wild type levels. Because the Fc domain is 
homodimeric, avidity effects created by the close proximity of two copies of the fusion 
peptides at the antibody C-terminus likely account for this increase in observed affinity. 
Both MutD fusions will require in vivo testing to truly evaluate the effect on half-life of 
these peptides. 
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DISCUSSION 
The challenges associated with IgA expression and purification have limited the 
use of this isotype as a therapeutic despite the wide range of inflammatory function that 
can be mediated by the FcαRI receptor. By engineering FcαRI binding into an IgG Fc 
scaffold to form MutD, we have introduced potent new function in the recruitment of 
neutrophils for ADCC while retaining close to wild type binding for most of the FcγRs. 
The MutD variant is particularly significant in that it is the first Fc domain engineered to 
have binding for receptors of multiple antibody isotypes. Deconvolution of the exact 
contribution towards inflammatory function mediated by each of the receptor classes 
(FcαRI and the FcγRs), as well as C1q from the complement cascade, is now required to 
better understand MutD function and guide the design of future variants. This 
undertaking is somewhat complicated by the widespread expression of both the FcγRs 
and FcαRI on human myeloid lineages [44, 153]. However, FcαRI is not expressed in 
mice owing to an ancient genomic translocation event that deleted the receptor gene 
[154]. Mice might therefore provide a model system to evaluate the FcγR function 
mediated by MutD. 
 Peculiarly, while binding to FcγRIIa and FcγRI is maintained, MutD does not 
bind FcγRIIIa even though the FcγR family shares a common binding site in the antibody 
hinge region. Analysis of the afucosylated IgG1 crystal structure complexed with 
FcγRIIIa, as shown in Figure 2.9, indicates that none of the Fc domain amino acids 
providing contacts with FcγRIIIa are in close proximity to the MutD mutations. Though it 
is plausible the MutD structure assumes a CH2 domain conformation which selectively 
excludes FcγRIIIa binding, there are also possible contacts between the glycans appended 
to N297 and the α1 loop in the CH2 domain of the Fc (dashed circle in Figure 2.9). The 
disruptions caused by exchange of this loop might have altered the glycan conformation 
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or even prevented glycan attachment thus eliminating binding to FcγRIIIa. Information 
provided by solving of the MutD crystal structure will be invaluable for guiding the 
design of next generation variants of MutD with restored FcγRIIIa binding.  
 
 
Figure 2.9:  Afucosylated IgG1 Fc Domain in Complex with FcγRIIIa (PDB: 3ay4).
Residues mutated in MutD are highlighted orange and the dashed circle 
shows the location of possible glycan contacts with the α1 loop of the IgA 
structure. 
 
Despite the loss of FcγRIIIa binding, MutD recruits IFN-γ activated neutrophils 
for the killing of Her2+ SkBr-3 cells with similar efficiency to IgA and shows 
significantly better killing than wild type IgG. The robust killing of tumor cells mediated 
by MutD recruitment of neutrophils could be very important for the treatment of in vivo 
cancers. The sheer abundance of the neutrophil population in circulation is a distinct 
advantage, especially since expansion can be rapidly accomplished via injection of G-
CSF [123]. As well as directing cytotoxic responses, neutrophils secrete a variety of 
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cytokines and chemokines to recruit additional immune cell subsets for inflammatory 
action [155]. For example, depletion of neutrophils from murine tumor models reduced 
cytotoxic T lymphocyte activation suggesting neutrophils play a vital role in modulating 
inflammatory adaptive immune responses [156]. The discovery of MutD provides access 
to the wide array of function mediated by FcαRI without any of the current regulatory 
and expression concerns surrounding the use of IgA or IgA antibodies in conjunction 
with IgG. The development of tumor models using FcαRI transgenic mice [56, 157] will 
be essential for evaluating therapeutic potential of MutD and future hybrid IgG/A 
variants. 
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Chapter 3: Effective Phagocytosis of Low Her2 Tumor Cell Lines with 
Engineered, Aglycosylated IgG Displaying High FcγRIIa Affinity and 
Selectivity 
INTRODUCTION 
Antibodies trigger a wide array of responses in leukocytes by linking antigenic 
targets on pathogens with FcγRs expressed on the surface of macrophages, granulocytes, 
dendritic cells, natural killer (NK) cells and B cells. Evidence suggests that the ratio of 
binding affinities of IgG1 in solution for the activating FcγRs and inhibitory FcγRIIb (A/I 
ratio) guides the extent of effector functions displayed by immune cells [48, 72, 158]. 
However, since signaling by FcγRs requires multivalent interaction with ICs, other 
parameters such as avidity of the ICs , FcγR expression level and cell surface distribution 
of the FcγRs on effector cells likely influence the nature of the response in addition to the 
A/I ratio. Although significant effort has been expended engineering Fcs for enhanced 
binding to FcγRIIIa to promote better NK cell killing, other cell subsets, including 
macrophages, can be strongly activated by FcγRIIa [75].  
There are two common polymorphisms within the FcγRIIa subclass which affect 
the binding affinity to IgG1 antibodies [116]. Individuals expressing the high affinity 
FcγRIIa-H131 allele are correlated in some studies with improved clinical response when 
treated with trastuzumab, rituximab or cetuximab [39-41]. Conversely, those 
homozygous for FcγRIIa-R131 have an increased risk of bacterial infection and 
autoimmunity due to the low affinity interaction with IgGs impairing immune complex 
clearance [159-162]. Because the low affinity FcγRIIa-R131 allele arises at a frequency 
between 0.47 - 0.57 in African Americans, 0.45 - 0.53 in Caucasians and 0.19 - 0.45 in 
Asians, the engineering of antibody Fc domains that can enhance responses in patients 
bearing the FcγRIIa-R131 allele is of significant mechanistic and clinical interest [162-
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164]. Particularly, the engagement of FcγRIIa is strongly implicated in the phagocytosis 
of tumor cells by macrophages, which were shown to comprise nearly 20% of infiltrating 
leukocytes in breast cancer biopsies [165]. 
 
 
Figure 3.1:  Overlaid FcγRIIa (PDB: 1H9V) and FcγRIIb (PDB: 2FCB) have High 
Structural Homology and Sequence Identity. 
Attempts to engineer IgG1 antibodies with enhanced FcγRIIa selectivity have 
either led to comparatively modest improvements in the A/I ratio (less than 6 fold change 
compared to wild-type) and/or  increased affinity for both FcγRIIa and FcγRIIb [71, 75, 
166]. Two predominant issues complicate the engineering of antibodies that display 
optimal FcγRIIa/FcγRIIb selectivity and FcγRIIa affinity for enhanced phagocytic 
potential: First, FcγRIIa shares 96% amino acid identity with FcγRIIb and therefore the 
generation of Fc ligands with discriminating power between the two is challenging 
(Figure 3.1) [167]. Second, because of the avidity effects involved when antibody-
decorated tumors interact with effector cells it is not easy to determine a priori whether 
high affinity to FcγRIIa, or a higher A/I ratio, or both are needed to enhance 
phagocytosis. Using aglycosylated antibodies as scaffolds for the reintroduction of FcγR 
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function presents a new approach to tackle these problems. The high flexibility of the 
CH2 domain in aglycosylated Fcs might allow for the identification of amino acid 
substitutions that stabilize certain conformers not accessible to glycosylated antibodies. 
We hypothesized that such substitutions might confer unusually high FcγRIIa affinity and 
selectivity with respect to binding to the highly homologous but inhibitory FcγRIIb for 
improved phagocytic potentiation. Accordingly, we report here that using a new library 
screening system we successfully isolated an engineered trastuzumab variant displaying 
>160 fold increased affinity for the FcγRIIa-R131 allele and a >25 increase in A/I ratio 
compared to clinical grade glycosylated trastuzumab (Herceptin). The Fc engineered 
trastuzumab was shown to elicit a striking increase in ADCP when using human 
macrophages as effector cells relative to Herceptin for both +3 (SKOV-3) and +2 (MDA-
MB-453) Her2 expressing cell lines [168]. To provide design criteria for further 
improving the efficacy of Fc variants a mathematical model was developed to establish 
the relationship between IgG binding to FcγRIIa/FcγRIIb and the activation of 
phagocytosis.  
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MATERIALS AND METHODS 
Library Construction 
An error prone PCR library using the trastuzumab-CH2-CH3 region of Fc5-2a as 
a template was created using standard techniques [169] and the two primers STJ#485 and 
STJ#67. VH-CH1 was then PCR amplified using the primers STJ#474 and STJ#486 from 
the template (pSTJ4-AglycoT). The two fragments, hinge-CH2-CH3 regions and VH-
CH1 regions, were assembled by gene assembly PCR using the primers STJ#474 and 
STJ#67 to generate the trastuzumab heavy chain (VH-CH1-Hinge-CH2-CH3) library. 
The amplified heavy chain library genes were ligated into SfiI-digested pPelBFLAG. The 
resulting plasmids were transformed into E. coli Jude-1 harboring the light chain plasmid 
(pBAD-AglycoT(L)-His). 
 
Culture and Spheroplasting of E. coli for Library Screening 
For screening, E. coli Jude-1 cells containing the heavy chain plasmid (pPelB-
VH-CH1-Hinge-CH2-CH3) and the light chain plasmid (pBAD-AglycoT(L)-His) were 
cultured overnight at 37 °C with 250 rpm shaking in TB supplemented with 2% (w/v) 
glucose and appropriate antibiotics (40 µg/mL of chloramphenicol and 50 µg/mL of 
kanamycin). The overnight cultured cells were diluted 1:100 in 110 mL of fresh TB. 
After incubation at 37 °C for 2 h and cooling at 25 °C with 250 rpm shaking for 20 min, 
protein expression was induced with 1 mM of isopropyl-1-thio-D-galactopyranoside 
(IPTG). Following protein expression for 20 h, spheroplasts were prepared from 36 mL 
of culture broth for library screening. 
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Library Screening 
Glycosylated FcγRIIa-R131-GST [170] was labeled with Alexa488 using an 
Alexa488 labeling kit (Invitrogen). A competitive screen was used to isolate clones with 
high binding affinity for FcγRIIa over FcγRIIb in which spheroplasts were incubated with 
fluorescent FcγRIIa-R131-GST-Alexa488 with excess amounts of non-fluorescent 
FcγRIIb-GST present (concentration of FcγRIIa-R131-GST-Alexa488: concentration of 
non-fluorescent FcγRIIb-GST = 30 nM: 100 nM for the 1st round, 10 nM: 100 nM for the 
2nd round, 10 nM : 100 nM for the 3rd round, 5 nM : 100 nM for the 4th round, and 5 
nM : 200 nM for the 5th round of sorting). More than 4 × 108 spheroplasts were sorted in 
the first round of screening on a MoFlo flow cytometer (Dako Cytomation) equipped 
with a 488 nm argon laser for excitation. In each round, the top 3% of the population 
showing the highest fluorescence was isolated and resorted immediately after the initial 
sorting. The heavy chain genes (VH-CH1-CH2-CH3) in the spheroplasts were amplified 
from the collected spheroplasts by PCR with two specific primers STJ#474 and STJ#67, 
ligated into SfiI restriction enzyme digested pPelBFLAG-Fc, and transformed in 
electrocompetent E. coli Jude-1 cells. The resulting transformants were grown on 
chloramphenicol containing LB agar plates and prepared again as spheroplasts for the 
next round of sorting. 
 
SPR Analysis  
Surface plasmon resonance (SPR) was performed using a BIAcore 3000 
instrument (GE Healthcare). Herceptin, AglycoT-Fc5-2a, AglycoT-Fc1001, AglycoT-
Fc1002, AglycoT-Fc1003, and AglycoT-Fc1004 were individually immobilized on CM5 
sensor chips by amine coupling as recommended by the manufacturer. Binding 
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experiments were performed in HBS-EP buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 
3.4 mM EDTA, and 0.005% P20 surfactant)(GE Healthcare). Dimeric FcγRIIa-131R-
GST, FcγRIIa-H131-GST, and FcγRIIb-GST receptors were injected in duplicate at a 
flow rate of 30 µl/min for 60 s with a dissociation time of 5 min. The chip was 
regenerated after each run by sequential injection of 50 mM glycine, pH 4.0, 50 mM 
glycine, pH 9.5, and 3 M NaCl for 2 min each. For each run, a bovine serum albumin-
coupled (BSA) surface was used to subtract non-specific receptor binding. Equilibrium 
dissociation constants (KD) for monovalent receptor binding were determined by fitting a 
2:1 bivalent analyte model ( 2A 2B AB B AB+ +  ) to the data using BIAevaluation 
3.2 software (GE Healthcare) in accordance with earlier analyses [171]. To determine 
binding to FcγRI, purified IgGs were immobilized on activated amine CM5 Biacore chips 
in 10 mM sodium acetate buffer (pH 5.0) and BSA in 10 mM sodium acetate (pH 5.0) 
was immobilized to a control lane on each chip for background receptor binding 
subtraction. 30 µl samples of purified FcγRI (R&D Systems) in HBS-EP running buffer 
were injected in duplicate and dissociation was monitored over a 5 min period. 10 mM 
glycine at pH 3.0 was used for chip regeneration between samples. The data were fit to a 
1:1 Langmuir binding model as described earlier to obtain kinetic constants [172]. 
 
ELISAs 
ELISA plates (Corning) were coated with 4 µg/mL of Her2 protein (Sino 
Biological) in 0.05M Na2CO3 (pH 9.5) overnight at 4 oC. The next day the plates were 
blocked at room temperature for 2 h with 2% milk in PBS containing 0.05% Tween 
(PBST) and washed four times in PBST at pH 7.4 before the addition of 4 µg/mL of 
antibody dissolved in PBS with 2% milk (PBSM). After 1 h of incubation, the plates 
were washed with PBST 4x and then 66 µl of FcγRIIIa-GST at 20 µg/mL added to the 
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first well followed by 1:4 serial dilution. The plates were incubated at room temperature 
for 1 h, washed with PBS 4x and 50 µl PBSM was added containing goat anti-GST HRP 
(GE Healthcare) 1:5000 for 1 h.  To develop the plates, the wells were washed 4x with 
PBST and 50 µl TMB substrate was added per well (Thermo Scientific). 50 µl of 1 M 
H2SO4 was used for neutralization and the final Abs450 was recorded. 
 
HER2 Cell Surface Density 
To qualitatively evaluate the density of HER2 receptors on the surface of SKBR-3 
(ATCC), SKOV-3 (ATCC), and MDA-MB-453 (ATCC) cells, 10 μg/mL of Herceptin or 
IgG1 pooled from human serum (Sigma-Aldrich) as a control were incubated with 106 
cells for 45 min on ice in 1 mL of Stain buffer (BD Biosciences). Subsequently, the 
Herceptin or IgG1 bound cells were washed with 1 mL of Stain buffer by centrifugation 
at 400 x g for 5 min, and labeled with 1:50 diluted donkey anti-human IgG (H+L) FITC-
conjugate Fab (Jackson ImmunoResearch Laboratories) on ice for 45 min.  The cells 
were washed twice more with 1 mL of Stain buffer following the centrifugation 
procedure above and cell fluorescence was analyzed by flow cytometry (BD 
FACSCalibur).   
 
Preparation of Human Monocyte-derived Macrophages 
PBMCs were isolated from fresh human pooled blood samples (Gulf Coast 
Regional Blood Center) by Histopaque (Sigma-Aldrich) gradient centrifugation. Briefly, 
20 mL Histopaque was added to 50 mL conical tubes followed by 30 mL of blood 
gradually. The mixture was centrifuged for 15 min in a swinging bucket rotor without 
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braking at 800 x g. PBMCs were aspirated from the sample and transferred to a fresh 
tube. The sample was washed twice with 50 mL PBS containing 2% FBS (Mediatech) 
and 1 mM EDTA by centrifuging without braking at 120 x g for 10 min to remove 
platelets from the sample. CD14+ monocytes were isolated by magnetic bead separation 
(Stemcell Technologies) according to the manufacturer’s instructions. Cells were 
resuspended in RPMI (Invitrogen) containing 15% FBS and seeded at 1.5 x 106 cell per 
well in 96 well plates containing 3 mL of the same media supplemented with 50 ng/mL 
GM-CSF (R&D systems). The cells were grown at 37 °C in 5% CO2 and at days 2 and 5 
of culture and an additional 1 mL of media with fresh cytokine was added to each well. 
After 7 days, non-adherent cells were aspirated and the plate was washed with 
Dulbecco’s PBS (Mediatech). 1 mL HyQTase (Thermo Scientific) solution was added for 
15 min at 37 °C for the detachment of macrophages from the plate surface. Recovered 
cells were washed with 50 mL RPMI media and resuspended in RPMI containing 10% 
Human AB serum (Mediatech). Macrophage differentiation was confirmed by staining 
with 10 µg/mL anti-CD14-APC (Clone M5E2, Biolegend) and 10 µg/mL anti-CD11b-
APC (Clone ICRF44, Biolegend).  
 
Quantification of FcγRs on Macrophages 
The anti-FcγRIIb antibody, 2B6-N297D [22] was transiently expressed and FITC 
labeled alongside an aglycosylated human IgG1 isotype control using a FITC conjugation 
kit (Invitrogen). Monocyte-derived macrophages were cultured as above and labeled 
separately with 20 μg/mL anti-FcγRI-FITC (Clone 10.1, Genetex), 10 μg/mL anti-
FcγRIIa-FITC (Clone IV.3, Stemcell Technologies), 20 μg/mL anti-FcγRIII-FITC (Clone 
3G8, Abcam), 1 μg/mL 2B6-N297D-FITC, 1 μg/mL human aglycosylated IgG1-FITC 
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isotype control as well as FITC conjugated murine isotype control antibodies for IgG1 
(20 μg/mL Clone 15H6, Biolegend) and IgG2b (10 μg/mL Clone MG2b-57, Biolegend). 
Receptor counts were determined in a FACS assay by comparing the fluorescent values 
of antibody labeled macrophages to standard curves generated by bead standards that 
capture precisely known numbers of each of the labeling antibodies (Quantum Simply 
Cellular anti-mouse and anti-human, Bangs Laboratories). 
 
ADCP Assays 
Tumor cells were recovered from culture flasks by tryspinization, labeled with 
PKH67 (Sigma-Aldrich) according to the manufacturer’s instructions and resuspended in 
RPMI with 10% human AB serum. These cells were seeded at 2 x 104 per well in 96 well 
V-bottom plates (Corning) followed by addition of macrophages at the appropriate 
effector: tumor cell ratio (1:5 MDA-MB-453, 1:10 SKOV-3) and antibodies, to a final 
concentration of 0.5 µg/mL. The plate was briefly spun at 2,000 rpm for 1 min and 
incubated at 37 °C with 5% CO2 for 2 h (MDA-MB-453) or 4 h (SKOV-3). Cells were 
detached from the plate by HyQTase treatment for 15 min and stained with 10 µg/mL 
anti-CD11b-APC and 10 µg/mL anti-CD14-APC on ice for 1 h. Phagocytosis was 
evaluated by FACS on an LSRFortessa (BD Bioscience), and reported as the fraction of 
double positive cells over the total number of tumor cells in the sample (see Figure 3.5 
for process overview). Fluorescent microscopy was performed on an Axiovert 200M 
(Carl Zeiss MicroImaging GmbH). 
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RESULTS 
Development and Characterization of a Full Length Antibody Display System in 
Bacteria 
Previous work showed that E. coli spheroplasts (bacteria lacking the outer 
membrane after chemical treatment to render periplasmic and inner membrane proteins 
accessible to exogenously added ligands), expressing engineered human Fc domains with 
the hinge region, bound FcγRI with affinity comparable to those determined in vitro 
using SPR analysis of binding kinetics [172]. However, we found that the binding of the 
aglycosylated Fc2a mutant, which had been engineered to bind FcγRIIa/FcγRIIb [166], 
was impaired when displayed in the homodimeric Fc display system [172]. Therefore, a 
full length IgG1 display system was developed by Dr Sang Taek Jung to accurately 
capture the conformational and steric effects present when antibodies interact with Fc 
binding ligands (Figure 3.2).  
 
 
Figure 3.2:  Full Length Display of IgG Antibodies in Bacteria. 
Nlpa anchors light chains to the inner membrane surface in the periplasm for 
assembly with soluble heavy chains and soluble light chains expressed 
concurrently. Spheroplasting disrupts the outer membrane to provide access 
for exogenous FcγRs that, if flurophore labeled, indicate binding when 
interrogated by flow cytometry.   
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For this purpose, the light chain (L chain) was fused at the N-terminal with the 
PelB leader peptide and the first 6 amino acids of the E. coli inner membrane lipoprotein 
NlpA which anchor it to the periplasmic side of the bacterial inner membrane [173]. To 
avoid steric constrains that might arise if both L chains of an IgG molecule are 
membrane-anchored, we constructed the dicistronic pBAD-AglycoT(L)-His plasmid 
which expresses NlpA anchored L chain (VL-Cκ) as well as unanchored L chain from the 
same promoter (Figure B.1A). Heavy chain polypeptides expressed by pPelB-
AglycoT(H)-FLAG and secreted into the periplasm assemble either with: (i) two 
unanchored L chains, (ii)  a membrane-anchored and an unanchored L chain, or (iii) two 
membrane-anchored L chains. The unanchored IgG in the periplasm is preferentially 
released from the bacteria following spheroplasting, whereas anchored IgG comprising 
one membrane-anchored and one unanchored L chain (or two membrane-anchored L 
chains) is retained on the surface of the spheroplasts. The Fc domain in the membrane-
anchored IgG is free to interact with exogenously added, fluorescently labeled FcγRs for 
fluorescence activated cell sorting analysis (FACS) and library screening. To validate the 
IgG display strategy, the H and L chains of AglycoT-Fc5 (aglycosylated trastuzumab 
with E382V/M428I [172]) and AglycoT-Fc2a (aglycosylated trastuzumab with 
S298G/T299A [166]) were cloned separately into pPelB-AglycoT(H)-FLAG vector and 
expressed in E. coli. Under optimized culture conditions, AglycoT-Fc5 expressing 
spheroplasts displayed high fluorescence following labeling with FcγRI-FITC (Figure 
B.1B) whereas spheroplasts expressing AglycoT-Fc2a could be labeled selectively with 
FcγRIIa-GST/anti-GST-FITC (Figure B.1C). In both instances, a large increase in 
fluorescent signal was observed relative to the negative control, indicating that inner 
membrane-anchored IgG display is well suited for the engineering of aglycosylated 
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antibody Fc variants that bind to other Fc receptors (FcγRI, FcγRIIa, FcγRIIb, 
FcγRIIIa/b, or FcRn).   
 
Isolation and Characterization of Aglycosylated IgG Fc Variants Displaying High 
Affinity and Binding Selectivity towards the FcγRIIa-R131 Allele 
An IgG that combined mutations from both Fc5 and Fc2a 
(E382V/M428I/S298G/T299A) was constructed and shown to display binding affinity to 
both FcγRI and FcγRIIa/FcγRIIb comparable to that of Fc5 and Fc2a respectively when 
expressed as individual variants (Figure B.1D). SPR analysis of the purified AglycoT-
Fc5-2a conducted by Tae Hyun Kang revealed that binding to FcγRI was significantly 
reduced relative to Herceptin (11 fold decrease or a 3-fold decrease relative to AglycoT-
Fc5). Interestingly, this antibody showed a small (40 %) but reproducible increase in the 
selectivity for FcγRIIa-R131 allele relative to FcγRIIb (AIIa-R131/I ratio) when 
compared to Herceptin and an even more significant increase in AIIa-R131/I relative to 
AglycoT-Fc2a (Table 3.1:). Therefore, AglycoT-Fc5-2a was used as a template for 
random mutagenesis and the isolation of variants that exhibit improved binding to the 
low affinity FcγRIIa-R131 allele and simultaneously increased AIIa-R131/I ratios. A 
library of random mutations in the Fc domain of AglycoT-Fc5-2a was created by error 
prone PCR to yield 4.8 × 109 transformants. Cells were incubated with a progressively 
increasing excess of unlabeled FcγRIIb-GST (extracellular domain of FcγRIIb fused with 
glutathione-S-transferase (GST) from Schistosoma japonicum), over highly homologous 
fluorescent FcγRIIa-GST-Alexa488 conjugate to help enrich variants displaying 
improved FcγRIIa/FcγRIIb selectivity. After five rounds of sorting, four individual clones 
showing markedly improved fluorescence upon incubation with 20 nM FcγRIIa-GST–
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Alexa-488 and 100 nM of FcγRIIb-GST relative to spheroplasted cells expressing 
AglycoT-Fc5-2a were isolated (Figure B.2 and B.3A). Cells expressing the clone termed 
AglycoT-Fc1001 (S298G, T299A, H268P, E294K, N361S and E382V, M428L (Figure 
3.4A)) exhibited the highest fluorescence under these conditions. Interestingly, the best 
performing variant in ADCP assays, AglycoT-Fc1004 (S298G, T299A, N390D, E382V, 
M428L (Figure 3.4B)) showed the lowest fluorescent signal.  
 
 
Figure 3.3:  Mutations Isolated in AglycoT-Fc1001 (A) and AglycoT-Fc1004 (B) are 
Shown on the 3D Structure of an Aglycosylated IgG1 Fc (PDB: 3S7G). 
Yellow = AglycoT-Fc2a base mutations, Blue = AglycoT-Fc5 base 
mutations, Red = AglycoT-Fc1001 mutations, and Purple = AglycoT-
Fc1004. 
Expression differences between the Fc1001 and Fc1004 variants are likely to be 
responsible for the qualitative difference between FACS signal and FcγRIIa binding; this 
can be addressed by two color sorting that also monitors antibody expression. Note that 
in AglycoT-Fc5-2a, residue M428 had been mutated to Ile, which was further changed to 
an Leu in AglycoT-Fc1004 and the three other selected clones pointing to the functional 
significance of this residue for effector FcγR binding (Figure B.2).  
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The four IgG variants corresponding to the sequences encoded by the highest 
fluorescence clones isolated by FACS were expressed in HEK293F cells to limit 
endotoxin contamination and purified (Figure B.3B). All IgGs contained the 
S298G/T299A mutations which block glycosylation at N297 and thus do not bind 
Concanavalin A. Binding of dimeric purified GST fusions of FcγRIIa-H131, FcγRIIa-
R131 and FcγRIIb to each IgG variant was determined by SPR analysis (Table 3.1). A 
bivalent binding model was used to fit the sensorgram curves and obtain monomeric 
binding constants in accordance with earlier studies (Figure B.4) [171]. This 
methodology resulted in equilibrium dissociation values, kon and koff rate constants for the 
binding of Herceptin and the various mutant Fcs to FcγRs that were in excellent 
agreement with the recent comprehensive binding data of all human IgG subclasses to 
effector FcγRs [116]. For easy comparison in Table 3.1, the binding data is reported as 
KD, mutant /KD, Herceptin ratios and also as (A/I)mutant /(A/I)Herceptin values. AglycoT-Fc1004 
IgG displayed the highest affinity for both FcγRIIa polymorphisms: a remarkable 163 
fold improvement in KD for the low affinity FcγRIIa-R131 relative to Herceptin and a 
more modest 5.7 fold affinity improvement for the high affinity FcγRIIa-H131 allele. The 
large increase in affinity towards FcγRIIa-R131 is consistent with the use of this receptor 
polymorphism for FACS screening. While AglycoT-Fc1004 showed somewhat higher 
affinity towards the inhibitory FcγRIIb, the much greater increase in FcγRIIa-R131 
affinity resulted in 25 fold improvement in AIIa-R131/I selectivity compared to Herceptin 
and a 16 fold increase in selectivity relative to its parental variant, AglycoT-Fc5-2a. 
AglycoT-Fc1001 displayed 21 fold higher FcγRIIa-R131 affinity than Herceptin and an 
AIIa-R131/I of 7.5 (5.3 fold increase relative to AglycoFc5-2a). The two other IgGs isolated 
from the screening displayed only marginal increases in FcγRIIa-R131 binding and lower 
affinity towards the FcγRIIa-H131 allele.   
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Table 3.1:  SPR Analysis. 
Showing the Ratio of Variant Affinity of Aglycosylated Trastuzumab Fc 
Variants to That of Glycosylated Herceptin for FcγRIIa-R131, FcγRIIa-
H131 FcγRIIb, and FcγRI 
 
 
The binding kinetics of the two highest affinity clones AglycoT-Fc1004 and 
AglycoT-Fc1001 and their parental AglcycoT-Fc5-2a towards FcγRI were evaluated by 
SPR and the data were fit with a 1:1 Langmuir binding model [171]. AglycoT-Fc5-2a 
displayed a 10 fold decrease in FcγRI binding compared to Herceptin, which was further 
reduced in AglycoT-Fc1004 and AglycoT-Fc1001 to almost a 50 fold lower level. 
Evidently, the S298G/T299A mutations that conferred binding to FcγRIIa and FcγRIIb to 
aglycosylated IgGs suppressed the ability of the Fc5 amino acid substitutions to bind 
FcγRI. The fact that AglycoT-Fc1004 has only two amino acid substitutions in the CH3 
domain (N390D, M428L), yet has 5 fold lower KD for FcγRI relative to its parental 
AglycoT-Fc5-2a template. Our data shows that the reason for the decreased FcγRI 
affinity of Fc1004 results from the N390D mutation and the subtle change I428L 
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(compared to I428M in the parental antibody Fc5-2a).  Both of these mutations are in the 
CH3 domain which is distal to the FcγR binding epitope, underscoring the significance of 
conformational flexibility in these interactions. This finding is consistent with the recent 
structural data that indicates in the absence of glycosylation the Fc domain displays a 
high degree of conformational flexibility and our hypothesis that mutations within the 
CH3 domain can stabilize particular conformers with unusual FcγR binding properties 
[112]. In particular, M428L is located near the hinge region of the CH2 and CH3 
domains where this mutation likely influences the local conformation and favorably 
impacts the binding of antibodies to FcRn [174].  
The isolated IgGs displayed no binding to either of the two FcγRIIIa 
polymorphisms (F158 and V158) as determined by ELISA (Figure B.3C). Interestingly, 
both AglycoT-Fc1001 and AglycoT-Fc1004 showed higher binding to the neonatal Fc 
receptor, FcRn, at endosomal pH 6.0 but not at physiological pH (Figure B.3D). This was 
most likely the consequence of the M428L mutation, which had been shown earlier to 
improve binding affinity for FcRn at pH 6.0 by 11 fold and thus confer extended IgG 
serum persistence and pharmacokinetics in animal models [174].  
 
Enhanced ADCP of Low and Medium Her2+ Cell Lines 
Surface expression of Her2 on SKBR-3, SKOV-3 and MDA-MB-453 Her2+ cells 
was evaluated by FACS following incubation with Herceptin and a fluorescently labeled 
secondary antibody. SKBR-3 cells showed a 2 fold higher FACS signal relative to 
SKOV-3 which in turn had a 2 fold greater Her2 binding signal than MDA-MB-453 cells 
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(Figure 3.4A). These results are consistent with the total Her2 expression in these cell 
lines as determined by Western blotting [175].  
 
 
Figure 3.4:  Expression Level of Her2 and FcγR on Tumor Cell Lines and Macrophages 
for ADCP Assay.
(A) Her2 expression level on tumor cell lines used for ADCP was confirmed 
by labeling with 10 µg/mL Herceptin or IgG1 pooled from human serum 
followed by fluorescent donkey anti-human IgG (H+L) FITC Fab at a 1:50 
dilution. (B) FcγR counts on macrophages were determined using a 
fluorescent Quantum Simply Cellular bead assay. Macrophages were 
labeled with 20 µg/mL anti-FcγRI-FITC, 10 µg/mL anti-FcγRIIa-FITC, 1 
µg/mL 2B6-N297D-FITC and 20 µg/mL anti-FcγRIII-FITC.   
 
CD14+ CD11b+ macrophages were prepared from pooled PBMCs (Peripheral 
blood mononuclear cells) following cultivation with GM-CSF cytokine [75]. The surface 
densities of FcγRI, FcγRIIa, FcγRIIb and FcγRIII on macrophages were determined by 
FACS. We observed high FcγRI, FcγRIIa and FcγRIIb levels in macrophages prepared at 
different times and from different pooled PBMC fractions (Figure 3.4B). Notably, the 
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level of FcγRI (CD64) was comparable to that of FcγRIIa and FcγRIIb in contrast to an 
earlier report that showed low level FcγRI expression in human macrophages [75].  
 
 
Figure 3.5: Schematic Diagram of ADCP Experimental Workflow. 
 
ADCP was determined by incubating PKH67 labeled, IgG opsonized tumor cells with 
macrophages at a low (1:5 MDA-MB-453 or 1:10 SKOV-3) ratio of target to effector 
cells. The numbers of CD11b+ CD14+ macrophages that stained with PKH67 (arising 
from associated/ingested tumor cells) were determined by FACS [75] (Figure B.6) and 
fluorescence microscopy (Figure 3.6C - E). As a positive control we used glycosylated 
trastuzumab with the mutation G236A (GlycoT-G236A), which has been reported to 
confer the highest AIIa-R131/I and AIIa-H131/I ratios reported in the literature (5.5 and 5.7 
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respectively, relative to wild-type IgG) and to mediate increased macrophage mediated 
ADCP of EpCAM+ LS180 cells [75]. We found that AglycoT-Fc1004 internalized 
approximately 75% more tumor cells (P<0.01) relative to Herceptin and 40% more 
relative to its glycosylated, Fc engineered GlycoT-G236A variant (Figure 3.6A and B, 
Figure B.6). Equally importantly, AglycoT-Fc1004 displayed the same high level of 
ADCP with both the SKOV-3 and with the even lower Her2 expressing MDA-MB-453 
cell line. These two cell lines correspond to approximately +3 and +2 Her2+ tumor cells 
respectively which have been shown to be recalcitrant to Herceptin treatment [176, 177]. 
Consequently, AglycoT-Fc1004 may provide the opportunity to treat patients having 
tumors with Her2 moderate or low expression that do not respond well to Herceptin. We 
expect binding to the low affinity FcγRIIa-R131 polymorphism to be particularly 
desirable since therapeutic responses in patients that are homozygotic or heterozygotic 
for this allele show poorer responses to anti-neoplastic antibodies [39-41]. On the other 
hand, AglycoT-Fc1001 could not induce phagocytosis of tumor cells above background 
for either cell line. Likewise, the addition of 2B6, an antagonistic FcγRIIb antibody, had 
no significant effect on ADCP with any of the engineered antibodies tested or with 
Herceptin, suggesting that tumor cell surface-bound ICs likely displace 2B6 from 
FcγRIIb allowing ITIM mediated signaling to occur.   
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Figure 3.6:  ADCP Mediated by Human Monocyte Derived Macrophages.
Experiments were performed using AglycoT-Fc1001 and AglycoT-
Fc1004 with +3 Her2+ SKOV-3 ovarian cancer (A) and +2 Her2+ MDA-
MB-453 breast cancer (B) tumor cell lines as target cells. ** Welch’s t test 
P < 0.01 for samples compared to No Ab negative control, ## Welch’s t 
test P < 0.01 for samples relative to G236A positive control. (C - E) 
Fluorescent microscopy images showing macrophages labeled with 10 
µg/mL anti-CD14-APC and 10 µg/mL anti-CD11b-APC (C), PKH67 
membrane labeled MDA-MB-453 tumor cells (D), and phagocytosed 
tumor cells (E).   
 
Mathematical Modeling of ADCP 
To gain insights on the puzzling lack of phagocytosis of Her2 expressing tumor 
cells opsonized with the AglycoT-Fc1001 antibody, a quantitative model to relate the 
formation IgG:FcγRIIa and IgG:FcγRIIb ICs to phagocytosis was developed by the 
Sarkar lab from the University of Pennsylvania (see Figure 3.7A).  
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Figure 3.7:  Mathematical Modeling Provides Insights into Design Rules Governing 
Phagocytic Potency of Fc Variants. 
(A) Schematic depicting the binding reactions considered in the 
mathematical model. (B and C) Validation of the mathematical model (red 
bars) with ADCP data (blue bars). ADCP data for trastuzumab and 
AglycoT-Fc1001 were used to fit intrinsic signaling potencies of the 
receptor subunits (Table B.5). This model was then directly used to predict 
ADCP responses for AglycoT-Fc1004 with both SKOV-3 cells (B) and 
MDA-MB-453 cells (C). (D) Predicted fraction of SKOV-3 cells 
phagocytosed for a range of KD_IIa-H131, KD_IIa-R131, and KD_IIb values. KD_IIb 
was held constant at 1 µM and KD_IIa-H131 and KD_IIa-R131 values were 
varied. Phagocytic responses for Herceptin (H), AglycoT-Fc5-2a (F), 
AglycoT-Fc1001 (1), AglycoT-Fc1002 (2), AglycoT-Fc1003 (3) and 
AglycoT-Fc1004 (4) were predicted based on their experimentally 
determined equilibrium binding constants to FcγRIIa-H131 and FcγRIIa-
R131 (see Table 1). (E) KD_IIa-R131 was held constant at 0.01 µM and KD_IIb 
and KD_IIa-H131 values were varied: fixed KD_IIb/KD_IIa-H131 ratios of 1 (white 
dash), 10 (red dash), and 100 (blue dash) are shown. (F) KD_IIa-H131 was 
held constant at 0.1 µM and KD_IIb and KD_IIa-R131 values were varied. The 
same ratios of A(R)/I affinity as in (E) are shown. 
Our simulations suggest that antigen-bound IgG, but not monomeric IgG, can 
elicit a significant phagocytic response because the clustered presentation of antigen-
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bound IgGs in the contact region results in an increased local concentration of Fc 
domains that leads to the displacement of monomeric IgG and promotes a sufficiently 
high level of FcγR crosslinks to elicit effector responses. This result is in complete 
agreement with in vivo observations that serum IgG alone, in the absence of ICs, cannot 
elicit FcγR signaling [34].  
To link biomolecular interactions at the cell surface to ADCP efficacy, we 
assigned an “intrinsic signaling potency” parameter to each receptor subunit and assumed 
that the signaling potency of each dimeric IgG:FcγR (used as a proxy for higher-order 
IgG:FcγR clusters) was equal to the sum of its constituents. The net signal generated by 
all FcγR complexes on the macrophage surface constituted the level of ADCP response 
(3). With the exception of the intrinsic signaling potencies for FcγRIIa-H131 and 
FcγRIIa-R131 (relative to FcγRIIb), all other parameters were obtained from 
experimental data, literature values or simulations (Table B.4). To parameterize the two 
relative signaling potencies for FcγRIIa-H131 and FcγRIIa-R131, the model was fit only 
to ADCP data for Herceptin and AglycoT-Fc1001 and then used to predict the expected 
ADCP response of AglycoT-Fc1004 (Figure 3.8B and C). Similarly, parameterization of 
the model using the data for any two antibodies within the Herceptin, AglycoT-Fc1001, 
and AglycoT-Fc1004 set accurately predicted the ADCP response for the third antibody 
(Figure B.7A - E). The model provides a framework for understanding the molecular 
basis for enhanced ADCP response. Figure 3.7D-F show heat maps of the predicted 
phagocytic responses for different KD_IIa-H131, KD_IIa-R131, and KD_IIb values. The IgG 
variants examined in this work were overlaid on Figure 3.7D based on their KD_IIa-H131 
and KD_IIa-R131 values to show their approximate expected ADCP responses (see Figure 
B.7E for actual predictions). The simulations show that enhanced ADCP most 
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dominantly correlates with increased affinity to FcγRIIa-H131, which is predicted to have 
a greater intrinsic signaling potency than FcγRIIa-R131 (Table B.5). This prediction is 
also consistent with clinical observations that FcγRIIa-R131 homozygous individuals are 
more susceptible to bacterial infections and autoimmune diseases [159-161], perhaps due 
to inefficient generation of activation signals in the absence of FcyRIIa-H131 subunits. 
It has been suggested that effector response can be predicted by the A/I ratio, 
defined as the ratio of IgG Fc affinity for FcγRIIa to that for FcγRIIb (6). To investigate 
the utility of A/I ratio in predicting phagocytosis, lines of constant AIIa-H131/I or A IIa-R131/I 
were plotted for fixed KD_IIa-R131 and KD_IIa-H131, respectively in Figure 4D (i.e., 
KD_IIb/KD_IIa-H131 in Figure 4E and KD_IIb/KD_IIa-R131 in Figure  4F). Even though a higher 
A/I ratio tends to elicit a higher effector response phagocytic activity can vary 
significantly even for a fixed A/I ratio, indicating that absolute receptor affinities also 
play a significant, if not dominant, role in shaping cellular response. Interestingly, for a 
fixed A/I ratio, increasing FcγRIIa-H131 affinity generally leads to increased 
phagocytosis (Figure 3.7E), while increasing FcγRIIa-R131 affinity leads to decreased 
phagocytosis (Figure 3.7F). This can be explained by the relative intrinsic signaling 
potencies of the receptor subunits (Table B.5). At a fixed AIIa-H131/I, increasing the 
affinity for FcγRIIa-H131 (potency > 1) would also increase the affinity for FcγRIIb 
(potency = –1), but the net effect would be increased activation due to the differential 
potencies. By contrast, at a fixed AIIa-R131/I, increasing affinities for both subunits would 
reduce ADCP response because FcγRIIb is more potent at signaling than FcγRIIa-R131 
(potency < 1). Our findings agree with recent crystal structure data that suggests the 
FcγRIIa-R131 polymorphism adopts a conformation that maybe less favorable for 
multimerization than FcyRIIa-H131, therefore limiting the proximity of ITAM domains 
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required to transduce activation signals [178]. The model suggests that efforts to improve 
the design of IgG Fc variants for enhanced ADCP should first focus on increasing affinity 
for FcγRIIa-H131 (Figure 3.7D and E) and, if not possible or insufficient, then on 
decreasing affinity for FcγRIIb (Figure 3.7E). If binding to the low affinity FcγRIIa-R131 
allele is required then both improved R131 affinity and A/I ratio are necessary for more 
potent ADCP (Figure 3.7F). While FcγRIIa and IIb have been established to be by far the 
most important receptors for phagocytosis by tumor cells [75, 179], the inclusion of 
FcγRI and FcγRIIIa in the model could be used to determine design criteria for 
glycosylated antibodies or future aglycosylated variants with more complex FcγR 
mediated effector function. 
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DISCUSSION 
So far, aglycosylated antibodies have been used for applications where 
inflammatory engagement of FcγRs or C1q complement proteins is undesirable [180]. 
Yet the generation of aglycosylated antibodies with unique affinities and selectivities 
may open the possibility for a new class of therapeutics with intriguing biological 
properties. To discover new aglycosylated Fc mutants, a bacterial display system has 
been developed in which full length IgG1 antibodies are tethered to the inner membrane 
of E. coli, leaving the Fc domain free to interact with fluorescently labeled FcγRs. By 
screening very large libraries (>108 variants) of IgGs containing randomly mutated Fc 
domains we isolated an aglycosylated antibody, AglycoT-Fc1004, that displays 
remarkably high affinity towards FcyRIIa-R131 as well as selectivity over FcγRIIb 
binding. To the best of our knowledge, this is the first report of an aglycosylated antibody 
that binds to FcγRs with affinity and selectivity which far exceed those of clinically used 
glycosylated antibodies, or of any engineered glycosylated mutants reported thus far, 
engineered either through mutagenesis programs or via glycoengineering [71, 75, 181, 
182].  
 The generation of highly FcγR selective Fc domains might allow for directed 
recruitment of certain immune effector cells, such as macrophages as shown here 
(because AglycoT-Fc1004 does not engage FcγRIIIa and has 50 fold lower affinity for 
FcγRI). So far, aglycosylated antibodies have been used for applications where 
inflammatory engagement of FcγRs or C1q complement proteins is undesirable [180]. 
The generation of aglycosylated antibodies with unique affinities and selectivities may 
open the possibility for a new class of therapeutics with intriguing biological properties. 
Fc engineered aglycosylated IgGs offer additional advantages by bypassing the need for 
N-linked glycosylation; eliminating glycan heterogeneity and broadening the range of 
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expression systems that can be used to produce large quantities of antibody. In several 
recent clinical trials, no evidence of aglycosylated antibody immunogenicity has been 
reported [180]. However, at this point it is unclear whether mutations to an aglycosylated 
structure will induce immunogenicity either through residue change or the generation of 
non-native conformational epitopes. The results from these studies will be reported in the 
future. 
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Chapter 4:  An Engineered Aglycosylated Fc Variant with High 
FcγRIIa-R131 Selectivity over FcγRIIb Shows NK Cell-Independent 
Killing of Her2+ Tumors in vivo 
INTRODUCTION 
The use of antibodies as therapeutics has revolutionized the treatment of cancer, 
infection and autoimmunity in modern medicine.  Engineering the antibody Fc domain to 
improve binding to activating Fc receptors on immune cells has the potential to further 
enhance inflammatory responses such as ADCC or ADCP. Recently, we isolated an 
aglycosylated variant with both high selectivity and affinity for FcγRIIa over inhibitory 
FcγRIIb as described in detail in Chapter 3 [96]. In particular, the variant Fc1004 
(S298G, T299A, E382V, N390D, M428L) exhibited selective binding to the low affinity 
polymorphic variant of FcγRIIa (160 fold improvement over glycosylated trastuzumab) 
which contains an arginine at position 131 rather than a histidine that defines the high 
affinity allele. As well as individual receptor affinity for the Fc domain, the activating to 
inhibitory ratio, defined as the affinity for the activating receptors in relation to the 
inhibitory FcγRIIb receptor, is a key predictor for ADCC and ADCP performance [183]. 
Despite a lack of binding to FcγRIIIa, the A/I ratio of Fc1004 (FcγRIIa-R131/FcγRIIb) 
was improved by more than 25 fold for which translated to significantly improved killing 
of Her2+ tumor cell lines by macrophages in vitro. While some clinical trials have 
demonstrated a correlation between the low affinity polymorphism of FcγRIIa and poor 
prognosis in monoclonal antibody therapy for cancer [39-41], the significance of the 
R131 allele is not conclusively established [184]. However, it is recognized that FcγRIIa-
R131 homozygotes have impaired clearance of immune complexes which can contribute 
to autoimmunity and increased susceptibility to bacterial infection [185].  
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Because of the widespread expression of FcγRIIa on most myeloid cell lineages, 
we hypothesized our enhanced Fc1004 variant might recruit multiple cell populations for 
the killing of tumors in vivo. The mechanism of several clinical antibodies (trastuzumab, 
rituximab) is thought to rely on NK mediated killing through engagement of FcγRIIIa 
[43, 119]. Yet, knockout of inhibitory FcγRIIb in mice, a receptor not expressed on NK 
cells [36], leads to enhanced tumor killing suggesting other cell subsets have a significant 
influence on tumor clearance [50]. In fact, the tumor microenvironment contains large 
numbers of infiltrating myeloid leukocytes following chemotherapy treatment, of which 
macrophages comprise nearly 20 % [186]. Often, tumor associated macrophages (TAMs) 
are indicative of poor prognosis for patients with breast, lung and lymphoma cancers 
[187-189]. Several reports suggest TAMs can suppress the adaptive immune system, 
remodel the surrounding cellular matrix and promote angiogenesis or metastasis [188, 
190]. Despite these pro-tumor effects, a recent study indicated TAMs retain their anti-
tumor activity if sufficiently activated suggesting these cells might be repurposed during 
monoclonal antibody therapy [191]. Likewise, tumor associated neutrophils (TANs) are 
strongly correlated with poor prognosis and also comprise a large portion of tumor 
infiltrating cells [192, 193]. Similar to macrophages, neutrophil hyper-activation via 
therapeutic antibody Fc engagement or by cytokines such as TGF-β can promote anti-
tumor effects [121, 156].  
Taken together this evidence suggests antibodies engineered for high binding to 
FcγRIIa might be able to potentiate NK cell-independent killing of tumor cells in vivo. 
Consequently, we demonstrate here preliminary evidence for killing of Her2+ human 
SkBr-3 breast cancer cells by Fc1004 using human macrophages (generated by in vitro 
differentiation of blood monocytes) and also in a NOD/SCID xenograft mouse model 
reconstituted using leukocytes from human FcyRIIa-R131 homozygous donors.  This 
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study provides a framework for further investigation into the mechanisms of tumor 
killing in vivo and suggests exciting new applications for the Fc1004 antibody. 
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MATERIALS AND METHODS 
Construction and Expression of Full Length trastuzumab Fc1004 and Control 
Antibodies 
 Plasmids used or constructed in this project are described in Table C1 and C2. 
The plasmids for expression of wild type trastuzumab IgG heavy chain (pMaz-IgH-
trastuzumab), trastuzumab kappa light chain (pMaz-IgL-trastuzumab) and trastuzumab 
IgG N297D heavy chain (pMaz-IgH-N297D-trastuzumab) were constructed as described 
previously [96]. DNA was prepared for each heavy chain and combined with an equal 
mass of light chain plasmid for transient transfection in HEK293F cells (Invitrogen). Five 
to six days after transfection, the cell suspension was centrifuged at 2000 rpm for 10 min 
to recover the supernatant fraction. Trastuzumab IgG and trastuzumab IgG N297D were 
purified over protein A affinity columns as follows. The supernatants were passed 
through 0.22 μm filters before addition to polypropylene columns packed with Protein A 
high capacity agarose resin (Thermo Scientific). The resulting flow-through was 
collected and passed twice more through the column before any unbound protein was 
washed away with >10 CV (Column Volume) of 1x PBS. All antibodies were eluted with 
3 mL of 100 mM citrate buffer (pH 3.0) and immediately neutralized with 1 mL of 1 M 
Tris (pH 8.0). Samples were buffer‐exchanged into 1x PBS using Amicon Ultra‐4 
(Millipore) spin columns with a 10 kDa cutoff. 
The polypeptide chain encoding the trastuzumab Fc1004 heavy and trastuzumab 
light chains were cloned into pcDNA3.4 plasmids for higher expression yields by Gibson 
cloning [136]. The plasmid backbone of pcDNA3.4 (Invitrogen) containing a wild type 
rabbit heavy chain was amplified using primers WK425 and WK 426. The trastuzumab 
Fc1004 heavy chain insert including the VH, CH1, CH2 and CH3 domains was amplified 
from pMaz-IgH-Fc1004-trastuzumab with primers WK429 and WK430. Likewise, the 
plasmid backbone for the light chain was prepared from pcDNA3.4 (Invitrogen) 
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containing a rabbit light chain by amplification with primers WK427 and WK428. The 
trastuzumab light chain (VL-Cκ) was recovered from pMaz-IgL-trastuzumab using 
primers WK431 and WK432. After incubation of both insert and backbone fragments in 
Gibson master mix for 1 hour at 50 °C to create pcDNA3.4-IgH-Fc1004-trastuzumab and  
pcDNA3.4-IgL-trastuzumab, the products were desalted and transformed into 
electrocompetent JUDE-1 E.coli cells. Following sequencing of individual colonies, bulk 
DNA stocks were prepared by Maxiprep (Qiagen) for transient transfection of expi293F 
cells (Invitrogen) according to the manufacturer’s instructions. Five to six days after 
transfection, supernatants were purified over protein A columns as above except an 
additional wash with 4 °C PBS containing 0.1 % triton X-114 was included to reduce 
endotoxin contamination of the purified antibodies. Antibody purity was assessed by 
SDS-PAGE gel and endotoxin levels were verified to be below 1 EU/mg using a 
chromogenic testing kit (Associates of Cape Cod). 
 
Endpoint PCR Genotyping 
 Genotyping of the FcγRIIa allele was performed based on optimized conditions 
from literature [194]. Briefly, genomic DNA was isolated from blood draw from 
anonymous donors in accordance with IRB protocol # 2012-08-0031 (Titled: Isolation of 
whole peripheral blood from healthy donors for antibody immunodiscovery) using a 
DNeasy blood and tissue kit (Qiagen). 25 μL PCR reactions were set up as described in 
Table 4.1. For detection of the FcγRIIa-H131 allele the forward primer WK124 and the 
reverse primer WK126 were used to produce a product of 949 bp. Similarly, detection of 
FcγRIIa-R131 used the forward primer WK125 and the reverse primer WK126 to make a 
fragment of the same size. Each genomic DNA sample was run with a set of control 
 88 
primers; WK127 forward (No homology to either polymorphism) and WK126 reverse to 
ensure amplification of the allele was specific.  
 
Table 4.1:  PCR Reaction Conditions for Endpoint Genotyping. 
Reagent Volume/Amount (μL) 
10x buffer (– MgCl2) 5 
MgCl2 (50 mM stock) 1.25 
dNTPs (10 mM stock) 2 
Genomic DNA (or control plasmid) 75-100 ng (1 ng plasmid) 
Fwd primer  0.25 (8 ng) 
Rev primer  0.25 (8 ng) 
Taq polymerase  0.5 (1.5 U) 
ddH2O to 25 
 
In addition, positive plasmid controls were included for each of the primer allele specific 
primer sets (pMaz-IgH-FcγRIIaH131-GST and pMaz-IgH-FcγRIIaR131-GST) which 
generate 179 bp fragments due to the lack of introns in the plasmid sequence encoding 
FcγRIIa.  The PCR reactions were cycled as follows; 45 cycles with 98 oC denaturation 
for 45 s, 63 oC annealing for 30 s and 72 oC extension for 90 s before a 7 min final 
extension step. The resulting products were run on a 1% agarose gel containing ethidium 
bromide for visualization by UV light.  
 
Taqman Probe Genotyping 
 Genomic DNA was isolated from consenting donors as above for use in TaqMan 
Genotyping assays (Invitrogen, SNP ID: rs1801274) reconstituted in TaqMan 
Genotyping Master Mix to a final volume of 25 μL (1 – 10 ng DNA in each reaction). 
Samples were run for 40 cycles of 15 s denaturation at 95 oC and a 1 min 
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annealing/extension step at 60 oC on a LightCycler 96 real-time PCR system (Roche). All 
samples were independently run in triplicate to verify the genotype result.  
 
Preparation of Human Monocyte-derived Macrophages.  
PBMCs were isolated from the fresh blood of genotyped homozygous FcγRIIa-
R131 or FcγRIIa-H131 donors by Histopaque (Sigma-Aldrich) gradient centrifugation. In 
short, 15 mL Histopaque was added to 50 mL SepMate conical tubes (Stemcell 
Technologies) followed by 15 mL of blood diluted 1:1 with PBS. The mixture was 
centrifuged for 15 min in a swinging bucket rotor without braking at 800 x g. PBMCs 
were aspirated from the sample and washed twice with 50 mL PBS containing 2 % FBS 
(Mediatech) and 1 mM EDTA by centrifuging without braking at 120 x g for 10 min. 
CD14+ monocytes were isolated by magnetic bead separation (Stemcell Technologies) 
according to the manufacturer’s instructions. Cells were resuspended in RPMI 
(Invitrogen) containing 10 % FBS as well as Penicillin/Streptomycin and seeded at 1.5 x 
106 cell per well in 96 well plates containing 3 mL of the same media supplemented with 
50 ng/mL GM-CSF (Peprotech). The cells were grown at 37 °C in 5 % CO2 and, at days 
2 and 5 of culture, an additional 1 mL of media with fresh cytokine was added to each 
well. After 7 days, non-adherent cells were aspirated and the plate was washed with 
Dulbecco’s PBS (Mediatech). 1 mL HyQTase (Thermo Scientific) solution was added for 
15 min at 37 °C for the detachment of macrophages from the plate surface. Recovered 
cells were washed with 50 mL RPMI media and resuspended in RPMI containing 10 % 
Human AB serum (Mediatech). 
 
 90 
ADCP Assays  
MDA-MB-453 tumor cells were grown in DMEM containing 10 % FBS. Cells 
were recovered from culture flasks by tryspinization, labeled with PKH67 (Sigma-
Aldrich) according to the manufacturer’s instructions and resuspended in RPMI with 
10% human AB serum. These cells were seeded at 5 x 103 per well in 96 well V-bottom 
plates (Corning) followed by addition of macrophages at the appropriate effector: tumor 
cell ratio (1:5 MDA-MB-453) and antibodies, to a final concentration of 5, 0.5 or 0.05 
µg/mL. The plate was briefly spun at 2,000 rpm for 1 min and incubated at 37 °C with 5 
% CO2 for 2 h (MDA-MB-453). Cells were stained with 10 µg/mL anti-CD11b-APC 
(Clone ICRF44, Biolegend) and 10 µg/mL anti-CD14-APC (Clone M5E2, Biolegend) on 
ice for 1 h. Phagocytosis was evaluated by FACS on an LSRFortessa (BD Bioscience), 
and reported as the fraction of double positive cells over the total number of tumor cells 
in the sample. 
 
Pharmacokinetic Study of Aglycosylated Fc1004 in Mice 
 C57BL/6 FcγR null mice transgenic for human FcγRIIa-R131 and FcγRIIb were 
obtained from Rockefeller University. The FcγR null background was generated by 
knockout of both the FcγRα locus (FcγRIIb, FcγRIII and FcγRIV negative) and the FcγRI 
gene [195]. The mice were divided into two cohorts and injected intraperitoneally (IP) 
with 8 mg/kg of trastuzumab Fc1004 (n=5) or clinical grade Herceptin (n=5). At 1 week 
intervals blood samples were recovered from the tail vein for a total of 3 weeks. Blood 
samples were allowed to clot and serum was recovered by spinning at > 10,000 rpm in 
microcentrifuge tubes for 10 min. ELISA analysis was used to quantify the relative 
abundance of the therapeutic antibodies in each serum sample. ELISA plates (Qiagen) 
were coated with 1 µg/mL of recombinant Her2 antigen (Sino Biological) in 1x PBS (pH 
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7.4) overnight at 4 °C. The next day the plates were blocked for 2 h at room temperature 
with 2 % milk in 1x PBS containing 0.05 % Tween (PBST) and washed three times in 
PBST at pH 7.4. To the first well, 66 µL of each serum sample was added followed by 
1:4 serial dilution in PBS containing 2 % milk. After 1 h of incubation at room 
temperature, the plates were washed and 50 µL PBSM was added containing 1:5000 goat 
anti-Human Heavy and Light HRP (Jackson ImmunoResearch) for 1 hour. To develop 
the plates, the wells were washed 3x with PBST, 50 µL TMB substrate was added per 
well (Thermo Scientific), 50 µL of 1 M H2SO4 was added to neutralize, and the 
absorbance at 450 nm was recorded.    
 
SkBr-3 Tumor Xenograft Cancer Model 
NOD/SCID mice were injected subcutaneously with 1 x 106 SkBr-3 Her2+ tumor 
cells and the tumors were grown until palpable. On day 0 of the experiment, the mice 
were split into three cohorts receiving either 12 mg/kg Fc1004 (n = 2), 12 mg/kg clinical 
grade Herceptin (n = 2) or PBS (n = 2) on day 0 via intraperitoneal injection. To provide 
functional immune cells, peripheral blood mononuclear cells (PBMCs) and peripheral 
blood cells (PBCs) from genoptyped FcyRIIa-R131 donors were adoptively transferred 
on the same day. In brief, fresh 15 mL blood samples were mixed 1:1 with PBS and 
layered over Histopaque (Sigma-Aldrich) in 50 mL conical tubes. The tubes were spun at 
800 g for 15 min with no brake. The PBMC fraction was recovered and the remaining 
pellet containing the PBC fraction was split between two 50 mL conical tubes. Red blood 
cells (RBCs) were lysed by a 10 min incubation step on ice with 45 mL cold shock buffer 
(155 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA). Both PBMCs and PBCs were 
washed twice with PBS and reconstituted for intravenous injection. 1 x 107 cells were 
delivered to each mouse at a PBC:PBMC ratio of 2:1. After 3 days, a maintenance dose 
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of 3 mg/kg of each antibody was injected IP along with PBS for the control cohort. 
Tumor progression was determined by sizing using Vernier calipers over the next 5 
weeks.  
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RESULTS 
Genotyping of Donors for FcγRIIa Polymorphism 
  First we examined the effect of FcγRIIa polymorphic status on the ability of 
human to eliminate cancer cells by ADCP. The FcγRIIa H131 and R131 alleles encoding 
genetic polymorphisms differ by a single nucleotide in the genome. PCR methods can be 
employed to determine the FcγRIIa polymorphism in blood samples from human donors. 
After isolation of genomic DNA, the sample is split between three PCR reactions each 
containing forward primers differing by a single 3` nucleotide and identical reverse 
primers [194]; two of the forward primers are specific for each of the polymorphic 
variants respectively while the third acts as a control primer with a 3` base mismatch to 
both polymorphisms (Figure 4.1A). Amplification should only occur if there is perfect 
homology between the forward primer and the DNA template resulting in a band at 949 
bp when run on an agarose gel. The control primer, with no homology to either 
polymorphism, is used to confirm specificity of the method during each reaction. As an 
additional positive control, plasmids encoding both FcyRIIa-R131 and H131 are included 
in separate reactions in place of the genomic DNA template. Successful amplification 
from the plasmid template produces smaller bands of 179 bp because of the removal of 
genomic introns from the sequence. This method was used to genotype several healthy 
donors as shown in Figure 4.1B.  
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Figure 4.1: PCR Endpoint Genotyping of Anonymous Donor Pool. 
A) Genomic DNA is isolated from small quantities of human blood for 
PCR. Amplification of the FcγRIIa gene occurs only if the primer has exact 
identity to the template DNA, single mismatches at the 3’ end of the primer 
yield no product. B) Agarose gel bands at 949 bp indicate presence of the 
allele. Plasmids containing each of the FcγRIIa allelic variants were run as 
controls. 
 
 
Despite the success of the endpoint genotype technique, a more accurate 
genotyping method was required as band intensity could differ significantly between 
donors (See donor 003 vs 005 in Figure 4.1B).  Thus we elected to use real-time PCR 
analysis using TaqMan probes for each of the FcγRIIa polymorphisms for genotyping 
(Figure 4.2). Of the 18 donors genotyped, the homozygous alleles were seen at a 
frequency of 0.28 compared to a heterozygous donor frequency of 0.44 in line with the 
reported frequencies for this allele [162-164] (Table C.3).  
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Figure 4.2: Genotyping Using Real-time PCR and Taqman Probes. 
The R131 probe was labeled with FAM fluorescent dye and the H131 probe 
was labeled with VIC dye. 
  
Effect of FcγRIIa Polymorphism on Killing of Her2+ Tumor Cells by Fc1004 
To evaluate the effect of FcγRIIa alleles on the potency of killing responses 
mediated by Fc1004, CD14+ CD11b+ macrophages were differentiated from monocytes 
isolated from the blood of genotyped donors for ADCP.  Flow cytometry was used to 
determine the number of PKH67-labeled MDA-MB-453 tumor cells internalized by 
macrophages stained with anti-CD11b APC and anti-CD14 APC antibodies. The MDA-
MB-453 tumor cell line is graded as +2 (moderate expression) for Her2 antigen surface 
expression by immunohistochemical staining on a scale that varies from 0 (no 
expression) to +3 (high expression) [168, 196]. Higher scores correlate with better 
clinical response to Herceptin therapy in patients bearing Her2+ tumors. This cell line 
was selected for comparison with previous ADCP assays described in Chapter 3. Clinical 
grade Herceptin was included as a positive control and antibodies containing the glycan 
deleting mutation N297D were included as a negative control. The removal of the glycan 
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at Asparagine 297 abrogates binding to the FcγRs, although some residual binding to 
FcγRI might remain if sufficient avidity is generated during immune complex formation 
[197].  
We found that at the highest antibody concentration of 5 μg/mL, homozygous 
R131 macrophages were able to engulf up to 40 % of tumor cells using Fc1004 compared 
to 20 % engulfment by H131 macrophages (Figure 4.3A and B). The percentage of 
phagocytosis for the R131 macrophage sample was consistent with that observed using 
pooled donor blood in the ADCP assays performed in Chapter 3.  At lower antibody 
concentrations, R131 macrophages were also more effective at phagocytosis than the 
H131 allele. Importantly, for macrophages isolated from the R131 donors, cell killing 
was significantly improved over clinical grade Herceptin with the exception of the lowest 
antibody concentration (0.05 μg/mL).   In all experiments the N297D variant showed 
significantly less killing than the other antibodies but was consistently above the no 
antibody controls.  
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Figure 4.3:  Representative ADCP Data for Genotyped Individuals in the Killing of 
Her2+ MDA-MB-453 Breast Cancer Cells. 
Antibodies at up to 5 μg/mL were incubated with tumor cells and mixed at a 
1:5 ratio with monocyte derived macrophages from either homozygous 
R131 (A) or homozygous H131 donors (B).  
 
In vivo Pharmacokinetics of Aglycosylated Fc1004 
Initially, uncertainly surrounded proposals to use aglycosylated antibodies for 
therapy because of potential immunogenicity, altered pharmacokinetic profiles and 
formulation instability [99]. Subsequent clinical trials with aglycosylated antibodies have 
allayed these concerns for the most part, as described in Chapter 1, but as yet no clinical 
trials have been undertaken with engineered aglycosylated antibodies. Hence, the 
pharmacokinetic behavior of engineered Fc1004 was investigated in mice. Fc1004 was 
expressed in HEK293F cells and purified by protein A affinity chromatography. 
Endotoxin levels were evaluated using a chromogenic Limulus Amebocyte Lysate assay 
and the protein preparations used were shown to have very low endotoxin levels.  (< 1 
EU/mg antibody). A low endotoxin level is necessary not only to prevent systemic 
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inflammation upon injection into mice but also to prevent activation of human immune 
cells used in the adoptive transfer tumor model described in the following section. 
 Transgenic mice expressing human FcγRIIa and FcγRIIb [195] were used in this 
study to account for the possibility that engagement of Fc1004 by human receptors in the 
mouse model might impact its biodistribution and half-life in the blood. Mice were 
injected with a single IP dose of either trastuzumab Fc1004 or clinical grade Herceptin at 
8 mg/kg and blood samples were recovered from the tail vein.  The concentration of 
Fc1004 antibody in serum samples was determined by ELISA using purified Her2 
antigen as the capture reagent.  While the average serum levels of Fc1004 and clinical 
grade Herceptin was comparable for the first two weeks but there was a statistically 
significant higher level of Fc1004 than Herceptin at the final timepoint after 3 weeks 
(Figure 4.4).  
 
 
 
Figure 4.4:  Pharmacokinetic Profile of Serum Persistence of Fc1004 as Compared to 
Clinical Grade Herceptin. 
Mice were injected with 8 mg/kg of Herceptin (n=5) or Fc1004 (n=5) and 
tail vein bleeds were drawn at weekly intervals for 3 weeks. Antibody 
persisting in the serum was measured by ELISA with Her2 antigen capture. 
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All data points were fit to an exponential decay model in Matlab to give half-lives 
for each of the antibodies as presented in Table 4.2. There was no significant difference 
between either of the antibodies despite the divergence in serum concentrations at the 
final time point.  The Fc1004 Fc domain contains the mutation M428L which was 
previously reported to confer 7 fold higher affinity for FcRn than wild type glycosylated 
antibodies [198]. When injected into rhesus monkeys, this improved affinity translated to 
a 1.8 fold improvement in half-life over the wild type version of the same antibody. The 
loss of glycosylation in the Fc domain is reported to have little effect on the affinity for 
FcRn and therefore we expect the M428L mutation in aglycosylated Fc1004 likely 
accounts for the difference in antibody concentration at the last time point [199, 200].   
 
Table 4.2:  Half-life of Fc1004 and Clinical Grade Herceptin Antibodies in Mouse 
Serum.
Data points were fit using Matlab software to an exponential decay model. 
Antibody Half Life (Days) 
95 % Confidence 
Min Max 
Fc1004 7.3 5.2 11.8 
Herceptin 5.3 4.0 7.7 
 
Enhanced Clearance of Her2+ Tumors in NOD/SCID Mice Reconstituted with 
Immune Cells from Human FcγRIIa-R131 Donors 
 Immunodeficient mice bearing human Her2 expressing tumor xenografts have 
been used extensively for the evaluation and mechanism of action of trastuzumab 
(Herceptin) in the treatment of human cancer [201-204]. Herceptin works in part by 
interfering with the dimerization of Her2 on the tumor cell surface and inhibiting multiple 
intracellular signaling pathways resulting in cell cycle arrest and apoptosis [205, 206]. 
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However, potent ADCC responses are also elicited though the recruitment of cell subsets 
with cytotoxic potential, such as NK cells, and thus immunodeficient mice cannot be 
used to evaluate killing by these mechanisms. Alternative immnocompetent mouse tumor 
models are available [207], but the testing of Fc engineered antibodies is particularly 
challenging due to several confounding factors. First, although mouse FcγRs do bind to 
human antibodies, both the FcγR classes and cellular expression patterns differ from 
humans [208].  Therefore, it is likely wild type mice do not suitably recapitulate the 
human immune system especially when considering the subtle balance of altered FcγR 
affinities in the engineered variants being tested. Second, to prevent rejection, syngeneic 
tumors compatible with the host mouse strain must be used with well characterized 
surface expression of a murine antigen against which a monoclonal antibody exists. 
However, the clinical antibodies often used as model drugs for evaluating new antibody 
therapeutics are against targets of human origin. Mouse tumor cell lines transgenic for 
surface bound human antigens might be used instead, although ensuring the long term 
stability of antigen expression levels in these cell lines is difficult in vivo in the absence 
of selection pressure provided in vitro by a selectable marker such as an antibiotic 
cassette.  
To circumvent these problems we used a NOD/SCID xenograft model with 
immune function reconstituted by the adoptive transfer of human leukocytes prepared 
from the blood of FcyRIIa-R131 homozygote donors. This approach allows for the use of 
human tumor cell lines as well as human effector cells to test engineered Fc variants. In 
pilot experiments, mice injected only with R131 peripheral blood leukocytes revealed a 
rapid decline in all cell subsets by FACS, with the exception of lymphocytes, after one 
week (Data not shown). As a result, leukocyte fractions were prepared from whole blood 
by Histopaque gradient separations and recombined at a ratio of 2:1 polymorphonuclear 
 101 
leukocytes (PMLs; including neutrophils, macrophages) to peripheral blood mononuclear 
cells (PBMCs; including lymphocytes, monocytes). Each mouse was injected 
subcutaneously with 1 x 106 human SkBR-3 breast cancer tumor cells (Figure 4.5), 
clinically graded as +3 for Her2 expression. A high Her2 expressing cell line was used 
maximize the likelihood of antibody mediated tumor regression in this preliminary study.  
  
 
Figure 4.5:  Experimental Design for Adoptive Transfer Tumor Xenograft Study. 
NOD/SCID mice were injected with 1x106 human SkBR3 cells prior to the 
start of the experiment. Once palpable tumors form antibodies at 12 mg/kg 
are injected I.P along with 1x107 PBCs and PBMCs reconstituted at a 2:1 
ratio after isolation from human homozygous R131 donors. A maintenance 
dose of 3 mg/kg was injected I.P 3 days after the initial injection. 
 
Once the SKBR-3 tumors had grown to a palpable size, a total of 1 x 107 reconstituted 
PMLs and PBMCs were injected via the tail vein. Concurrently, the mice were dosed 
with 12 mg/kg of each antibody intraperitoneally in accordance the dosage rates reported 
for 4D5, the trastuzumab murine precursor, in previous xenograft studies [201]. Based on 
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the half-life of the Fc1004 antibody reported in Table 4.2, a maintenance dose of 3 mg/kg 
was injected intraperitoneally after 3 days. The size of tumors was followed until either 
complete remission was observed or the mice were sacrificed (Figure 4.6).  
 
 
Figure 4.6:  Adoptive Transfer Tumor Xenograft Study. 
NOD/SCID mice bearing SkBr3 Her2+ tumors were injected with Fc1004 
(n=2), clinical grade Herceptin (n=2) or PBS (n=2). Tumor size was 
measured with Vernier calipers at regular intervals for 34 days. 
 
An immediate reduction in tumor size was noted after a time of 3 days following 
the first antibody injection and the rate of decrease in tumor size was considerably faster 
in the mice treated with Fc1004 than Herceptin. As expected, the mice receiving a R131 
donor leukocyte injection and PBS instead of antibody did not show any reduction in 
tumor size during the experiment. However, tumor growth was observed to plateau in this 
model, possibly due to antibody independent control of the tumor provided by the donor 
leukocytes injected. This finding suggests a more robust tumor model will be required in 
future studies with faster growing tumor cell lines. Despite concerns surrounding the 
slow growth of the SkBR-3 tumors, one of the mice injected with Fc1004 showed 
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complete remission following the antibody maintenance dose and all the remainder of the 
treated cohorts had tumors eliminated by day 47 (25 days after the start of treatment).  
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DISCUSSION 
The mechanism behind the clinical effect of many monoclonal antibodies, 
including trastuzumab and rituximab, has long been linked to NK effector cells. NK cells 
are powerful agents in the innate arm of immunity, particularly because they are one of 
the few cell types that lack expression of inhibitory FcγRIIb and therefore the cytotoxic 
responses they mediate are less regulated than other effector cells. Nevertheless, in 
accordance with recent studies that suggest other cell populations might contribute 
significantly to the clearance of tumors [121, 191], we report preliminary evidence of 
NK-cell independent killing of Her2+ tumors by an engineered aglycosylated antibody. 
As Fc1004 has no detectable binding to FcγRIIIa, the only FcγR expressed on NK cells, 
it is likely tumor killing is mediated by other cell subsets such as neutrophils and 
macrophages. Future studies are required to elucidate in detail the mechanism behind the 
potent action of Fc1004 in vivo. In addition, we have identified in vitro that Fc1004 
selectively enhances the macrophage ADCP response of low affinity FcγRIIa-R131 
homozygous donors who respond more poorly to antibody treatments in certain instances. 
The ADCP response of heterozygous donors to Fc1004 treatment is currently under 
evaluation. Previous studies have shown that heterozygotes expressing both FcγRIIa 
polymorphisms can use wild type antibodies to mediate in vitro ADCP with a phenotype 
similar to individuals homozygous for high affinity FcγRIIa-H131 [161]. Based on the 
dominance of the high affinity allele, we anticipate Fc1004 will show a similar but 
inverted trend because of exceptional affinity for the FcγRIIa-R131 polymorphism. Thus, 
the phagocytic killing of tumor cells by heterozygous donors is expected to parallel 
Fc1004 mediated ADCP using macrophages differentiated from FcγRIIa-R131 
homozygotes. Successful demonstration of enhanced ADCP by heterozygous donors 
would greatly expand the potential therapeutic relevance of Fc1004.   
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While aglycosylated antibodies have been used in vivo for anti-inflammatory 
function, we believe this is the first report of an engineered aglycosylated antibody with 
enhanced in vivo inflammatory potency. This is significant for several key reasons and 
provides the rationale for further in vivo studies to test Fc1004 in more robust cancer 
models. Importantly, the pharmacokinetic data indicate that the serum persistence of the 
aglycosylated Fc1004 antibody is at least as long as its wild type glycosylated 
counterpart. Thus it is likely that there is no significant instability in serum introduced by 
the removal of glycans or the mutations introduced to the antibody structure. 
Furthermore, these changes have not significantly increased the immunogenicity of the 
antibody, which would result in the generation anti-Fc1004 antibodies and a more rapid 
clearance from serum.  As well as the therapeutic activity offered by engineered 
aglycosylated antibodies, the discovery of additional variants with selective binding 
FcγRs might help in understanding antibody mechanism and the cell subsets that are most 
influential in the treatment of certain diseases.  
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Chapter 5:  Future Directions and Perspectives 
ENGINEERING NEW FC MUTANTS 
Millions of years of evolution have produced a finely balanced relationship 
between antibody subclass and the Fc receptors that can be engaged to potentiate immune 
function. Activating the immune system too strongly can result in systemic inflammation 
triggered by cytokine storms and even death. As a result the immune system has evolved 
inhibitory receptors to limit inflammation while still protecting the host from invading 
pathogens [209]. However, overriding these checkpoints through Fc engineering has 
emerged as a key strategy to treat diseases such as cancer where strong inflammatory 
function is desired. As a result, the pharmaceutical industry has invested heavily in the 
development of Fc domains with improved effector function. As these engineered Fc 
domains progress through to clinical trials, new strategies will be required to further 
improve the potency of antibodies and extend the range of applications for existing 
monoclonal antibodies. In this work two new engineered Fc domains have been described 
with interesting therapeutic potential. The generation of antibodies that bind receptors 
from multiple isotypes as exemplified by the discovery of MutD opens the possibility for 
combining functions from other antibody classes to create Fc domains for specific 
purposes. For example, it might be possible to harness the FcεRI receptor in combination 
with binding to the FcγRs in order to improve ADCC of tumor cells [210]. Further 
optimization of the MutD variant might also be possible through reintroduction of 
binding to FcγRIIIa or enhanced binding to FcγRIIa. Interaction with additional receptors 
could aid recruitment of additional immune cell subsets such as NK cells or enhance 
current interactions with the neutrophil subset. Likewise, engineered aglycosylated 
antibodies have demonstrated impressive discrimination in the receptors that can be 
bound, and in the case of Fc1004, even single amino acid polymorphic variations can be 
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distinguished (FcγRIIa-R131 vs FcγRIIa-H131). We have hypothesized the exceptional 
flexibility of aglycosylated antibodies allows the sampling of conformation space that 
cannot be accessed by glycosylated antibodies. By introducing point mutations to the 
structure certain conformations favorable for binding to select Fc receptors can be fixed. 
In future studies, the engineering of variants with high affinity and selectivity for FcγRIIb 
would be especially beneficial for applications where anti-inflammatory properties are 
desirable such as autoimmunity or anaphylaxis. Similarly, variants with selectively high 
binding to FcγRIIa-H131 might be found to complement the high FcγRIIa-R131 binding 
of Fc1004.  
While Fc receptors are well established binding ligands for antibodies, a new 
class of Fc binding proteins, termed Fc receptor-like proteins (FcRL), has been recently 
described. Certain members of this class bind with affinity comparable to IgG interaction 
with FcγRs to mediate both inflammatory and anti-inflammatory activity [211]. As more 
becomes known about their function, these proteins may emerge as viable targets for Fc 
engineering efforts focused on creating better therapeutics.  
 
INVESTIGATING THE MECHANISM AND POTENTIAL OF ENGINEERED FC VARIANTS 
To understand the therapeutic potential of newly discovered Fc variants the 
mechanisms of action must first be investigated. Along with the variants described in this 
work, the previously reported aglycosylated Fc5 variant discovered in the Georgiou lab 
might have applications in certain therapeutic niches [95].  The mutations in Fc5 confer 
selective binding to FcγRI with high affinity (~5 nM) and were demonstrated to recruit 
dendritic cells for ADCC, a function that glycosylated antibodies cannot perform. The 
ability to activate dendritic cells suggests utility of Fc5 for inducing adaptive immune 
responses. FcγRI on expressed on dendritic cells is shown to be is unique in mediating 
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effective cross presentation of antigen to MHC class I molecules to activate CD8+ 
cytotoxic T lymphocytes  as well as presentation on MHC II molecules for CD4+ T cell 
induction [212]. The degree of activation is heavily regulated by antibody affinity for the 
inhibitory FcγRIIb receptor [213]. Yet, despite FcγRIIb binding, clinical data indicates 
some monoclonal antibodies are able to induce both anti-tumor cytotoxic T cell activity 
and increase the serum titer of anti-tumor antibodies in patients [214]. As Fc5 lacks 
detectable binding to FcγRIIb, enhanced levels of antigen presentation would be expected 
to improve T cell activation over current therapeutic antibodies. Figure 5.1 outlines an 
experimental plan to measure and compare antibody mediated T cell activation in vitro. 
Dendritic cells are differentiated from blood derived monocytes and pulsed with dead 
tumor cells previously opsonized with antibody variants. Following dendritic cell co-
culture with autologous T cells, the small fraction of tumor antigen specific T cells will 
be induced to proliferate and express large amounts of inflammatory IFN-γ cytokine that 
can be detected by intracellular FACS. More T cell proliferation and IFN-γ expression 
indicates the Fc variant is able to mediate better antigen presentation.  
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Figure 5.1:  Experimental Design for the Evaluation of Engineered Fc Domain Mediated 
Antigen Presentation for Enhanced T Cell Activation. 
Blood is isolated from donors and PBMCs are collected. Dendritic cells are 
differentiated from monocytes and pulsed with antibody opsonized dead 
tumor cells before co-culture with autologous T cells. Activation of T cells 
is determined by quantification of intracellular IFN-γ levels using FACS.    
 
Applications for Aglycosylated Fc1004  
Other therapeutic applications might be found for Fc1004 antibodies, which have 
high binding to FcγRIIa-R131, and can recruit macrophages for tumor cell ADCP in 
vitro. For example, recent investigations into the mechanisms of action of the anti-CTLA-
4 antibody ipilimumab in mouse models have found the activation of tumor associated 
macrophages indirectly contributes to the clearance of melanoma lesions [215]. In part, 
ipilimumab acts as a CTLA-4 antagonist on cytotoxic T lymphocytes (CTLs) to prevent 
continual CD80/CD86 stimulation that can lead to T cell exhaustion reduced efficacy of 
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tumor clearance [216] (Figure 5.2). However, Treg cells within the tumor 
microenvironment also express high levels of CTLA-4 and serve to regulate CTL 
responses further. Tumor biopsies from mice revealed ipilimumab depletion of these Treg 
cells from the tumor microenvironment was dependent on infiltrating CD11b+ 
macrophages. Thus, in the absence of inhibitory signals, tumor antigen specific CTLs can 
become hyper-activated to mediate potent anti-tumor ADCC. 
 
 
Figure 5.2:  Partial Mechanism of Ipilimumab Action. 
The blockage of anti-CTLA-4 on cytotoxic T lymphocytes prevents 
inhibitory signals by CD80 and CD86 ligands on antigen presenting cell 
surfaces.   
 
Because Fc1004 enhances macrophage ADCP, we hypothesize ipilimumab containing 
the Fc1004 mutations would have improved in vivo efficacy in the removal of Treg cells 
over wild type ipilimumab and improved CTL action in reducing tumor burden. To test 
this hypothesis, the treatment of B16 tumors grown in transgenic mice expressing human 
FcγRIIa and FcγRIIb [195] might be explored using an anti-mouse CTLA-4 antibody 
(9D9, [217]). The use of transgenic mice bearing human FcγR genes is essential to 
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capture the refined binding specificity of Fc1004 especially since mouse FcγRs might an 
altered affinity profile for human antibodies. As a preliminary step, an ADCP assay was 
performed to confirm the suitability and function of macrophages differentiated from the 
bone marrow of the FcγRIIa/FcγRIIb transgenic mice (Appendix D). As shown in Figure 
5.3, trastuzumab Fc1004 is able to engulf Her2+ MDA-MB-453 tumor cells more 
effectively than either wild type IgG or the N297D aglycosylated negative control. 
Importantly, this preliminary data supports the testing of Fc1004 in an in vivo mouse 
model.  
 
 
Figure 5.3:  ADCP of Her2+ MDA-MB-453 Breast Cancer Cells by Transgenic 
FcγRIIa/b Mouse Macrophages. 
Trastuzumab antibodies were incubated at 5ug/mL with a ratio of 1:5 tumor 
cells to bone marrow monocyte derived macrophages. 
 
The plasticity of the antibody structure allows for the facile interchange of Fc 
domains between monoclonal antibodies to create mutants with altered target specificity 
for new applications. The work in this dissertation has described two new engineered 
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variants, Fc1004 and MutD, with enhanced potency in the clearance of tumor cells and a 
multitude of possible applications.  By engineering both aglycosylated and cross isotype 
hybrid Fc domains we have demonstrated new approaches that might be used to develop 
the next generation of antibody therapies.  
  
 
  
  113 
Appendix A 
Table A.1:  Plasmids Used in Chapter 2. 
Plasmids Relevant characteristics Reference or Source 
pTrc-DsbA IgA CH2 CH3 IgA Fc domain with truncated tailpiece (Residues 222-
445)  in bacterial expression vector 
This study 
pMaz-IgH-FcαRI-GST FcaRI gene in pMaz-IgH for dimeric mammalian 
expression 
This study 
pMaz-IgH-FcγRI-His FcyRI gene in pMaz-IgH for monomeric mammalian 
expression 
This study 
pMaz-IgH-FcγRI-GST FcyRI gene in pMaz-IgH for dimeric mammalian 
expression 
[96] 
pMaz-IgH-FcγRIIaR131-GST FcyRIIa gene in pMaz-IgH for dimeric mammalian 
expression 
[96] 
pMaz-IgH-FcγRIIb-GST FcyRIIb gene in pMaz-IgH for dimeric mammalian 
expression 
[96] 
pMaz-IgH-FcγRIIIa-GST FcyRIIIa gene in pMaz-IgH for dimeric mammalian 
expression 
[96] 
pMaz-IgH-MutB Mutant B Fc domain only in dimeric mammalian 
expression vector 
This study 
pMaz-IgH-MutC Mutant C Fc domain only in dimeric mammalian 
expression vector 
This study 
pMaz-IgH-MutD Mutant D Fc domain only in dimeric mammalian 
expression vector 
This study 
pMaz-IgH-trastuzumab Wild type IgG1 trastuzumab heavy chain mammalian 
expression vector 
[96] 
pMaz-IgL-trastuzumab Wild type IgG1 trastuzumab kappa light chain 
mammalian expression vector 
[96] 
pMaz-IgH-IgA-trastuzumab Wild type IgA1 trastuzumab mammalian expression 
vector 
This study 
pMaz-IgH-N297D-trastuzumab IgG1 trastuzumab heavy chain mammalian expression 
vector with glycosylation knockout at N297 
[96] 
pMaz-IgH-MutD-trastuzumab Mutant D trastuzumab in a mammalian expression 
vector 
This study 
pcDNA3.4-FcγRIIb-His Soluble His tagged monomeric FcγRIIb mammalian 
expression vector  
This study 
pcDNA3.4-FcγRIIaR131-His Soluble His tagged monomeric FcγRIIaR131 
mammalian expression vector 
This study 
 
Table A.2:  Primers Used in Chapter 2. 
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Primer Name Primer nucleotide sequence (5’  3’) 
JL-Gibson F TGAGCGGCCGCTCGAGGC  
JL-Gibson R TTTGCCCGCCAGCCTGTCGATGGTCTTCTGGGTGAA  
JL-GS-C-Rn-1 CGACAGGCTGGCGGGCAAAGGCGGCGGCGGCAGCCAGAGATTCTGCACCGGCCACTTCGGCG  
JL-GS-C-Rn-2 GCCTCGAGCGGCCGCTCAGCCGTTGCAGGGGTGCAGGCCGCCGAAGTGGCCGGTGCA  
JL-GS-L-Rn-1 CGACAGGCTGGCGGGCAAAGGCGGCGGCGGCAGCCAGAGATTCGTGACCGGCCACTTCGGCG 
JL-GS-L-Rn-2 GCCTCGAGCGGCCGCTCAGCCGTTGGCGGGGTACAGGCCGCCGAAGTGGCCGGTCAC  
TKA4 GCGTTGGAAGACCTTGCGCTTGGTAGCGAAGCG  
TKA5 CGCTTCGCTACCAAGCGCAAGGTCTTCCAACGC  
TKA6 CGTTGGAAGACCTTCTGGCGGGTAGCGAAGCGAATCTG  
TKA7 CAGATTCGCTTCGCTACCCGCCAGAAGGTCTTCCAACG  
TKA8 CTGTCGGGTTGCGCAGCGCCGTGGAATCATGGC  
TKA9 GCCATGATTCCACGGCGCTGCGCAACCCGACAG  
TKB1 GGTTGCGCAGAACCGTGGGCGCATGGCAAAACATTCAC  
TKB2 GTGAATGTTTTGCCATGCGCCCACGGTTCTGCGCAACC  
TKB3 GCGCAGAACCGTGGAATGCGGGCAAAACATTCACCTG  
TKB4 CAGGTGAATGTTTTGCCCGCATTCCACGGTTCTGCGC  
TKB7 CGAAAGATGTTCTGGTGGCGTGGCTGCAGGGAAGCC  
TKB8 GGCTTCCCTGCAGCCACGCCACCAGAACATCTTTCG  
TKC1 TGCAGGGAAGCCAAGCGCTGCCCCGTGAAAAG  
TKC2 CTTTTCACGGGGCAGCGCTTGGCTTCCCTGCA  
TKC5 GATACGTTCAGCTGCGCGGTGGGCCATGAGGC  
TKC6 GCCTCATGGCCCACCGCGCAGCTGAACGTATC  
TKD1 ATGGTGGGCCATGCGGCACTTCCGCTG  
TKD2 CAGCGGAAGTGCCGCATGGCCCACCAT  
TKD5 GCCATGAGGCACTTCCGGCGGCCTTTACTCAAAAAAC  
TKD6 GTTTTTTGAGTAAAGGCCGCCGGAAGTGCCTCATGGC  
TKE1 GAGGCACTTCCGCTGGCCGCGACTCAAAAAACTATTGATC  
TKE2 GATCAATAGTTTTTTGAGTCGCGGCCAGCGGAAGTGCCTC  
WK209 CGAGGCTGATCAGCGAGCT  
WK314 TGATCTAGAAGCTCGCTGATCAGCCTC  
WK346 GCCTTTCTCTCCACAGGCGCGCACTCCGTGCCGAGCACCCCCC  
WK347 CGAGGCTGATCAGCGAGCTTCTAGATCAGTGATGGTGATGATGGTGTTTGCCC 
WK353 GGACAATGGTCACCGTCTCCTCAGCGAGCCCGACGTCTCC  
WK354 GGCTGATCAGCGAGCTTCTAGATCATTTGCCCGCCAGACGATCAATAGTTTTTTGAGTAAAGGCCA
GCGG  
WK364 ACCGTCAGTCTTCCTCTTCCCCCCCGCGTTGGAAGACCTTCTGCTTGGTAGCGAAGCGAATGGCGT
CACATGCGTGGTGGTGGA  
WK366 CCCATCGAGAAAACCATCTCCAAAGCCAGCGGCAACACCTTCAGACC  
WK370 TCAGTCTTCCTCTTCCCCCCAGCCCTGGAGGACTTGCTG 
WK385 CGTACCGTGTGGTCAGCGTCCTCCCTGGATGTGCCGAGCCTTGGAATCACGGCAAGGAGTACAAG
TGCAAGGTCTC 
WK386 CCTGTCGATGGTCTTCTGGGTGAAGGC 
WK425 TGAGCGGCCGCTCGAG 
WK426 ACACTGGACACCTTTGAGCACAGC  
WK448 CGCTGTGCTCAAAGGTGTCCAGTGTCAAGCTGCTCCCCCAAAGGCTG  
WK450 CGCTGTGCTCAAAGGTGTCCAGTGTACACCTGCAGCTCCCCCAAAGG  
WK459 CGCTGTGCTCAAAGGTGTCCAGTGTCAGGAAGGGGACTTTCCCATGCC 
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WK460 GTGGTGATGGTGATGATGGTTCTGCGTCGTGTAATCTTGGTGGATG 
WK461 GTGGTGATGGTGATGATGCCCCATTGGTGAAGAGCTGCCC 
WK462 GTGGTGATGGTGATGATGGGGAGCTTGGACAGTGATGGTCAC 
WK463 CGCCTTATCCGGTAACTATCGTCTTG  
WK464 GACTCAAGACGATAGTTACCGGATAA 
 
Table A.3: Oligonucleotides Used in Chapter 2. 
Primer Name Oligonucleotide sequence (5’  3’) 
WK188 TTTCTCTCCACAGGCGCGCACTCCGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTC
CTGGGGGGACCGTCAGTCTTCCTCTTCC 
WK190 GGTCTTCGTGGCTCACGTCCACCACCACGCATGTGACCTCAGGGGTCCGGGAGATCATGAGGGTG
TCCTTGGGTTTTGGGGGGAAGAGGAAGACTGACGGTCCC 
WK191 GGTCTTCGTGGCTCACGTCCACCACCACGCACGTCACGTTGGCCTCGCTGCCCAGCAGCAAGTCCT
CCAGGGCTGGGGGGAAGAGGAAGACTGACGGTCCC 
WK192 GGTCTTCGTGGCTCACGTCCACCACCACGCACGTCACGCCGTTGGCCTCGCTGCCCAGCAGCAAG
TCCTCCAGGGCTGGGGGGAAGAGGAAGACTGACGGTCCC 
WK194 GTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGC
ATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTAC 
WK196 GGAGACCTTGCACTTGTACTCCTTGCCATTCAGCCAGTCCTGGTGCAGGACGGTGAGGACGCTGA
CCACACGGTACGTGCTGTTGTACTGCTCCTCCCGCGG 
WK198 GCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCC
AAAGCCAGCGGCAACACCTTCAGACCCGAGGTGCATCTGC 
WK200 GCACGTCCTTGGGGCTGAAGCCCCTCGCAAGGCAGGTGAGAGTGACCAGCTCGTTCAGGGCGAG
CTCCTCGCTGGGAGGGGGCAGCAGATGCACCTCGGGTCTGAAG 
WK202 CTTCAGCCCCAAGGACGTGCTCGTGAGGTGGCTGCAGGGCTCCCAGGAGCTGCCCAGGGAGAAG
TACCTGACCTGGGCCAGCAGGCAGGAGCCCAGCCAAGGCACC 
WK204 CCTCGTGGCCAACCATGCAAGAGAAAGTGTCGCCCTTCTTCCAGTCCTCCGCAGCGACCCTCAGGA
TGCTGGTGACGGCGAAGGTGGTGGTGCCTTGGCTGGGCTC 
WK206 CTTGCATGGTTGGCCACGAGGCCCTGCCCCTGGCCTTCACCCAGAAGACCATCGACAGGCACCAC
CATCATCACCACTGATCTAGAAGC 
WK207 CGAGGCTGATCAGCGAGCTTCTAGATCAGTGGTGATGATGGTGGTG 
WK188 TTTCTCTCCACAGGCGCGCACTCCGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTC
CTGGGGGGACCGTCAGTCTTCCTCTTCC 
WK190 GGTCTTCGTGGCTCACGTCCACCACCACGCATGTGACCTCAGGGGTCCGGGAGATCATGAGGGTG
TCCTTGGGTTTTGGGGGGAAGAGGAAGACTGACGGTCCC 
WK191 GGTCTTCGTGGCTCACGTCCACCACCACGCACGTCACGTTGGCCTCGCTGCCCAGCAGCAAGTCCT
CCAGGGCTGGGGGGAAGAGGAAGACTGACGGTCCC 
WK192 GGTCTTCGTGGCTCACGTCCACCACCACGCACGTCACGCCGTTGGCCTCGCTGCCCAGCAGCAAG
TCCTCCAGGGCTGGGGGGAAGAGGAAGACTGACGGTCCC 
WK194 GTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGC
ATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTAC 
WK196 GGAGACCTTGCACTTGTACTCCTTGCCATTCAGCCAGTCCTGGTGCAGGACGGTGAGGACGCTGA
CCACACGGTACGTGCTGTTGTACTGCTCCTCCCGCGG 
WK198 GCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCC
AAAGCCAGCGGCAACACCTTCAGACCCGAGGTGCATCTGC 
WK200 GCACGTCCTTGGGGCTGAAGCCCCTCGCAAGGCAGGTGAGAGTGACCAGCTCGTTCAGGGCGAG
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CTCCTCGCTGGGAGGGGGCAGCAGATGCACCTCGGGTCTGAAG 
WK202 CTTCAGCCCCAAGGACGTGCTCGTGAGGTGGCTGCAGGGCTCCCAGGAGCTGCCCAGGGAGAAG
TACCTGACCTGGGCCAGCAGGCAGGAGCCCAGCCAAGGCACC 
WK204 CCTCGTGGCCAACCATGCAAGAGAAAGTGTCGCCCTTCTTCCAGTCCTCCGCAGCGACCCTCAGGA
TGCTGGTGACGGCGAAGGTGGTGGTGCCTTGGCTGGGCTC 
WK206 CTTGCATGGTTGGCCACGAGGCCCTGCCCCTGGCCTTCACCCAGAAGACCATCGACAGGCACCAC
CATCATCACCACTGATCTAGAAGC 
WK207 CGAGGCTGATCAGCGAGCTTCTAGATCAGTGGTGATGATGGTGGTG 
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Figure A.1: SDS-PAGE Gel Showing Expression of IgA Fc Alanine Scanning Mutants 
Expressed in HEK293F Cells. 
 
 
Figure A.2:  Characterization of Aglycosylated IgA Expressed in Bacteria. 
A) ELISA analysis of completely aglycosylated IgA Fc domain binding to 
FcαRI as compared to full length glycosylated IgA from human serum. B) 
4-20% SDS-PAGE gel analysis of aglycosylated IgA. 
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Figure A.3:  Sequence Alignment of IgA/G Variants with Wild Type IgG. 
 
Figure A.4: Characterization of IgA/G Domain Swap Variants.
A) 4-20 % SDS-PAGE of variants expressed in HEK293F cells, B) ELISA 
analysis of variant binding to dimeric FcαRI-GST  
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Figure A.5:  SPR Analysis of MutD Affinity for FcγRIIa, FcγRIIb and FcαRI at 
Equilibrium. 
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Figure A.6: Kinetic Analysis of MutD Affinity for FcγRI by SPR. 
 
 
 
Figure A.7: Experimental Workflow for Neutrophil ADCC Assays. 
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Appendix B 
MATERIALS AND METHODS 
Molecular Biology Techniques  
All plasmids and primers used in this study are described in Table B1 and B2. A 
gene encoding the human IgG1 Fc (comprising the hinge, CH2, and CH3 domains), was 
ligated into pPelBFLAG on SfiI restriction endonuclease sites to generate pPelBFLAG-
Fc. pTrc99A-DsbA-Fc2a-FLAG was constructed by PCR amplification of the Fc2a gene 
containing mutations S298G and T299A in the CH2 region using two primers (STJ#422 
and STJ#147) with the template pTrc99A-DsbA-Fc-FLAG [172], and ligated into SacII / 
HindIII restriction enzyme-treated pTrc99A-DsbA-Fc-FLAG. To construct pSTJ4-
AglycoT-Fc2a, the Fc2a gene was amplified by primers STJ#290 and STJ#291, with 
pTrc99A-DsbA-Fc2a-FLAG as a template. The amplified PCR fragments were ligated 
into SalI / EcoRV digested pSTJ4-AglycoT to generate pSTJ4-AglycoT-Fc2a. pSTJ4-
AglycoT-Fc5-2a (E382V/M428I/S298G/T299A) was generated by amplifying the Fc5-2a 
gene using two primers (STJ#490 and STJ#220) and pSTJ4-AglycoT-Fc5 as a template, 
followed by SacII / EcoRI restriction enzyme digestion, and ligation into digested pSTJ4-
AglycoT.  
Trastuzumab heavy chains encoding either wild type human Fc or the Fc5, Fc2a, 
or Fc5-2a mutants were amplified using the primers STJ#474 and STJ#67 with the 
respective templates pSTJ4-AglycoT, pSTJ4-AglycoT-Fc5, pSTJ4-AglycoT-Fc2a, or 
pSTJ4-AglycoT-Fc5-2a. Each fragment was ligated into the pPelBFLAG vector using the 
SfiI restriction enzyme sites to generate pPelB-AglycoT(H)-FLAG, pPelB-AglycoT(H)-
Fc5-FLAG, pPelB-AglycoT(H)-Fc2a-FLAG, and pPelB-AglycoT(H)-Fc5-2a-FLAG. 
pBADNlpAHis-M18 was constructed by ligating the NlpA fused M18 scFv gene 
amplified from pMoPac1-FLAG-M18 [218], and digested with XbaI–HindIII restriction 
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enzymes, into pBAD30-KmR [218] digested with the same restriction endonucleases. 
Ligation of the trastuzumab VL-Cκ gene, amplified using two primers (STJ#475 and 
STJ#476) and template pSTJ4-AglcoT, into pBADNlpAHis-M18 using SfiI restriction 
sites generated pBADNlpA-VL-Cκ-His. The PelB leader peptide-fused trastuzumab VL-
Cκ gene was amplified with primers STJ#16 and STJ#340 from pSTJ4-AglycoT as the 
template, digested with XbaI / HindIII endonucleases, and ligated into pBADNlpA-VL-
Cκ-His digested with the same endonucleases to generate pBADPelB-VL-Cκ. pBAD-
AglycoT(L)-His was constructed by ligating XbaI digested PCR fragments amplified 
using the primers STJ#70 and STJ#332 with pBADPelB-VL-Cκ as a template into XbaI 
digested pBADNlpA-VL-Cκ-His.   
The Fc1001, Fc1002, Fc1003, Fc1004, FcG236A, and FcN297D genes were PCR 
amplified from AglycoT(H)-Fc1001-FLAG, AglycoT(H)-Fc1002-FLAG, AglycoT(H)-
Fc1003-FLAG, AglycoT(H)-Fc1004-FLAG, AglycoT(H)-FcG236A-FLAG, and 
AglycoT(H)-FcN297D-FLAG, respectively by using the primers STJ#290 and STJ#498, 
then digested with SalI and XbaI restriction enzymes, and ligated into the mammalian 
expression vector, pMAZ-IgH-GlycoT [172], to generate pMAZ-IgH-GlycoT-Fc1001, 
pMAZ-IgH-GlycoT-Fc1002, pMAZ-IgH-GlycoT-Fc1003, pMAZ-IgH-GlycoT-Fc1004, 
pMAZ-IgH-GlycoT-FcG236A, and pMAZ-IgH-GlycoT-FcN297D, respectively.     
For 2B6-N297D gene synthesis [219], 2B6  variable domains from heavy and 
light chains were gene assembled by PCR with Phusion polymerase (New England 
Biolabs) from primers WK#158 – WK#169 for the light chain and WK#172 – WK#187 
for the heavy chain  (25 cycles with 98 oC denaturation 1 min, 55 oC denaturation 1 min 
and 72 oC extension 2 min were performed before a 10 min final extension step). 
Correctly assembled genes were amplified with the light chain primers WK#158, 
WK#170 and heavy chain primers WK#171, WK#187 by overlap extension (OLE) PCR 
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[220]. Briefly, the megaprimer generated in the previous step was added with Phusion 
polymerase at a 1:250 molar ratio to heavy chain template (pMAZ-IgH-GlycoT-
FcN297D) and light chain template (pMAZ-IgL-GlycoT) (25 cycles of amplification 
were performed with 98 oC denaturation 1 min, 55 oC denaturation 1 min and 72 oC 
extension 10 min steps). Remaining template plasmid in the PCR reaction was digested 
with Dpn1 endonuclease for 1 h at 37 oC and the final mixture was transformed into Jude-
1 cells (F' [Tn10(Tetr) proAB+ lacIq Δ(lacZ)M15] mcrA Δ(mrr-hsdRMS-mcrBC) 
80dlacZΔM15 ΔlacX74 deoR recA1 araD139 Δ(ara leu)7697 galU galK rpsL endA1 
nupG) [221].  
pMAZ-FcγRIIaH131-GST was cloned by the OLE PCR method as described above 
using a megaprimer generated with primers WK#100 and WK#101 from pDNR-LIB-
FcγRIIa (ATCC: MGC-23887). The second PCR step cloned this megaprimer fragment 
in place of FcγRI in pMAZ-FcγRI-GST, a plasmid derived by OLE PCR from pMAZ-
IgH GlycoT by cloning the FcγRI-GST cassette from pcDNA3(oriP)-FcγRI [170] with 
primers WK#56 and WK#57. pMAZ-FcγRIIaR131-GST was generated by OLE PCR using 
pMAZ-FcγRIIaH131-GST as a template to generate a megaprimer with primers (WK#100 
and WK#116).  
For the construction of pPelBHis-FcγRIIIaV158, the FcγRIIIaV158 gene was PCR 
amplified using primers STJ#76 and STJ#82 and the template pCMV-SPORT6-FcγRIIIa 
(ATCC: MGC-45020), and then ligated into pPelBHis [172] using the SfiI sites. pMAZ-
FcγRIIIaV158-GST was cloned by OLE PCR from pMAZ-FcγRIIIaV158, a monomeric 
mammalian derivative of pPelBHis-FcrRIIIaV158, with primers WK#91 and WK#92 used 
to generate the megaprimer. The recipient vector was pMAZ-FcγRIIaH158-GST. pMAZ-
FcγRIIIF158-GST was likewise cloned by OLE PCR from pMAZ-FcγRIIIaV158-GST with 
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primers WK#91 and WK#94 used for megaprimer synthesis and pMAZ-FcγRIIIaV158-
GST as the recipient vector. 
 
IgG Display in E. coli for FcγR Binding 
pBAD-AglycoT(L)-His was transformed with either pPelB-AglycoT(H)-FLAG, 
pPelB-AglycoT(H)-Fc5-FLAG, pPelB-AglycoT(H)-Fc2a-FLAG, or pPelB-AglycoT(H)-
Fc5-2a-FLAG for wild type trastuzumab, trastuzumab-Fc5, trastuzumab-Fc2a, or 
trastuzumab-Fc5-2a, respectively into E. coli JUDE-1. The transformed E. coli cells were 
cultured overnight at 37 °C with 250 rpm shaking in TB (Terrific Broth; Becton 
Dickinson Diagnostic Systems Difco™) supplemented with 2% (wt/vol) glucose, 
chloramphenicol (40 µg/mL) and kanamycin (50 µg/mL). The overnight cultured cells 
were diluted 1:100 in fresh 7 mL of TB medium with chloramphenicol (40 µg/mL) and 
kanamycin (50 µg/mL) in 125 mL Erlenmeyer flask. After incubation at 37 °C for 2 h 
and cooling at 25 °C for 20 min with 250 rpm shaking, protein expression was induced 
with 1 mM of isopropyl-1-thio-D-galactopyranoside (IPTG). 20 h after IPTG induction, 6 
mL of the culture broth was harvested by centrifugation and washed two times in 1 mL of 
cold 10 mM Tris-HCl (pH 8.0). After re-suspension in 1 mL cold STE solution (0.5 M 
Sucrose, 10 mM Tris-HCl, 10 mM EDTA, pH 8.0), the cells were incubated at 37 °C for 
30 min on a tube rotator, pelleted by centrifugation at 12,000 x g for 1 min and washed in 
1 mL of cold Solution A (0.5 M Sucrose, 20 mM MgCl2, 10 mM MOPS, pH 6.8). The 
washed cells were incubated in 1 mL Solution A with 1 mg/mL of hen egg lysozyme at 
37 °C for 15 min. After centrifugation at 12,000 x g for 1 min, the resulting spheroplast 
pellets were resuspended in 1 mL of cold PBS. 300 µl of the spheroplasts were further 
diluted in 700 µl of PBS and labeled with 30 nM FcγRI-FITC to analyze binding. For 
FACS analysis of FcγRIIa binding, spheroplasts were incubated with 30 nM FcγRIIa C-
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terminal fused to GST [170], washed in 1 mL of PBS, and labeled with polyclonal goat 
anti-GST-FITC (Abcam) diluted 1:200 in 1 mL of PBS. After incubation for 1 h with 
vigorous shaking at 25 °C protected from light, the mixture was pelleted by 
centrifugation at 12,000 x g for 1 min and resuspended in 1 ml of PBS. The fluorescently 
labeled spheroplasts were diluted in 2.5 mL of PBS and analyzed on BD FACSCalibur 
(BD Bioscience). 
 
Protein Expression and Purification 
AglycoT-Fc1001, AglycoT-Fc1002, AglycoT-Fc1003, AglycoT-Fc1004, GlycoT-
G236A, AglycoT-N297D and the N297D variant of an anti-FcγRIIb 2B6 antibody [219] 
were produced by transient transfection of HEK293F cells (Invitrogen). pMAZ-IgL and 
pMAZ-IgH vectors for each of the variants were purified from overnight E. coli cultures 
by Midiprep (Qiagen). 293Fectin Transfection Reagent (Invitrogen) was used to transfect 
cells cultured in GIBCO FreeStyle™ 293 Expression Medium (Invitrogen) following the 
manufacturer’s instructions. After 6 days, the cells were pelleted by centrifugation at 
2,000 rpm for 10 min and the supernatant was recovered. 25x PBS was added to the 
supernatant to make a 1x final concentration and the solution was passed through a 0.22 
µm filter. Protein A high capacity agarose resin (Thermo Scientific) was added to a 
polypropylene column and allowed to settle. The packed slurry was equilibrated with 1x 
PBS before addition of the buffered supernatant. The flow through was collected and 
passed twice more through the column. Unbound proteins were washed away with >10 
CV (Column Volume) of 1x PBS. IgGs were eluted with 3 mL of 100 mM glycine-HCl 
(pH 2.7) and immediately neutralized with 1 mL of 1 M Tris (pH 8.0). Samples were 
buffer-exchanged into 1x PBS using Amicon Ultra-4 (Millipore) spin columns with a 10 
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kDa cutoff. Purity of purified samples was assessed by 4-20% gradient SDS-PAGE gel 
(NuSep). 
FcγRIIa-R131-GST, FcγRIIa-H131-GST, FcγRIIb-GST and FcγRIIIa-F158-GST 
were produced by transient transfection of HEK293F cells (Invitrogen) using the pMAZ-
IgH expression vectors described. Receptors with GST fusion partners were purified by 
Glutathione Sepharose (GE Healthcare) affinity chromatography. 25x PBS was added to 
filtered supernatants to a 1x concentration and the mixture passed twice over the column. 
The column was washed with 100 mL of 1x PBS to remove nonspecifically bound 
protein. 4 mL of 1x PBS containing 10 mM reduced glutathione was used for elution into 
10 kDa filter columns. 
 
Construction and Parameterization of Mathematical Model 
A mathematical model was developed to better understand the interaction 
between Her2-expressing cells (SKOV-3 or MDA-MD-453) and macrophages. Within a 
“contact” area, Her2-bound IgG can bind to FcγRs, but this interaction is not possible 
outside of this region because of physical constraints imparted by the curvature of the two 
cells (Fig. 4A). This contact area was estimated to be 1/3 of the surface area of the 
smaller SKOV-3/MDA-MD-453 cells based on geometric considerations. A lower bound 
of 1/10 of the surface area has been calculated for a non-deforming bead [222], but the 
actual contact area is significantly higher because macrophages deform and spread 
around IgG-bound cells [223, 224]. Model nomenclature and parameter values are 
provided in Table B.4. 
We considered three types of FcγRs on macrophages: FcγRIIa-H131, FcγRIIa-
R131, and FcγRIIb. The number of FcγRIIa and FcγRIIb were experimentally quantified 
(Figure B.5B), and the FcγRIIa-H131 and FcγRIIa-R131 variants were assumed to exist 
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in 50/50 proportions [163]. FcγRs partitioned between the contact area and the free (non-
contact) area with equilibrium constant Kdiff: 
 
diffK
free contactFcγRIIx FcγRIIx   
where  [ ]
[ ]
[ ]
[ ]
free
diff
contact
FcγRIIx MacrophageSurface Area-Contact Area
K
FcγRIIx Contact Area
= =  
and  FcγRIIx   FcγRII-H131, FcγRII-R131 or FcγRIIb=  
 
All Her2 receptors on SKOV-3 and MDA-MD-453 cells were considered to be evenly 
distributed and receptor numbers were calculated from experimental quantification of 
relative expression levels (Figure B.5A) and total absolute values from literature [225, 
226]. The effective concentration of cell-bound IgG ([L0]) was calculated in an “effective 
contact volume,” defined as the product of contact_area and cell_gap. These cell-bound 
IgGs were free to interact with FcγRIIx contact with ligand depletion: 
 
D_xK
contact cell-boundL + FcγRIIx    FcγRIIx  
where KD_x = KD_IIa-H131, KD_IIa-R131, or KD_IIb from SPR data for different Fc 
variants (Table B.3). 
 
To mimic conditions in our in vitro experiments, as well as in normal physiology, 
10 μM serum IgG ([IgG]s) was included in the system. Serum IgG was assumed to be in 
excess and could bind FcγRIIs anywhere on the macrophage surface without ligand 
depletion: 
 
D_x_IgGK
S free free I boundIgG  + FcγRIIx    FcγRIIx  
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D_x_IgGK
S contact contact I boundIgG  + FcγRIIx    FcγRIIx  
where KD_x_IgG = KD_IIa_IgG or KD_IIb_IgG. 
 
Since receptor crosslinking leads to cell activation or inhibition, we assumed that dimers 
represent the minimal signaling unit (and serve as proxies for any higher-order receptor 
clusters). Any IgG-bound FcγRIIs were allowed to dimerize with equilibrium 
dissociation constant Kcross. Kcross was chosen to be 2500 #/μm2, which maximizes the 
difference in the number of crosslinked receptors with and without MDA-MB-453 cells 
(chosen for this signal optimization since they express fewer Her2 molecules than 
SKOV-3 cells and therefore have lower signals). All possible combinations of dimers 
were allowed between the three FcγRII subunits with the same crosslinking constant, 
whether occupied by serum IgG or Her2-bound IgG. However, geometric constraints 
limited receptors in the contact area to only crosslink with those in the contact area, while 
receptors outside of the contact area could only crosslink with those outside: 
 
crossK
cell-bound cell-boundFcγRIIx  + FcγRIIx    FcγRIIx  FcγRIIx−  
crossK
contact I bound contact I boundFcγRIIx  + FcγRIIx    FcγRIIx  FcγRIIx−  
crossK
free I bound free I boundFcγRIIx  + FcγRIIx    FcγRIIx  FcγRIIx−  
 
No discrimination was made between crosslinked receptors in and out of the contact area 
because all of them could lead to an activating or inhibitory signal. However, local 
concentration effects made the density of dimers (and potentially higher-order clusters) 
much higher in the contact area. 
 The diffusion, binding, and crosslinking reactions above yield the following 
system of equations (x = IIa-H131, IIa-R131, or IIb): 
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[ ] [ ]difffree contactFcγRIIx K  FcγRIIx=      (E1, E2, E3) 
[ ] [ ]
( ) [ ] [ ]
0 SK MD cell-bound
D_xcontact cell-bound
AV
L FcγRIIx
FcγRIIx K FcγRIIx
N cell_gap
 −
 × =
 × 
 (E4, E5, E6) 
[ ] [ ] [ ]D_x_IgGS free free I boundIgG FcγRIIx =   K FcγRIIx     (E7, E8, E9) 
[ ] [ ] [ ]D_x_IgGS contact contact I boundIgG FcγRIIx =   K FcγRIIx                        (E10, E11, E12) 
[ ] [ ] [ ]crosscell-bound cell-boundFcγRIIx FcγRIIx =   K FcγRIIx:FcγRIIx   (E13 to E18) 
[ ] [ ] [ ]crosscontact I bound cell-boundFcγRIIx FcγRIIx =   K FcγRIIx:FcγRIIx   (E19 to E27) 
[ ] [ ] [ ]crossfree I bound free I boundFcγRIIx FcγRIIx =   K FcγRIIx:FcγRIIx   (E28 to E33) 
 
where [FcγRIIx] is in #/μm2. Conservation of mass gives: 
[ ] ( )
[ ]
all FcγRIIx in free area macrophage total surface area contact_area
all FcγRIIx in contact area contact_area Mac_IIx
× −
+ × =
         
                                                              (E34, E35, E36)  
 
This system of equations was solved in Matlab using fsolve to obtain the 36 unknowns. 
Finally, the resulting distribution of FcγRII dimers was correlated to the experimental 
output of ADCP. The relative contribution of activating/inhibiting homodimers to this 
cellular response is not known and, although there is evidence that heterodimers (FcγRIIa 
crosslinked with FcγRIIb) do form [227], it is not known whether they activate or inhibit. 
Therefore, we did not assign any a priori functions or signaling weights to these species, 
but rather allowed their contributions to be determined by the model by assigning an 
“intrinsic signaling potency” to each subunit. The signaling potency for FcγRIIb was 
fixed at -1 (negative for inhibitory) and the signaling potencies for FcγRIIa-H131 and 
FcγRIIa-R131 were allowed to vary freely. We then assumed that the signaling potency 
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of any given dimer was equal to the sum of potency of individual receptors. The overall 
response was calculated from: 
 
 phagocytosis ∝ ( )FcγRIIx : FcγRIIx signaling potency of the respective dimer×∑  
 
 The level of phagocytosis was then compared to experimental data for only two Fc 
variants to obtain the intrinsic signaling potencies for FcγRIIa-H131 and FcγRIIa-R131. 
Fitted potency values are presented in Table B.5. 
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Table B.1:  Plasmids Used in Chapter 3. 
Plasmids Relevant characteristics Reference or Source 
pPelBFLAG Cmr, lac promoter, tetA gene, skp gene, C-terminal FL
AG tag 
[172] 
pPelBFLAG-Fc IgG1-Fc gene in pPelBFLAG [172] 
pTrc99A-DsbA-Fc-FLAG dsbA fused IgG1-Fc gene, C-terminal FLAG tag in 
pTrc99A 
[172] 
pTrc99A-DsbA-Fc2a-FLAG dsbA fused IgG1-Fc2a gene, C-terminal FLAG tag in 
pTrc99A 
This study 
pSTJ4-AglycoT Trastuzumab IgG1 gene in pMAZ360 [172] 
pSTJ4-AglycoT-Fc5 Trastuzumab IgG1-Fc5 gene in pMAZ360 [172] 
pSTJ4-AglycoT-Fc2a Trastuzumab IgG1-Fc2a gene in pMAZ360 This study 
pSTJ4-AglycoT-Fc5-2a Trastuzumab IgG1-Fc5-2a gene in pMAZ360 This study 
pPelB-AglycoT(H)-FLAG Trastuzumab IgG1 heavy chain gene in pPelBFLAG This study 
pPelB-AglycoT(H)-Fc5-FLAG IgG1-Fc5 heavy chain gene in pPelB-AglycoT(H)-FLAG This study 
pPelB-AglycoT(H)-Fc2a-FLAG IgG1-Fc2a heavy chain gene in pPelB- AglycoT(H)-FLA
G 
This study 
pPelB-AglycoT(H)-Fc5-2a-FLAG IgG1-Fc5-2a heavy chain gene in pPelB- AglycoT(H)-FL
AG 
This study 
pPelB-AglycoT(H)-Fc1001-FLAG IgG1-Fc1001 heavy chain gene in pPelB- AglycoT(H)-FL
AG 
This study 
pPelB-AglycoT(H)-Fc1004-FLAG IgG1-Fc1004 heavy chain gene in pPelB- AglycoT(H)-FL
AG 
This study 
pPelB-AglycoT(H)-FcG236A-FLA
G 
IgG1-FcG236A heavy chain gene in pPelB- AglycoT(H)-
FLAG 
This study 
pMoPac1-FLAG-M18 NlpA fused M18 scFv gene, C-terminal FLAG tag in 
pMoPac1 
[218] 
pBAD30-KmR Kmr, BAD promoter [218] 
pBADNlpAHis-M18 NlpA fused M18 scFv, C-terminal polyhistidine tag in 
pBAD30 
This study 
pBADNlpA-VL-Cκ-His NlpA fused trastuzumab VL-Cκ domain, C-terminal 
polyhistidine tag and c-myc tag in pBAD30-KmR 
This study 
pBADPelB-VL-Cκ-His PelB fused trastuzumab VL-Cκ domain, C-terminal 
polyhistidine tag and c-myc tag in pBAD30-KmR 
This study 
pBAD-AglycoT(L)-His PelB fused trastuzumab VL-Cκ domain followed by Nlp
A fused trastuzumab VL-Cκ-His in pBAD30-KmR for 
dicistronic expression 
This study 
pMAZ-IgH-GlycoT Trastuzumab IgG1 heavy chain gene in pMAZ-IgH-H23  [172] 
pMAZ-IgH-GlycoT-Fc1001 IgG1-Fc1001 heavy chain gene in pMAZ-IgH-GlycoT  This study 
pMAZ-IgH-GlycoT-Fc1002 IgG1-Fc1002 heavy chain gene in pMAZ-IgH-GlycoT  This study 
pMAZ-IgH-GlycoT-Fc1003 IgG1-Fc1003 heavy chain gene in pMAZ-IgH-GlycoT This study 
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pMAZ-IgH-GlycoT-Fc1004 IgG1-Fc1004 heavy chain gene in pMAZ-IgH-GlycoT This study 
pMAZ-IgH-GlycoT-FcG236A IgG1-FcG236A heavy chain gene in pMAZ-IgH-GlycoT  This study 
pMAZ-IgH-GlycoT-FcN297D IgG1-FcN297D heavy chain gene in pMAZ-IgH-GlycoT  This study 
pMAZ-IgH-2B6-N297D 2B6-N297D IgG1 heavy chain gene in pMAZ-IgH-
GlycoT 
This study 
pMAZ-IgL-GlycoT Trastuzumab IgG1 light gene in pMAZ-IgH-H23  [172] 
pMAZ-IgL-2B6-N297D 2B6-N297D IgG1 light chain gene in pMAZ-IgH-GlycoT [172] 
pDNR-LIB-FcγRIIa FcγRIIaH131 gene in pMAZ-IgH-GlycoT ATCC 
pCMV-SPORT6-FcrRIIIa FcγRIIIaV158 gene in pMAZ-IgH-GlycoT ATCC 
pMAZ-FcγRI-GST FcγRI-GST gene in pMAZ-IgH-GlycoT This study 
pMAZ-FcγRIIaR131-GST FcγRIIaR131-GST gene in pMAZ-IgH-GlycoT This study 
pcDNA3(oriP)-FcγRI FcγRI gene with C-Terminal GST fusion for mammalian 
expression 
[170] 
pMAZ-FcγRIIaH131-GST FcγRIIaH131-GST gene in pMAZ-IgH-GlycoT This study 
pMAZ-FcγRIIIaV158-GST FcγRIIIaV158-GST gene in pMAZ-IgH-GlycoT This study 
pMAZ-FcγRIIIaF158-GST FcγRIIIaF158-GST gene in pMAZ-IgH-GlycoT This study 
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Table B.2:  Primers Used in Chapter 3. 
Primer 
Name Primer nucleotide sequence (5’  3’) 
STJ#16 TTGTGAGCGGATAACAATTTC 
STJ#67 AATTCGGCCCCCGAGGCCCCTTTACCCGGGGACAGGGAGAGGCTCTTCTGCGTG 
STJ#70 CTACCTGACGCTTTTTATCGC 
STJ#76 CGCAGCGAGGCCCAGCCGGCCATGGCGGGCATGCGGACTGAAGATCTC 
STJ#82 CGCAATTCGGCCCCCGAGGCCCCTTGGTACCCAGGTGGAAAGAATG 
STJ#147 GGCAAATTCTGTTTTATCAGACCGCTTCTG 
STJ#220 CAATTTTGTCAGCCGCCTGAGCAGAAG 
STJ#290 TTTTAGGGTTTTAGGGGTCGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCG 
STJ#290 TTTTAGGGGTCGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCG 
STJ#291 GGCCACCGGATATCTTATTATTTACCCGGGGACAGGGAGAGG 
STJ#332 GGGAATTCTAGACTATTAGCACTCTCCCCTGTTGAAGCTCTTTG 
STJ#340 TTTAAGGGAAGCTTCTATTAGCACTCTCCCCTGTTGAAGCTCTTTG 
STJ#422 CTAGGGAGCCGCGGGAGGAGCAGTACAACGGCGCGTACCGTGTGGTCAGCGTCCTC 
STJ#474 CGCAGCGAGGCCCAGCCGGCCATGGCGGAGGTTCAATTAGTGGAATCTG 
STJ#475 CGCAGCGAGGCCCAGCCGGCCATGGCGGATATTCAAATGACCCAAAGCCCG 
STJ#476 CGCAATTCGGCCCCCGAGGCCCCGCACTCTCCCCTGTTGAAGCTCTTTG 
STJ#490 CTAGGGAGCCGCGGGAGGAGCAGTACAACGGCGCGTACCGTGTGGTCAGTGTCCTC 
STJ#498 TTTTAGGGTCTAGATCATTTACCCGGGGACAGGGAGAGG 
WK#56 TCCACAGGCGCGCACTCCCAAGTGGACACCACAAAGGCAGTG 
WK#57 GGCTGATCAGCGAGCTTCTAGATCAGGATCTTTTTGGAGGATGGTCGC 
WK#91 CTCCACAGGCGCGCACTCCGGCATGCGGACTGAAGATCTCCC 
WK#92 CCACGCGGAACCAGCTCGAGTTGGTACCCAGGTGGAAAGAATGATG 
WK#94 GTTCACAGTCTCTGAAGACACATTTTTACTCCCGAAAAGCCCCCTGCAGAAG 
WK#100 CTCTCCACAGGCGCGCACTCCCAAGCTGCTCCCCCAAAGGCTGT 
WK#101 CCACGCGGAACCAGCTCGAGCCCCATTGGTGAAGAGCTGCCC 
WK#116 GCTTGTGGGATGGAGAAGGTGGGATCCAACCGGGAGAATTTCTGGG 
WK#158 CTCCACAGGCGCGCACTCCGAAATTGTGCTGACTCAGTCTCCAGACTTTC 
WK#159 GGTGACTTTCTCCTTTGGTGTCACGCTCTGAAAGTCTGGAGACTGAGTCAGCACAATTTC 
WK#160 AGAGCGTGACACCAAAGGAGAAAGTCACCATCACCTGCAGGACCAGTCAGAGC 
WK#161 GCTGGTACCAATGTATGTTTGTGCCAATGCTCTGACTGGTCCTGCAGGTGAT 
WK#162 ATTGGCACAAACATACATTGGTACCAGCAGAAACCAGATCAGTCTCCAAAGCTCC 
WK#163 GACTCCAGAGATAGACTCAGAAACATACTTGATGAGGAGCTTTGGAGACTGATCTGGTTTCT 
WK#164 TCATCAAGTATGTTTCTGAGTCTATCTCTGGAGTCCCATCGAGGTTCAGTGGCAGTGG 
WK#165 GGTGAGGGTGAAATCTGTCCCTGATCCACTGCCACTGAACCTCGATGG 
WK#167 ATCAGGGACAGATTTCACCCTCACCATCAATAGCCTGGAAGCTGAAGATGCTG 
WK#168 GCCAGGTATTACTTTGTTGACAGTAATACGTTGCAGCATCTTCAGCTTCCAGGCTATTGAT 
WK#169 CAACGTATTACTGTCAACAAAGTAATACCTGGCCGTTCACGTTCGGCGGAGG 
WK#170 CGATGGGCCCTTGGTGCTAGCTTTGATCTCCACCTTGGTCCCTCCGCCGAACGTGAACG 
WK#171 GCGGCCGCCGTGCGTTTGATCTCCACCTTGGTC 
WK#172 CTCCACAGGCGCGCACTCC 
WK#173 CTCCACAGGCGCGCACTCCCAGGTTCAGCTGGTGCAGTCTGG 
WK#174 CCCCAGGCTTCTTCACCTCAGCTCCAGACTGCACCAGCTGAACCTG 
WK#175 AGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGG 
WK#176 GTATCCAGTAGTTGGTAAAGGTGTAACCAGAAGCCTTGCAGGAGACCTTCACTGAGG 
  134 
WK#177 CTTCTGGTTACACCTTTACCAACTACTGGATACACTGGGTGCGACAGGCGCC 
WK#178 CCATCCACTCAAGCCCTTGTCCAGGCGCCTGTCGCACCCAGT 
WK#179 TGGACAAGGGCTTGAGTGGATGGGAGTGATTGATCCTTCTGATACTTATCCAAATTAC 
WK#180 CATGGTGACTCTGCCCTTGAACTTTTTATTGTAATTTGGATAAGTATCAGAAGGATCAATCACTC 
WK#181 AATAAAAAGTTCAAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAG 
WK#182 CTCAGGCTCCTCAGCTCCATGTAGGCTGTGCTCGTGGATGTGTCTGTGGT 
WK#183 CCTACATGGAGCTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTAC 
WK#184 CGGAATCACCGTTTCTCGCACAGTAATACACGGCCGTGTCGTCAGAT 
WK#185 TGTGCGAGAAACGGTGATTCCGATTATTACTCTGGTATGGACTACTGGGGGC 
WK#186 GAGACGGTGACCGTGGTCCCTTGCCCCCAGTAGTCCATACCAGAGTAATAAT 
WK#187 AAGGGACCACGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG 
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Table B.3.  Kinetic On and Off Rates for Trastuzumab Fc Variant Binding to FcγRs as 
Determined by SPR Analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
#Affinity reported in previous study [172], using the same method. 
  
Variant 
FcγRI FcγRIIa-H131 
Kon 
(M-1 s-1) 
koff 
(s-1) 
KD 
(nM) 
kon 
(M-1 s-1) 
koff 
(s-1) 
KD 
(µM) 
Herceptin 1.8 x 105 2.7 x 10-4 1.5# 7.2 x 105 8.5 x 10-2 0.12 
AglycoT-Fc5-2a 1.5 x 105 2.3 x 10-3 16 3.1 x 105 1.2 x 10-1 0.37 
AglycoT-Fc1001 4.3 x 105 3.3 x 10-2 77 2.6 x 105 5.4 x 10-2 0.20 
AglycoT-Fc1002 N/A N/A N/A 1.5 x 105 2.8 x 10-2 0.19 
AglycoT-Fc1003 N/A N/A N/A 3.3 x 105 5.9 x 10-2 0.18 
AglycoT-Fc1004 4.0 x 105 2.6 x 10-2 64 5.3 x 105 1.1 x 10-2 0.021 
Variant 
FcγRIIa-R131 FcγRIIb 
kon 
(M-1 s-1) 
koff 
(s-1) 
KD 
(µM) 
koff 
(s-1) 
kon 
(M-1 s-1) 
KD 
(µM) 
Herceptin 1.2 x 105 3.7 x 10-2 0.31 3.7 x 10-2 1.2 x 105 1.3 
AglycoT-Fc5-2a 1.3 x 105 3.6 x 10-2 0.27 3.6 x 10-2 1.3 x 105 1.6 
AglycoT-Fc1001 2.6 x 105 3.9 x 10-3 0.015 3.9 x 10-3 2.6 x 105 0.47 
AglycoT-Fc1002 1.8 x 105 4.0 x 10-2 0.22 4.0 x 10-2 1.8 x 105 1.9 
AglycoT-Fc1003 2.6 x 105 3.2 x 10-2 0.12 3.2 x 10-2 2.6 x 105 1 
AglycoT-Fc1004 3.2 x 105 6.2 x 10-4 0.0019 6.2 x 10-4 3.2 x 105 0.2 
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Table B.4: Parameters Used to Generate FcγRIIa/b Activation Model. 
Parameter Description Value Reference or Source 
Physical parameters 
SK_dia Diameter of SKOV-3 cell 10 µm [228] 
MD_dia Diameter of MDA-MB-453 cell 10 µm [168, 228] 
Mac_dia Diameter of macrophage 21 µm [229] 
Cell_gap Gap distance between SKOV-3/MDA-MB-453 cell and macrophage 12 nm [230, 231] 
Contact_area Contact area of FcγRII receptors on macrophage 104.7 µm2 [222-224] 
    
Expression level parameters 
SK_HER2 HER2 expression level on SKOV-3 7.36 x 105 [225, 226] 
MD_HER2 HER2 expression level on MDA-MB-453 4.00 x 105 [225, 226] 
Mac_IIaH Number of FcγRIIa-H131 on macrophage 171271 This work 
Mac_IIaR Number of FcγRIIa-R131 on macrophage 171271 This work 
Mac_Iib Number of FcγRIIb on macrophage 291150 This work 
[IgG]s Free serum IgG concentration 10 µM This work 
[L0]SK SKOV-3 Her2-bound IgG effective concentration 324.2 μM This work 
[L0]MD MDA-MB-453 Her2-bound IgG effective concentration 176.2 μM This work 
    
Affinity parameters 
Kdiff 
Equilibrium constant for partitioning of FcγRII  
receptors in/out of the contact area on  
macrophage 
16.64 This work 
Kcross 
Equilibrium dissociation constant for the  
crosslinking of FcγRII receptors 2500 /µm
2 This work 
KD_IIa_IgG 
Equilibrium dissociation constant between serum 
IgG and FcγRIIa-H131/FcγRIIa-R131 0.72 µM [145] 
KD_IIb_IgG 
Equilibrium dissociation constant between serum IgG a
nd FcγRIIb 2.4 µM [145] 
KD_IIa-H131 
Equilibrium dissociation constant between Fc  
variants and FcγRIIa-H131 (Table S3) This work 
KD_IIa-R131 
Equilibrium dissociation constant between Fc  
variants and FcγRIIa-R131 (Table S3) This work 
KD_IIb 
Equilibrium dissociation constant between Fc  
variants and FcγRIIb (Table S3) This work 
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Table B.5: Intrinsic Signaling Potencies of FcγRIIa-H131, FcγRIIa-R131, and FcγRIIb. 
ADCP data considered 
Intrinsic signaling potency 
FcγRIIa-H131 FcγRIIa-R131 FcγRIIb* 
Fitting Herceptin and AglycoT-Fc1001 only  2.8 0.4 -1 
Fitting Herceptin and AglycoT-Fc1004 only 2.0 0.3 -1 
Fitting AglycoT-Fc1001 and AglycoT-Fc1004 only 11.3 0.1 -1 
* The signaling potency of FcγRIIb was always held fixed at -1, since the goal of each fit was to determine 
the relative potencies among the three receptor subunits. 
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Figure B.1:  E. coli Bacterial Expression System for the Display of Full Length IgGs.
(A) Expression cassettes for the display of covalently anchored full length 
IgGs. (B and C) Fluorescence histograms of spheroplasts expressing full 
length AgylcoT-Fc5 (E382V/M428I) binding to 30 nM FcγRI-FITC (B) or 
AgylcoT-2a (S298G/T299A) binding to 30 nM FcγRIIa-GST followed by 
1:200 diluted goat anti-GST-FITC (C). (D) AglycoT-Fc5-2a shows high 
affinity binding for 30 nM FcγRI, FcγRIIa, and FcγRIIb. 
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Figure B.2: Sequences and Corresponding FACS Signals for Isolated Fc Variants. 
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Figure B.3:  Characterization of Isolated Aglycosylated Fc Variants.
(A) Fluorescent histogram of variant binding to 30 nM FcγRIIa as detected 
by secondary goat anti-GST-FITC diluted at 1:200 from a 1 mg/mL stock. 
(B) SDS-PAGE showing full length trastuzumab Fc variants purified from 
HEK293F cells; M: molecular weight ladder, 1: AglycoT-Fc1001, 2: 
AglycoT-Fc1002, 3: AglycoT-Fc1003, and 4: AglycoT-Fc1004. (C and D) 
ELISA analysis of isolated aglycosylated Fc variants and Herceptin for (C) 
binding to FcγRIIIa, and (D) binding to FcRn at pH 6.0 and 7.4. 
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Figure B.4: Biacore Sensorgrams for FcγRIIa-R131-GST, FcγRIIa-H131-GST and 
FcγRIIb-GST Binding to Aglycosylated Mutants. 
Antibody variants were immobilized on CM5 chips and soluble dimeric 
FcγRs used as analytes. A bivalent kinetic model was used to fit a minimum 
of four concentrations in duplicate for each variant. 
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Figure B.5: Expression Level of Her2 and FcγR on Tumor Cell Lines and Macrophages 
for ADCP Assay. 
(A) Her2 expression level on tumor cell lines used for ADCP was serum 
followed by fluorescent donkey anti-human IgG (H+L) FITC Fab at a 1:50 
dilution. (B) FcγR counts on macrophages were determined using a 
fluorescent Quantum Simply Cellular bead assay. Macrophages were 
labeled with 20 µg/mL anti-FcγRI-FITC, 10 µg/mL anti-FcγRIIa-FITC, 1 
µg/mL 2B6-N297D-FITC and 20 µg/mL anti-FcγRIII-FITC 
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Figure B.6:  ADCP Analysis for Ovarian Cancer Cells Expressing Medium HER2 
Density (SKOV-3) and Low HER2 Density (MDA-MB-453). 
Tumor cells were labeled with PKH67 membrane dye, opsonized with 0.5 
μg/mL antibody and mixed with macrophages at a 1:5 ratio for MDA-MB-
453 and 1:10 for SKOV-3 tumor cells. Macrophages were labeled with 10 
μg/mL anti-CD11b-APC and 10 μg/mL anti-CD14-APC before FACS 
interrogation. (A - F) FACS dot plots for SKOV-3 with No Ab (A), 
AglycoT-N297D (B), Herceptin (C), GlycoT-G236A (D), AglycoT-Fc1001 
(E), and AglycoT-Fc1004 (F). Blue population = macrophages, Red 
population = SKOV-3 cells, green = double positive phagocytosed SKOV-3 
cells. (G - L) FACS dot plots for MDA-MB-453 with No Ab (G), AglycoT-
N297D (H), Herceptin (I), GlycoT-G236A (J), AglycoT-Fc1001 (K), and 
AglycoT-Fc1004 (L). Blue population = macrophages, Red population = 
MDA-MB-453 cells, green = double positive phagocytosed MDA-MB-453 
cells. 
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Figure B.7.  The Model Returns Similar Predictions for Receptor Signaling Potency 
Independent of Experimental Data Used for Parameterization. 
(A and B) ADCP data for Herceptin and AglycoT-Fc1004 were used to 
obtain intrinsic signaling potency values in the model, which was then used 
to predict phagocytic response of AglycoT-Fc1001 with both SKOV-3 cells 
(A) and MDA-MB-453 cells (B). Blue bars represent experimental values 
and green bars represent model predictions. (C and D) ADCP data for 
AglycoT-Fc1001 and AglycoT-Fc1004 were used to obtain intrinsic 
signaling potency values in the model, which was then used to predict 
phagocytic potency of AglycoT-Fc1001 with both SKOV-3 cells (C) and 
MDA-MB-453 cells (D). Blue bars represent experimental values and 
orange bars represent model predictions. (E) Predicted phagocytic responses 
of other Fc variants. Based on KD_IIa-H131, KD_IIa-R131, and KD_IIb 
values from SPR analysis (Table S3), phagocytic response was predicted by 
the mathematical model for both SKOV-3 cells (dark red bar) and MDA-
MB-453 cells (light red bar). Intrinsic signaling potencies for FcγRIIa-H131, 
FcγRIIa-R131 and FcγRIIb were the same as in Fig. 4 (2.8, 0.4, and -1 
respectively). 
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Appendix C 
Table C.1:  Plasmids Used in Chapter 4. 
Plasmids Relevant characteristics Reference or Source 
pMaz-IgH-FcγRIIaR131-GST FcyRIIa gene in pMaz-IgH for dimeric mammalian 
expression 
[96] 
pMaz-IgH-FcγRIIaH131-GST FcyRIIa gene in pMaz-IgH for dimeric mammalian 
expression 
[96] 
pMaz-IgH-N297D-trastuzumab IgG1 trastuzumab heavy chain mammalian expression 
vector with glycosylation knockout at N297 
[96] 
pMaz-IgH-Fc1004-trastuzumab IgG1 trastuzumab heavy chain mammalian expression 
vector with Fc1004 Fc domain 
[96] 
pMaz-IgL-trastuzumab Wild type IgG1 trastuzumab kappa light chain 
mammalian expression vector 
[96] 
pcDNA3.4-IgH-Fc1004-
trastuzumab 
IgG1 trastuzumab heavy chain mammalian expression 
vector with Fc1004 Fc domain 
This study 
pcDNA3.4-IgL- trastuzumab IgG1 trastuzumab light chain mammalian expression 
vector  
This study 
 
Table C.2:  Primers Used in Chapter 4. 
Primer Name Primer nucleotide sequence (5’  3’) 
WK124 CCAGAATGGAAAATCCCAGAAATTCTCTCA 
WK125 CCAGAATGGAAAATCCCAGAAATTCTCTCG 
WK126 CCATTGGTGAAGAGCTGCCCATGCTGGGCA 
WK127 CCAGAATGGAAAATCCCAGAAATTCTCTCT 
WK425 TGAGCGGCCGCTCGAG 
WK426 ACACTGGACACCTTTGAGCACAGC 
WK427 TAGCGGCCGCTATAAGGGTTCGAT 
WK428 GGCACATCTGGCACCTGGGAG 
WK429 
WK430 
CTGTGCTCAAAGGTGTCCAGTGTGAAATGGCGGAGGTTCAATTAGTGG 
CTCTCCCTGTCCCCGGGTAAATGAGCGGCCGCTCGAGG 
WK431 CCCAGGTGCCAGATGTGCCGAAATGGCGGATATTCAAATGACCCAAAGC 
WK432 CCGGTAGGGATCGAACCCTTAACACTCTCCCCTGTTGAAGCTCTTTG 
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Table C.3:  Genotypes of Anonymous Donors and Frequencies of Observed Alleles 
Donor genotype Number Frequency 
Homozygous R/R 5 0.28  
Heterozygous H/R 8 0.44 
Homozygous H/H 5 0.28 
 18  
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Appendix D 
MATERIALS AND METHODS 
Transgenic Mouse ADCP Assay 
Bone marrow was isolated from C57BL/6 FcγR null mice transgenic for human 
FcγRIIa-R131 and FcγRIIb (Rockefeller University).  The cells were resuspended in 
RPMI (Invitrogen) containing 10 % FBS and passed through a 70 μM filter (BD 
Biosciences) for seeding in T75 flasks (Corning). The culture was supplemented with 20 
ng/mL of murine GM-CSF and incubated at 37 °C in 5 % CO2. On days 2 and 5 of 
culture the growth media was exchanged and non-adherent cells were aspirated. After 7 
days, the plate was washed with Dulbecco’s PBS (Mediatech) and 10 mL HyQTase 
(Thermo Scientific) solution was added for 15 min at 37 °C for the detachment of 
macrophages from the plate surface. Recovered cells were washed with 50 mL RPMI 
media and resuspended in RPMI containing 10 % FBS. MDA-MB-453 tumor cells were 
grown in DMEM containing 10 % FBS. Cells were recovered from culture flasks by 
tryspinization, labeled with PKH67 (Sigma-Aldrich) according to the manufacturer’s 
instructions and resuspended in RPMI with 10 % human AB serum. These cells were 
seeded at 5 x 103 per well in 96 well V-bottom plates (Corning) followed by addition of 
macrophages at the appropriate effector: tumor cell ratio (1:5 MDA-MB-453) and 
antibodies, to a final concentration of 5 µg/mL. The plate was briefly spun at 2,000 rpm 
for 1 min and incubated at 37 °C with 5 % CO2 for 2 h (MDA-MB-453). Cells were 
stained with 5 µg/mL anti-CD11b-PE/Cy7 (Clone M1/70, Biolegend) on ice for 1 h. 
Phagocytosis was evaluated by FACS on an LSRFortessa (BD Bioscience), and reported 
as the fraction of double positive cells over the total number of tumor cells in the sample. 
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